

Contents

! A E F A !ae

F A A 5 S ###

! A E F AE E ! ###

Corporate Information

Boa of ieco

Executive Directors

. A di ( )
. A ie
. A (de

Non-executive Directors

. A
. Lij

Independent Non-executive Directors

. (e oe(ei e de e 18,)
. (A i oe(ei e de e 18,)
. de e ei oe(ei e de e 18,)
. (A de (appoi e de e 18,)
. (e (appoi e de e 18,)
. L i (appoi e de e 18,)

Audit Committee

. (e ( )
. L i
. A

Nomination Committee

. L i ( )
. (A de
. A di

Remuneration Committee

. (A de ( )
. (e
. L i

Strategy and Risk Management Committee

. A di ( )
. (e
. L ij

Supervisory Committee

. S F j ( )
. (A i 'o
. E ief
. A e ia
. (E ia

Joint Company Secretaries

. A ia
. i S

Authorized Representatives

. A (de e
. i S

Auditor

ice ae o e ooe de ia LL

Le A io a o (de de La

iffo ce

ei e e ffice (ea ffice i e
!

S i oa
(de ei e ia i ic
e o , ej
e!

o e:

e 18, , . (a e ei e a i epe e -ec ie ieco, ec i of e e ea ie i ee e be of e i ie of e ; . (A ie e a i epe e -ec ie ieco, ec i of e A i i ee, e be of e ea ie i ee e be of eS ae i a e ie of e ; e . i e ei e a i epe e -ec ie ieco, ec i of e i ea ie i ee e be of eA i i ee of e .

Corporate Information

! ...d...p...a... ! ...ace of B ...e ... (... ...

...0 /F, ...a... S... H... ...a...d...a... ...é... ...e
...248 ...ee...' ...o...a... E...a...
...a...c...a...
(... ...

(S...a...e ...e...i ...a...

... ...p ...e ...a...e (... ... ...e ...o Se ...ice ...M...i...e...
S ...o... 1712-1716, 17 ...F...oo...
(...o...p...e ...e ...é... ...e
183 ...ee...' ...o...a... E...a...
...a...c...a...
(... ...

S...oc... ...o...e

...2102

... ...p...a... ' ...eb...i...e

... ...o...p...d...

... ...e ...o ...e...a...i...o...

...e...e...p ...o...e: (86) 577 8877 168...
F...a...: (86) 577 8878...117
E...a...i...: ...i...@... ...o...p...d...

Financial Highlights

Consolidated Statements of Comprehensive Income Data

	For the year ended December 31,				
	2020	2019	2018	2017	2016
	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000
Revenue	1,031,284	880,662	745,972	666,436	415,048
Profit before income tax	87,904	55,523	106,010	64,863	92,132
Income tax expense	(28,949)	(17,845)	(31,941)	(22,027)	(26,588)
Profit for the year	58,955	38,678	74,069	47,836	65,551
Profit for the year attributable to:					
Shareholders of the Company	70,000	57,678	80,556	49,071	68,832
Non-controlling interests	(11,045)	(19,061)	(5,627)	(1,235)	(3,281)

Consolidated Statements of Financial Position Data

	As of December 31,				
	2020	2019	2018	2017	2016
	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000
Total assets	2,248,947	2,117,352	1,840,724	1,640,041	1,603,382
Total liabilities	934,523	855,843	635,451	573,104	560,012
Total equity	1,314,424	1,261,509	1,205,273	1,110,437	1,041,370
Equity attributable to:					
Shareholders of the Company	1,211,846	1,164,484	1,120,995	1,051,834	1,000,383
Non-controlling interests	102,578	97,025	84,278	58,602	40,987

Chairman's Statement

ea S a e o e ,

a e ao a c a i ea fo e o p. e face of e ob a o o a i i ea e
(e COVID-19 epidemic), e o p co i e a e e o e co e of

Management Discussion and Analysis

B ie e ie a oo

Psychiatric Specialized Medical Service Industry in China

i e e eo e of od a eco o a e fo a i of peope' ife e, e ppo of a i a poide a ei ce a e fo ea e of p c ia ic i o e , pi a ep c ia ic pedai e opi a i a e bed e eo ap i ce e 21 ce . ac 15, e Sa e o d p o a e e ie of e a i a e ica a ea ca e Se ice S ! (15-) , ic p opo e of e opi ie ea ocai of p c ia ic e ica a ea ca e eo ce, i p ofe io a p c ia ic ea ca e i io a e a pa , p c ia epa e of e ea opi a a ea ii a pa a p a e ica a ea ca e i io a co i e abii ai de fo p c ia ici e a eba i, oe abi a o p c ia ic ea ca e ice e a e o e. Be efi fo poic co a e o ep c ia ic e ica i , epi a ep c ia ic pedai e opi a p a ce a i c ea i i ifica oe i eo ea p c ia ic pedai e e ica ice i i a e ie e pa a i i o paid a paid ee p o i .

A p e , e i ib io of p c ia ic e ica eo ce i a o a e ei a iffe ce. e ea abe c eof eo ce i ib io affec e a e effide c of epoiio of p c ia ic e ica ice. e ica a ea ca e eo ce a e e ea co ce a e i a edie a ep bic opi a , ic ca e e i ib io of p c ia ic pedai e e ica eo ce.A o e be a ai of e ica o e i p c ia ic ea ca e i a a ei ce a e a e p o e i ece ea , e a e i i ide co pa e o e eope co ie. ei co eofi io a affi e ea o eofaco c a oea e ica a a .

A 17, , e aio a ea ca e Sec i A i ai o i e e i i pio of poi e oide of e id of e e + e ica Se ice e ica ce! e (《關於完善「互聯網+」醫療服務價格和醫保支付政策的指導意見》), ic pedfe a epaid of e e + e ica ice a be co po a e i o epaid poide ofei i e ica ice fo iro a e . Feb a 17, , e e a e op of o ec ai of eSa e o d o ! e io a o of -1 i e e ic a o S e ica ea e a a e of ! aie i Seee e a io e e -1 (《關於加強新冠肺炎疫情期間嚴重精神障礙患者治療管理工作的通知》) (Fe i i o Fa [ ] o.), ic e ie a e a ea e ica i io a pe e epe ie a co o of -1 , pe i - opi a fecio a e a poe e e ica ca e fo paie i ee e a i o e ia oe i -1 a e a e , ea e a co i ca e fo paie i ee e a i o e o a a de. ea ie, e oe e i o ce fa o abe poide o e e ea ca e fe , a e ie a e ei cio of eco e a e of e e ea e a be f e e a e of epe ie of i e ica afe a ai oic e ei ibe e e ea ca e ice i eco e a e of e ica i ce b e . o p c ia ic ea e ee of - e e ica io a e a co i o p c oo ica co aio a p c o e ap , a e e ea e o e i oe app opia e, a e e ea e , acce o e ica i ce, pe cipio o fo a o e e e eo e po of e e ea e a e a i a eco p o pe o pei o i e b poide.

Management Discussion and Analysis

Business Review

Business Review

For the year ended December 31, 2020, the Company's economic capital ratio (non-GAAP measure) and risk solvency ratio (non-GAAP measure) remained at adequate levels, and the Company's solvency was stable and sufficient. In addition, the Company continued to optimize its product structure, actively developed protection-oriented products, and continued to improve the quality of its business. Specifically, in 2020, the Company:

For the year ended December 31, 2020, the Company's embedded value (non-GAAP measure) and new business value (non-GAAP measure), the

Management Discussion and Analysis

2020, ie e eop i b e, e op co e o e e co o aio co cio a p o ei o ea co peii e e. H, e opp o oe i b a o e b-peda co cio. Seco , i co e o ce ei e e e de ce a e ca io a e a o aio o fadi a e e p a e o i ee a c capabiiie. i , i op i e i a eo ce op oi ea o ppo fo e e eop e of e op.

e ea a e of -1 epi ic 20, e o e e of aio die a e p e e e e c pe e io a co o ea e o e ic e a e of p bic, ic, o ace a e e , affece e ea ca e e ice e e eof e op e f a e of 20. a io, e op a e appoiio fo oo i pai e o e of B80 iio a eb e o eof Beij i { opi a a o e a epece e o e -1 epi ic pe e io a co o ea e.

A e -1 epi ic a e effeci e co o i a e op co e o abep oaci ea e c a fadi a e e pio of o a p o cio a co cio e e ea ca eb e, eb e of e op a e o eco e e eco a e of 20, a ac ie i ifica o a a oe i e epo i ei o. i of i ob ca fo f ope a ac iiie, e op oe o e pec a i i pe e e ec e -1 epi ic.

B e { i i

2020, e i o pa a aifie a a i -ec e epi ie a e abi e a ec a i of i -e ca io e a io a c oo-e epi e coope a io b e ei i o co ac i ie iie, ob e po ei e a abe e eop e of e op. a io, e app o a of apo -oco a e o a io i ej a o ce a

Management Discussion and Analysis

(iii) i h e a[o f a[e o e e a[[ca[o a[ice e e i e fo o ope a[o . [ea[ca[e fa d i i e a[e e i e ob a[e e ica[p ac ice ice e be fo e ca[[o d b [e e , ic a[a[a[ai pei o

Management Discussion and Analysis

e e e ' co of e e ef o o e ' o pi a

e e ef o o e ' o pi a co i of fee c a e ' fo e o pai ii a ' ei pai e ice a e o p' a io o pi a , i c i ea e e ice a ' p a ace ica a e . e abe be o e fo a b ea ' o of o e e, co of e e e a ' o p of fo e o e ' o pi a fo e pe io ' i ica e ':

	For the year ended December 31,	
	2020	0 1
	(RMB'000)	(B000)
Treatment and general healthcare services		
e e e	755,879	587,874
o of e e e	506,496	441,786
o p of	249,383	146 88
Pharmaceutical sales		
e e e	222,587	0 5,616
o of e e e	194,544	174,3 8
o p of	28,043	31,218
Owned hospitals		
e e e	978,466	7 3,40
o of e e e	701,040	616,184
o p of	277,426	177,0 6

i e epo i ! e io ', e e ef o o e a ' e o p' o e ' o pi a o e ' o B 78.5 i io , ep e e i a i c ea e of B1850 i io a co pa e ' i 0 1 , a ' ' e o ei c ea ei e e ef o o e a ' e o a i (o pi a , a a i (o pi a , ei a i (o pi a , i ai i (o pi a , i a i (o pi a , ac a i ! coo ica (o pi a a ' ei ic (o pi a a ' e i io of oo e ' o pi a , a e , e o i (o pi a a ' ' a (o pi a a co pa e ' i a of 0 1 . i e epo i ! e io ', e o p of of e o p' o e ' o pi a i c ea e ' b 56.5% a co pa e ' i 0 1 , a ' ' e o ei c ea ei i pai be ' a a e a ei pai pe i pe be ' a .

Management Discussion and Analysis

In the reporting period, our revenue reached RMB133.9 billion, representing an increase of 6.4% as compared with 2019, primarily due to the increase of paid outpatient visits by 12.3% and the increase of paid inpatient beds by 12.5%. Proportion of revenue from value-added services to our total revenue decreased to 13.7% (2019: 15.8%).

In the reporting period, the increase of both inpatient and outpatient service prices led by the change in case mix increased by 8.6% as compared with 2019, and increased to 77.3% of our total revenue from operations (2019: 74.1%); our pharmaceutical sales increased by 8.3% as compared with 2019, accounting for 22.7% of our total revenue from operations (2019: 25.9%), of which: ratio of inpatient pharmaceutical sales to inpatient revenue decreased to 14.6% (2019: 16.5%), ratio of outpatient pharmaceutical sales to outpatient revenue decreased to 74.3% (2019: 76.1%).

Cost of revenue of the Group's owned hospitals primarily consisted of pharmaceutical and consumables, employee benefit expense, depreciation of right-of-use assets, depreciation and amortization, utilities fee. The above items for the cost of revenue of the Group's owned hospitals for reporting periods:

	For the year ended December 31, 2020 (RMB'000)	2019 (RMB'000)
Pharmaceutical and consumables	247,235	222,516
Employee benefit expense	240,185	206,523
Depreciation of right-of-use assets	31,203	24,380
Depreciation and amortization	75,906	62,804
Medical expense	42,653	35,140
Utilities fee	24,081	17,325
Other	39,777	41,216
Cost of revenue of owned hospitals	701,040	616,184

In the reporting period, cost of the Group's owned hospitals increased to RMB10 billion, representing an increase of 13.8% as compared with 2019, which was mainly attributable to increase in the cost of the owned hospitals. Main reasons: (i) increase of 11.1% in pharmaceutical and consumables expense as an increase of pharmaceutical sales; (ii) increase of 16.3% in employee benefit expense in line with the increase in operation of owned hospitals; (iii) depreciation of right-of-use assets increased by 4.5% as compared with as of 2019; and (iv) depreciation and amortization increased by 2.% as compared with as of 2019, and case by case depending on the actual situation.

Management Discussion and Analysis

F[illegible] e co c e pe pecifie, e p opo io[illegible] of p a[illegible] ace ica a[illegible] co[illegible] abe e[illegible] e co of e[illegible] e of o[illegible]e[illegible] o pi a[illegible] ec ea[illegible]e[illegible] o 35.3% ([illegible]1: 36.1%). e p opo io[illegible] of e[illegible] p o ee be[illegible] a[illegible] e pe[illegible] e o co of e[illegible] e of o[illegible]e[illegible] o pi a[illegible] Inc ea[illegible]e[illegible] o 34.3% ([illegible]1: 33.5%). e p opo io[illegible] of e[illegible]ep ed ai[illegible] of i -of- ea[illegible] e o e e i[illegible]ep ed ai[illegible] a[illegible] o i ai[illegible] o co of e[illegible] e of o[illegible]e[illegible] o pi a[illegible] a 15.3% ([illegible]1: 150 %). [illegible] e epo[illegible] !eio[illegible], ec[illegible] e of eco c e a[illegible]ea[illegible]ea co[illegible]pa[illegible]e[illegible] i a of[illegible]1.

e[illegible] ef[illegible] o e ea ca[illegible]e ea[illegible]e[illegible] b[illegible]e

e e[illegible] ef[illegible] o e ea ca[illegible]e ea[illegible]e[illegible] b[illegible]e of e o p[illegible] a[illegible] Inc[illegible]e e[illegible] ef[illegible] [illegible]a[illegible]ed a[illegible] co[illegible] b[illegible]e , e[illegible] ef[illegible] a[illegible]e of p a[illegible] ace ica a[illegible]"e[illegible]ica[illegible]eice a[illegible] e[illegible] ef[illegible] [illegible]fo[illegible]ai[illegible] ec[illegible]oo b[illegible]e , ec. [illegible] e epo[illegible] !eio[illegible], e[illegible] ef[illegible] eo e ea ca[illegible]e ea[illegible]e[illegible] b[illegible]e of e o p[illegible] o[illegible]e[illegible] o B38.1 [illegible]i ai[illegible], of ic[illegible] [illegible]a[illegible]ed a[illegible] co[illegible] b[illegible]e e[illegible] e a B16.8[illegible]i ai[illegible] ([illegible]1: B[illegible]1.7[illegible]i ai[illegible]); e[illegible] e f[illegible] a[illegible]e of p a[illegible] ace ica a[illegible]"e[illegible]ica[illegible]eice a B1[illegible]0[illegible]i ai[illegible].

e[illegible] ef[illegible] ep ope b[illegible]e

e o p' e[illegible] e of ep ope b[illegible]e [illegible]c[illegible]e p ope ea[illegible] [illegible]co[illegible]e, p ope a[illegible]e [illegible]co[illegible]e, ec. [illegible] e epo[illegible] !eio[illegible], e[illegible] e of ep ope b[illegible]e [illegible]ec ea[illegible]e[illegible] o B14.7[illegible]i ai[illegible] ([illegible]1: B[illegible]3.7[illegible]i ai[illegible]),[illegible] a[illegible] [illegible]e o e a[illegible]e [illegible]co[illegible]e of B[illegible]3[illegible]i ai[illegible] f[illegible] [illegible]i po a of[illegible] e[illegible] e[illegible] p ope b[illegible] o o[illegible]a[illegible] [illegible] e epo[illegible] !eio[illegible] ([illegible]1: B[illegible]2.6[illegible]i ai[illegible]).

Gross Profit and Gross Profit Margin

[illegible] e epo[illegible] !eio[illegible], o a o p oi of e o p a[illegible] o[illegible]e[illegible] o B[illegible]2.6[illegible]i ai[illegible], e[illegible]e[illegible] a[illegible] Inc ea[illegible]e of 480 % a co[illegible]pa[illegible]e[illegible] i [illegible]1. e o p oi of eo[illegible]e[illegible] o pi a b[illegible]e e a[illegible] o[illegible]e[illegible] o B277.4[illegible]i ai[illegible], e[illegible]e[illegible] a[illegible] Inc ea[illegible]e of 56.5% a co[illegible]pa[illegible]e[illegible] i [illegible]1. e abe beo e fo a[illegible]b ea[illegible]e[illegible]o[illegible] of e o p oi[illegible] a[illegible] of[illegible]iffe[illegible] b[illegible]e e fo e[illegible]e[illegible]io[illegible] [illegible]ic ea[illegible]e[illegible]:

	For the year ended December 31, 2020	[illegible]1
ea[illegible] a[illegible] e[illegible]e a ea ca[illegible]e e ice	33.0%	[illegible]4. %
[illegible] a[illegible] ace ica a e	12.6%	15.[illegible]2%
Owned hospitals businesses	28.4%	[illegible]2.3%
[illegible] ope a[illegible] o e b[illegible]e e	47.6%	[illegible]0 .5%
Consolidated gross profit margin	29.3%	[illegible]3.8%

[illegible] e epo[illegible] !eio[illegible], co oi[illegible]a[illegible]e[illegible] o p oi[illegible] a[illegible] of e o p[illegible] Inc ea[illegible]e[illegible] o[illegible].3% ([illegible]1: [illegible]3.8%), of ic e o p oi[illegible] a[illegible] of ea[illegible] a[illegible] e[illegible]e a ea ca[illegible]e e ice [illegible]Inc ea[illegible]e[illegible] b 8.1 pe ce[illegible] a epo[illegible] a co[illegible]pa[illegible]e[illegible] i a of[illegible]1. e o p oi[illegible] a[illegible] of p a[illegible] ace ica a e [illegible]ec ea[illegible]e[illegible] b [illegible].6 pe ce[illegible] a epo[illegible] a co[illegible]pa[illegible]e[illegible] i a of [illegible]1.

Management Discussion and Analysis

Tax and Surcharge

In the reporting period, the tax and surcharge of the Company was RMB5.41 million (2021: RMB5.21 million).

Management Discussion and Analysis

Finance Expenses – Net

[illegible]

Management Discussion and Analysis

Gains from Change in Fair Value

In the reporting period, gains from changes in fair value decreased by RMB6.6 million, mainly due to the decrease in fair value of overseas investment properties.

Credit Impairment Losses

In the reporting period, credit impairment losses recognized by the Group amounted to RMB23.1 million (2019: RMB16.3 million). Credit impairment losses for accounts receivable of the Group amounted to RMB23.3 million (2019: RMB20.4 million), accounting for 2.3% of the Group's operating revenue (2019: 2.4%). As at December 31, 2020 and 2019, provision for bad debts of accounts receivable of the Group's overseas business amounted to RMB0.3 million and RMB21.4 million, respectively, accounting for 3% and 7.1% of total accounts receivable of overseas business in the respective year.

Asset Impairment Losses

In the reporting period, asset impairment losses amounted to RMB80 million, which was mainly provision for obsolescence of inventories of Beijing International Exhibition Center and overseas subsidiaries of the Company.

Non-Operating Income (Expenses)

Non-operating income mainly comprised of government grants, while non-operating expenses mainly comprised of donations and losses on disposal of non-current assets. The breakdown of non-operating income and non-operating expenses for respective periods:

	For the year ended December 31, 2020 (RMB'000)	2019 (RMB'000)
Recognition of contract liabilities adjustment	–	25,666
Government grants	59	2,755
Net non-operating income	850	1,068
Non-operating income	909	29,489
Loss on disposal of non-current assets	436	13,240
Donations expenses	8,537	2,187
Net non-operating expenses	1,928	3,486
Non-operating expenses	10,902	18,913

In the reporting period, net non-operating income of the Company decreased by RMB28 million, mainly due to the write-off income recognized for the recognition of contract liabilities adjustment in 2019; in the reporting period, non-operating expenses of the Company decreased by RMB8 million, mainly due to decrease of loss on disposal of non-current assets.

Management Discussion and Analysis

Income Tax Expense

[illegible] e expo [illegible] !eio[illegible], [illegible] co[illegible] e a e pe[illegible] e[illegible] c ea e[illegible] o B28[illegible] i io[illegible] ([illegible] : B17.3[illegible] i io[illegible]), ep e e[illegible] [illegible] c ea e of 67.4% a co[illegible] pa e[illegible] i [illegible] . A fo e ea of [illegible] [illegible], o ac a a a e e 32[illegible] % [illegible] 31.1%, e peci e .

H[illegible] a d a ! o i i o[illegible]

Inventory

A of ece[illegible] be 31, [illegible] , [illegible] e o ba [illegible] ce [illegible] o [illegible] e[illegible] o B37.5[illegible] i io[illegible] (a of ece[illegible] be 31, [illegible] : B23.6[illegible] i io[illegible]),

Management Discussion and Analysis

Investment Properties

A of ece be 31, 2 2 , e ba ce of e ed p ope ie o e o B 7.8 i io (a of ece be 31, 2 1 : B10 , i io), e e ed ! a e o of B e e of o (i e E ca io e a e e (od 2, od 3 a od 4) a ! a e o of B e e of o (i e E ca io e a e e (2/ F o 11/F) e b o o a e e o io , ee a o i ifica c a ei efai a e of e e ed p ope ie . Se o efo o ab e a e e ei of ei e ed p ope ie e b a e e of e e o ! e io :

e ed p ope	! a e o of B e e of o (i e E ca io e a e e (od 2, od 3 a od 4)
A e	So ea co e of o (i e E ca io e a e e, a a S ee, o i , ej ! o ce, e!
e ee of e o p	75%
a ea (A o .) (S . .)	1, 5 .41
o a f oo a ea (A o .) (S . .)	

Management Discussion and Analysis

Accounts Payables

A of ece be 31, 2 2 , acco p abe ec ea e o B6 .6 i io (a of ece be 31, 2 1 : B75.6 i io).

Contract Liability

A of ece be 31, 2 2 , co ac iabii i c ea e o B130 i io (a of ece be 31, 2 1 : B8.6 i io).

Other Payables

A of ece be 31, 2 2 , o e p abe ec ea e o B76.6 i io (a of ece be 31, 2 1 : B133.3 i io).

[i i i ag a eo ce

e abe beo e fo ei fo aio a e ace f o eco oi e ca fo a e e of e o p fo e pei o i ica e :

	For the year ended December 31, 2020 (RMB'000)	2 1 (B000)
e ca e ea e f o ope a ag ac i i ie	199,656	111,8 0
e ca e i i e ag ac i i ie	(186,320)	(14 ,531)
e ca e ea e f o i a d ac i i ie	22,052	7,762
ei c ea e/(ec ea e) i ca a ca e i a e	35,141	(2 ,115)

Net Cash Generated from Operating Activities

i e epo i ei o, e ca e ea e f o ope a ag ac i i ie a o e o B1 .7 i io, p i ai co i i of e p of of B5 0 i io, a j e of B31.1 i io fo a e i pai e o e a ce i pai e o e a a j e of B123.8 i io fo ep ed aio a o i aio of aio a e . a e i o i ca a e e i ca o f o of B44.5 i io. e a ca o f o of B21.3 i io a ib abe oo aio a e pai .

Net Cash Used in Investing Activities

i e epo i ei o, e ca e i i e ag ac i i ie a o e o B186.3 i io, p i ai e o e a o of B188 i io fo p c a i p ope , p a e ip , ,( ) 0 c00 1 0 -1.556 (pai o e e

Management Discussion and Analysis

Net Cash Generated from Financing Activities

In e epo in !eio, e ca e e a e f o in ad ac i i ie a o f e o B22.1 i i .

Significant Investment, Acquisition and Disposal

e o p a o i ifica in e e , ac i i io a d i po a in e epo in !eio.

eb e e

Bank Borrowings

A of ece be 31, 2 2 , e ba a ce of b e bo o in of e o p a o f e o B426.5 i io (a of ece be 31, 2 1 : B300 i io), p i a ib abe o epa e of bo o in of B200 i io a d a in ce e bo o in of B6.5 i io in e epo in !eio.

Contingent Liability

A of ece be 31, 2 2 , e o p a o co in e iabi i o a ee a o f a e a eia pac o e in da poii o ope aio of e o p.

Asset Pledge

e o p i o a e a e pe e in e epo in !eio.

Lease Liabilities

e ea e iabi i ie of e o p in ai co i of ope a ea e a e . A of ece be 31, 2 2 , e e a e of e ea epa e e e -ca ce abe ea e a ee , a e e c a d o of B32.5 i io ic i e i in e ea, ee B18 .8 i io.

Financial Instruments

Fi da in e of e o p co i of acco ece abe, o e -c in da a e , o e ece abe, ca f ca e i a e , b bo o in , acco pa abe a d o e pa abe. e o pa ' da a e a d a e a d di io ee i e o ee effeci ea e a e e a e .

Exposure to Fluctuation in Exchange Rates

e o p epoi ce a o i in da a e in fo d c de, ic a in o e i e off c aio in e ec e a e of a d B. e o pi e po e o fo d ec e i e acco .

Management Discussion and Analysis

As of ece be 31, 2 2 , e o p a o e ei ai ie ad i e o e ea i e o c c i . e a e of e o pa a ec c i b coe o i o e o e of e fo i c c ae, i co i e e a i ifica fo i c c e o e o c ee ai e.

Gearing Ratio

As of ece be 31, 2 2 , e o p' ea io (o ai abiii ie i e b o a e) i c ea e o 41.6% (a of ece be 31, 2 1 : 0 .4%), a e o i c ea e of ba bo o i .

Employees and Remuneration Policy

As of ece be 31, 2 2 , e o p a o a of 3,338 f - e o ee (a of ece be 31, 2 1 : 2,845 f - e o ee). e e o i ei o, e o ee' e ai (c a ie o e fo of e o ee be e) o e o a o e B33 .0 i io (2 1 : B288.7 i io). e a e e o ee' e ai i B0 5.6 o e ea (c od e ica ce c e e o a c e bo e b e o). e e ai i ee e e i efe ce o e a ee e e ai a e ifica , e pe ce e fo ce of a e o ee.

o e of obii e ei of io a e a e co e ec ica pe o e of e o p, e o pa af e E i ce i e Sc e e fo e ea 2 18 of e o a i (o i a o., . (e Equity Incentive Scheme), ic a co i e e a a o e a ea a e e a ee of e o pa fo e ea 2 17 ic a bee co e e o e 13, 2 18 (e 2017 AGM). e o e ie pedi e, capi a i e e e be o a a e a e ea a o e e e ea o ce e of e o pa a e a , 2 18 a e pe e in dic a of e o pa a e a 0 , 2 18.

Af e eco i e ai a a o a a e 2 17 A , a co i a ai a e 8 ee of e eco e ei of e Boa of e o pa e o A 2 , 2 18, ea ac a a co pi e of 165 pe o , a ea a a e e be of S a e a e a 1,818,5 S a e.

Af e eco i e ai a a o a a e 15 ee of e eco e ei of e Boa of e o pa co e o A 26, 2 1 , ce i e S a e ee a e o e eco p a e pa idpa . e eco p a e pa idpa c e co e ec ica pe o e of e o pa a o e pe o o, e opi io of e Boa , a be ce ii e. e a of e eco p a e a c e eco pi e of 37 pe o , a e o a be of S a e a e a 273,161 S a e. A 14 pe o o ai ab e o bcibe, ea ac a a co pi e of 23 pe o , a ea a a e e be of S a e a e a 10 ,516 S a e, e e in 0 .23 1% of o a i e a e capi a of e o pa a e a e. e e ai a e o a efo o in abe. e pa idpa a pa e bcipio a o c ac a e b e a o of a ie ie b e a pice (B0 .47 pe S a e).

e Boa i pea e opee i a epo a e a ie co oi a e Fda a ed of e opfo e ea e e ece be 31, 2 .

I Fdpa Aci ie

e pFdpa aci ie of e op a eope a a e o of ea ca efadie a pFai foc o poiF p cia ic peda ca e ac o a io ei o F a ei of epFdpa aci ie of epFdpa bi ia ie of e o pa a e e o F oe o e Fda S a ed Fee F o e ie Fee F bi ia ie S c e of e op of i a epo .

ecipio of e ea io ip be ee e op a i Fpo ee, cie a ppie a e e o F a ed ic io a A a i Fpo ee a d e ea io ! oic a epo of e Boa a jo o e a S ppie of i a epo , e peci e .

B Fe ei e

eb Fe ei e o e opi e o F e a ed ic io a A a i of i a epo . e f e e eop ed of e op a e a io i e a Fce a ie a e op a be e poe o a e e o F e a ed ic io a A a i B Fe oo k of i a epo .

Fda (i i a e

e ope a e a Fa of a e a iabiie of e opfo e ea e e ece be 31, 2 a e e o F e Fda (i i of i a epo . e op' Fda e fo e ea e e ece be 31, 2 a e e o F eco oi a e a ed of co pe ed i ei co e of i a epo .

Fe e ea io

! ea e efe o e ecio ea e opo a e o e ce epo o ica io i S a e o e a Fe e ea io of i a epo .

Ei o ed a ! oide

e opi co do ofi ei o ed a poecio obi a io a aci e ee o pe ed eco-fie ec ooie a o io ee fea be. i epec o e ica a e a ed , e op a ed a e aie i pa ie o a a epope i po a fo a ofi ea ca efadiie F acco a ce i appicabe a a e a io . oe appicabe a a e a io a e o ea ia Fpac o eb Fe ope a io of e op. ea of e ei o ed a poide of e o pa a e e o F e Fei o ed a, Soda a o e ce epo F epe ed p bi e b e o pa F eco e, ic ca be acce e a o o a e a ebie of e o pa a e (o o Soc E c a e.

Report of the Board

Compliance with Laws and Regulations

The Company continuously monitors the changes in laws and regulations applicable to the Company, and the Company has established a compliance system, applicable to all of the Company's employees, to ensure the Company's compliance with laws and regulations. The Company's Chief Compliance Officer is responsible for the execution of the Board's resolutions.

Laws and regulations applicable to the operations of the Company's clinical laboratories include the Mental Health Act (《中華人民共和國精神衛生法》), the Law of the People's Republic of China on Basic Medical and Health Care and Promotion of Health (《中華人民共和國基本醫療衛生與健康促進法》) (collectively referred to as the "Law"), the Administrative Measures on Medical Institutions (《醫療機構管理條例》) and the Implementation Rules of the Administrative Measures on Medical Institutions (《醫療機構管理條例實施細則》).

The operations of the Company's clinical laboratories are subject to various licensing and filing requirements. Please refer to the section headed "Regulatory Overview" in the Prospectus for details.

The Company's PRC legal advisor has confirmed that the Company has obtained all material licenses and permits for the operations of its clinical laboratories in the PRC and is not aware of any material non-compliance incidents in relation to the Company's clinical laboratories in the PRC during the Reporting Period.

Environmental Policies

For the year ended December 31, 2021, the Company complied with environmental policies.

Relationship with Employees, Customers and Other Stakeholders

The Company's success depends on the support of its employees, customers and other stakeholders. The Company has established a long-term incentive plan to attract, retain and motivate talented employees to contribute to the Company's growth and development. The Company has also established a share award scheme to recognize the contributions of certain employees and to provide them with incentives in order to retain them for the continuous operation and development of the Company. Please refer to the section headed "Statutory and General Information — D. Share Incentive Plans" in the Prospectus for details.

Results and Dividends

The Group's profit for the year ended December 31, 2021 and the Company's financial position as at that date are set out in the consolidated financial statements on pages 127 to 128 of this annual report.

The Board proposed a final dividend of RMB3.2 per share (equivalent to approximately HK$3.9 per share) for the year ended December 31, 2021, amounting to approximately RMB358.7 million in aggregate. Pursuant to Article 153 of the Articles of Association, the proposed final dividend is subject to the approval of the Shareholders at the annual general meeting of the Company to be held on June 10, 2022. The proposed final dividend will be paid to the Shareholders whose names appear on the register of members of the Company on June 20, 2022.

Report of the Board

i i e

e Bo oe o eco e epo of a i e fo e ea e ece be 31, 0 .

a e cio o E e pio

acco ce i e E epie co e a a of e eo e' ep bic of a (《中華人民共和國企業所得稅法》) i p e aio e aio ic c e o effec o a 1, 08, e o pa i e ie o i o pa epie co e a a e of 0 % o be a f of e o - ei e epie Sa e o e o e appea o e ei e of be fo Sa e ib e ca i e . A Sa e o ei e e e e of a i i a Sa e o e, c Sa ee i e, o e ee, a o ee, o o e o ai aio o o p, a be ee e a Sa e e b o - ei e epie Sa e o e . e efo e, o i ba i, epie co e a a be i e f o i e pa abe o c Sa e o e . f o e of Sa e e oc a e Sa e o e a , pea e ie abo e ee a poce e i o a e o ee. e o pa i ic co p i e a o e ei e of ee a o e a oi i o pa e epie co e a o be a f of e ee a Sa e o e ba e o e ei e of be fo Sa e a of e eco a e.

f ei i a o e of Sa e a e o o aca ei e o ei e of eco ie ic a a ee a a e of 0 % fo eca i e o e i e! e ee a a ee , e o pa o i o pa i i a co e a o be a f of e ee a Sa e o e a a a e of 0 %. So ei i a o e of Sa e be ei e of eco ie ic a a ee a a e of e a 0 % i e! e ee a a ee , e o pa a i o pa i i a co e a o be a f of e ee a Sa e o e a a a e of 0 %. i ca e,if e ee a i i a o e of Sa e i o ec a ee a o i e e o e appica io of 0 % a a e, e o pa ca app fo e ee a a ee pefe e ia a ea e poi e a e ee a Sa e o e bi ee i e ce e ie b e oice of e a a ee o o p e a e o Se ice ie . e o pa i a i i e a ef f e e appo a of eco pe a a oi . So ei i a o e of Sa e be ei e of eco ie ic a a ee a a e of o e 0 % b e a 0 % i e! e a a ee , e o pa a i o pa ei i a co e a a e a ee ac a a e acco ce i e ee a a ee . e ca e a ei i a o e of Sa e a e ei e of eco ie ic a a ee a a e of 0 % i e! e a a ee , o ic a o e e o a a ee i e! , o o e ie, e o pa a i o pa ei i a co e a a a e of 0 %.

Report of the Board

S a e a i a

e ai of e o e e in e a ecai a of e o p ' in e epo in !eio ' a e e o in oe o e H d a S a e e 4 oe(3) o eco oi ' e ' in d a a e e of i a a epo .

e e e

e ai of o e e in e e e e of e o p ' in e epo in !eio ' a e e o in e o oi ' e ' S a e e of a e in S a e o ' e ' E i a ' oe o e H d a S a e e 4 oe (31), (32) a ' (33) o eco oi ' e ' in d a a e e of i a a epo .

i ib ab e e e e

A of ece be 31, , e i ib ab e e e e of e o p ee B31 .4 i io .

Report of the Board

ebe e i e

Fo e ea e e ece be 31, , e o i e ebe e.

E i -i e A ee e

Fo e ea e e ece be 31, , oe i -i e a ee e e ee e i ob e o , o e i e.

o aio

Fo e ea e e ece be 31, , ec ai abeco ib io a o e o aio a eb e o a o e o a o e B8.5 i io i a e a e.

S bi ia ie

e i of e o a ' p i dpa bi ia ie a of ece be 31, a e e o i oe o e i da S a e e e o i e i o e e ii e e i bi ia ie S c e of e o of i a a e o .

i ec o

e i ec o i e e o i ei o a p o e a e of i a a e o a e:

Executive Directors

. A di (a a)
. A ia e
. A o e

Report of the Board

S pe i o

eS pe i o ' e epo ' ei o ' p o e ' eof i a epo ' e:

. S F j (a)
. (A ' o
. E ief
. A e i
. (E i

B e eie ' A a i of e ' ica o of H da e fo ' ce

Fo b e eie ' a i of e ' ica o of ' da pe fo ' ce of e o fo e ea e ' e ' ece be 31, , pea e efe o e ecio of H da (i i ' a e ic io ' A a i i a epo .

ie co ' ' S pe i o ' ee ' ac io , A e o o ac of Si ifica ce

Sa e a ' i coe ' oe o e H da Sa e e ea e ' pa ie ' e ea e ' pa ac io of i a epo , o ac io , a e o co ac of i ifica ce o ic e o pa o a ofi o ' co pa ie , bi ' ie o fe o bi ' ie , a apa ' ic a ieco o a S pe i o , o e i co ec e ' i ieco o S pe i o , a ' a ei a ee , e e ' ec o ' ec , bi e a of ece be 31, o a ' e ' e epo ' ei o .

o o ' Sa e o e ' ee ' o ac of Si ifica ce

Sa e a ' i coe ' oe o e H da Sa e e ea e ' pa ie ' e ea e ' pa ac io of i a epo , i e of e o o ' Sa e o e a o a ' a ei a ee , i e ' ec o ' ec , ' a co ac of i ifica ce, e e fo epoi io of e ice o o e ie, o eb e of e o po o ic e o pa o a ofi bi ' ie a apa ' e epo ' ei o .

a a e e o ac

' e epo ' ei o , e o pa ' ' o e ' o a ' a e e co ac i epec o e ieb e o ecoeb e of e o pa .

Report of the Board

o -co peiio A ee e

! o e o -co peiio A ee e , ea o e o o S a e o e a a ee o o, o oc e a i / e epeci e co e a odia e( ) (a app opia e) (o e e o)o o, d e ec o ec , co pee i e o p'

Report of the Board

Name of Directors	Class of Shares	Nature of Interest	Number of Shares	Total Number of Shares	Approximate Percentage in Shares of the Same Class[1]	Approximate Percentage of the Company's Total Issued Share Capital[1]
. A di	d e ic S a e	Be ficia o e	18,3 ,2 (L)	22,144,7 (L)	0 7%	.68%
		ee of po e	3,7 4,0 (L)[4]			
. A i e	d e ic S a e	Be ficia o e	3,7 4,0 (L)	22,144,7 (L)	0 7%	.68%
		ee of po e	18,3 ,2 (L)[4]			
. A (d e	d e ic S a e	Be ficia o e	3, 84,3 (L)	5,527,3 (L)	00 %	7.41%
		ee in a co o e co po a io	1,543,000 (L)[3]			
	(S a e	Be ficia o e	, 000 (L)	, 000 (L)	1.6 %	0 .41%

o e:

(L): L d poii d

(1) e a e o % pe ce a e a e ca c a e d e ba i of 55,2 ,000 d e ic S a e a d , 3 ,000 (S a e (a a e a e of 74,6 ,0 0 S a e) i e b e d pa a a ece be 31, 2 .

(2) . A di ii e po e of . A i e a d ee fo e, . A di i e e d e o be ee e d e ic S a e e b . A i e, a d . A i ei e e d e o be ee e d e ic S a e e b . A di b i e of! a of e SF .

(3) . A (d ei e de e a pa e of bo d i a d e e d a e d L.! . (Xinshi Kangning), ic i a i e pa e ip, a d o appo a e 34.57% d i a d . e fo e, b i e of! a of e SF , . A (d ei e d e o be ee e d a e d ic S a e e b i a d d e pa .

Sa e a % co e abo e, a a ece be 31, 2 , o e o e ee of e Bo a , de of e ie co , eS pe i o o cie fe ec i e of e pa a d ee o o poii d eS a e, % S a e d e eb e of e pa o d of i a od a e co po a io (i e ee i e o be: (i) oi % e o e pa a d e (d of Soc E c a ep a o i ii 7 d 8 of! a of e SF (c % ee a d o poii ic e ie co , eS pe i o a d cie fe ec i e of e pa ee a ed o e e % e c poii of e SF); (ii) o eco e % e ei e ep b e pa p a o Secio 352 of e SF ; o (iii) oi % e o e pa a d e (d of Soc E c a ep a o e o e o e.

Report of the Board

e e of S b a i a S a e o e

A a ece be 31, 2 2 , acco o e ei e ep b e o pa p a o Secio 336 of e SF a o f a a i o o, o ca be a ce a e a f e ea o abe e i b e ieco , e fo o pe o /e iie (o e a e ieco , e S pe io o cie f ec i e of e o pa) a a ee o o poiio ic o f a o be i coe o e o pa a e f o S oc E c a ep a o iiio 2 a 3 of ! a of e SF , o be i ec o i ec ee e 5% o o e of e o a a e of a c a of a ecapi a ca i o e o a d c ce a e a ee of e o pa :

Name	Class of Shares	Nature of Interest	Number of Shares	Approximate Percentage in Shares of the Same Class(1)	Approximate Percentage of the Company's Total Issued Share Capital(1)
a o a i e e F . (Defu Fund) (廣州德福股權投資基金合夥企業(有限合夥)(「德福基金」))	o e ic S a e	Be efi a o e	15,384,541(L)	7.84%	.6 %

Report of the Board

Name	Class of Shares	Nature of Interest	Number of Shares	Approximate Percentage in Shares of the Same Class[1]	Approximate Percentage of the Company's Total Issued Share Capital[1]
ii op c.	S ae	e d a ec i ee i ae	1,345,7 (L)	6 6%	1.8 %
bi e A io LL	S ae	e d a e	1,454,000 (L)	7.5 %	1 5%
bi e a LL	S ae	e d a e	,10 ,00 (L)	11.1 %	.88%
bi e a e F ie	S ae	Be ficia o e	1,27 ,00 (L)	6.6 %	1.7 %
e a a e d op ie	S ae	e d a e	,118, 88(L)	0 5%	.84%
bi e a e ,L.	S ae	Be ficia o e	10, 50,000 (L)	5.44%	1.41%
BS op A	S ae	ee i ac o e co po a io	4, 350, 6(L)	.86%	5.41%

o e:

(L): Lo po i io

(1) e a e o i pe ce a e a e c a c a e o e ba i of 55,60,000 o e ic S ae a 1 ,30 ,00 S ae (a a e a e of 74,60 ,00 S ae) i e b e o p a a of ece be 31, .

(2) a o L a a ! L.i e e a pa e of e F , ic i a ie pa e ip. e efo e, b i e of a of e SF , a o L a a ! L.i ee e obe ee e i a e o eic S ae e b e F i e o p a .

(3) a o A o obie o p a a o., L .i a ie pa e of e F , ic o app o a e 5 .45% ee i e F . e efo e, b i e of a of e SF , a o A o obie o p a a o., L .i ee e obe ee e i a e o eic S ae e b e F i e o p a .

(4) . ii e po e of . A (o e, a ec ie ieco, a e efo e, . ii ee e obe ee e i e o eic S ae e b . A (o eb i e of a of e SF .

(5) S a ai Le i e e d L.! . (
a ai Le i e e d L.! . (

Report of the Board

(7) S a i S e e v e a e o., L . (上海盛歌投資管理有限公司)i e e a pa e of S a i i a e v e a e L . (上海乾剛投資管理合夥企業(有限合夥)) a S a i a i a v e a e L . (上海檀英投資合夥企業(有限合夥)). e efo e, b i e of! a of e SF , S a i S e e v e a e o., L . (上海盛歌投資管理有限公司)i ee e obe ee e a e e ic S a e e b S a i i a v e a e L . (上海乾剛投資管理合夥企業(有限合夥)) a S a i a i a v e a e L . (上海檀英投資合夥企業(有限合夥))i e e .

(8) 青島金石灝汭投資有限公司)i o e b i i e a e o., L . (金石投資有限公司). e efo e, i i e a e o., L . (金石投資有限公司)i ee e obe ee e i e e ic S a e e b i ao i i e a e o., L . (青島金石灝汭投資有限公司)i e e pa b i e of! a of e SF .

Sa e a i co e abo e, a a ece be 31, 2 , o e o e e of e i eco , oo e pe (o e a a i eco , a S pe i o o cie fe ec i e of e pa) a , o a ee e o a ei ee o o poiio i eS a e o e i S a e ic o fa obe i co e o e pa e e poiio of iii 2 a 3 of! a of e SF , o ic e ee eco e i e ei e ep b e pa p a o Secio 336 of e SF .

i eco ' a S pe i o ' i o Ac i e S a e o eb Sec ii e

Sa e a e E i ce i e Sc e e, a o e i e epo ! eio a e pa o a ofi bi ie a pa o a a e e oe abe e i eco , e S pe i o , o cie fe ec i e of e pa (c i d po e o ci e e 18 ea of a e) o ac i e be ef b ea of ac iii of S a e i , o ebe e of, e pa o a o e bo co po a e.

o ec e a ac io

e Bo a co fi a o de e of e ea e pa a ac io e o i oe o e H d a S a e e ea e pa ie a e a e pa a ac io of i a a epo co i e co ec e ac io o co i i co ec e ac io e ape e 14A of e (o i e. i e epo i ! eio , e o p a o e ee i o a co ec e ac io o co i i co ec e ac io ic a e e i e obe i co e i i a a epo p a o e (o i e.

Report of the Board

! c a e, Sa e o e ed pid of i e Sec i ie

o e of e p o oe e ea a abe o -e e eop ed of e o pa a opoec ei ee of e ea ei e o effeci ie , in e epo ! eio , e o pa ep c a e a o a of 8 , 0 (S a e o e (o o Soc E c a e, i a a e a ec a co i e ai (ec e pe e) of ($15,888 , 0 . ei of e ep c a e ea e a fo o :

Repurchase period	Total number of H Shares repurchased *(S a e)*	Price paid per share Highest *($)*	Lowest *($)*	Total consideration *($)*
a c 2 2	35 000	17 0	17.8	624,2 0
Ap i 2 2	715,2 0	18.56	17.0	12 , 3,51
a 2 2	, 40 0	160 0	15.8	148,54
e 2 2	14 , 00	15.8	14.0	2,122,74
	8 , 0			15,888 , 0

e abo e ep c a e (S a e ee ec ce e o 13, 2 2 .

Sa e a i co e abo e, in e epo ! eio , d e e o pa o a of i bi ie p c a e , o o e ee e a of e o pa ' i e ec ii e .

! e-e pi e i

e ea e o po oii o fo p e-e pi e i e eA ice o e ! o pa a ic obi e e o pa o offe e S a e o a po o a a ba i oe i in S a e o e .

B a e Bo o in

e ai of eb a e bo o in of e o p a of ece be 31, 2 2 a e e o in oe o e H d a S a e 4 o e (1) a (26) o ec o oi a e in d a a e of i a a epo .

a e o A e

e ai of ec a e o a e of e o p a of ece be 31, 2 2 a e e o in oe o e H d a S a e 4 o e (1) a (26) o ec o oi a e in d a a e of i a a epo .

Report of the Board

o po a e o e a ce

e Boa i of op io a e o pa a co pie i a co e po oii a e eco e be p acice e o e o o e epo !eio.! d pa co po a e o e a ce p acice a op e b e o pa a e o e ecio ea e o po a e o e a ce epo of i a a epo .

S idec of ! bic Foa

Ba e o ei fo aio a i p bic a ab e o e o pa a i e o e eof e iec o a e a e ! acicab e a e, e o pa a a a e e p bic foa of ei e S a e a e ie e e (o i e .

o eof e ei e of e be

For determining the entitlement to attend and vote at the AGM

e ei e of be of e o pa i be co e f o e 15, 21 o e 18, 21, bo a c ie, ic pei o o a fe of e S a e i be effec e. o e o ee e ei i of S a e o e o a e ie o a e a o ea eA , a S a e a fe oc e acco pa ie b e ee a S a ece ifica e be o e i e o pa ' (S a e ei a, o p e a e (o o e o Se ice ie a S op 1712-1716, 17 Foo , (ope e e, 183 ee' oa Ea , a c a, (o o a e a 4:8 p . o e 11, 21.

po a E a fe e epo !eio

e po a e a fe e epo !eio a e e o oe o e a da S a e E a fe e ba a ce ee a e of i a a epo .

A i o i ee

e A i o i ee of e Boa of ie co of e o pa a eie e o pa ' a e op' a e , a e a ie co oi a e a da a e fo p epa e acco a ce i e a Acco

Report of the Board

A i o

e i d a a e fo e ea e e 0 o / 31, a e bee a i e b ! ice a e o e oope o i
!.

e o p a o c a e i a i o i e p a ee ea .

Fo a o be a of e Boa
GUAN Weili
a a

e a , e !
A i 16, 21

Report of the Supervisory Committee

o eS ae o e :

, eS pe i o o i ee ba e o ea i e of afe a in ei ee of e o pa , a S ae o e a e o ee, a in co pia ce i e ee a , e aio a eA ice, ca ie o o i ep i dpe of o e , pe fo e i pe i o f cio , a effeci e pe ie ep e fo ce of ie of i eco , cief e ec i e a o e eio a a ed e be of e o pa , ic p a e a poii e oei a i e ope aio a e eo o ed of e o pa .

In e epo in ! eio , ea c e be of eS pe i o o i ee p ed ei e e o pa ' ope aio a e eo o ed pa , ca ie o ca io pe iio a in pecio of e a f ope aio , in a da co ii o , ac a e of p ocee , e a e pa a acio , e e i ce i e p a of o po ee a o e a e of e o pa , a p oi e ea ab e ei o a opi io o e Boa . a o ic a effeci e o io e a pe ie e o pa ' a a ed in ain i ifica poide a ed io o e a e a ecom pie i e a , e aio a eA ice a a ei ei ee of eS ae o e .

eS pe i o o i ee co i e a e i eco , ecief e ec i e a o e eio a a ed e be of e o pa a e ab e o ic ob e e di fi da e ie, o ac i e , oe e d e di a oi fai f in e be in ee of e o pa a o o ein acco ce i eA ice. A of e ae of app o a of i epo , o e of e i eco a cief e ec i e a o e eio a a ed e be of e o pa a bee fo o a e ab e e di a oi , a e ei ee of e o pa o fi e po ei ee of eS ae o e a e po ee of e o pa , o a eb eac e a a e aio o eA ice.

, 21, eS pe i o o i ee i co in e o ai f i o e pe iii e po ibiiie, f e p o oe e a a i e ope aio of e o pa , co a pa a eio o e pe ed aio of e o pa ' ajo a e ie, a ee p ab ea of e ajo ed io a ain a e a ei ac of ea c ed io a ain poce e of e o pa , o a o p o e e o pa ' co po a e o ce c e a poec ei a in ee of e o pa a S ae o e .

Fo a o be a of eS pe i o o i ee
SUN Fangjun
ai a

ej a , e!
Ap i 16, 21

Corporate Governance Report

e [illegible] eco[illegible] e [illegible] [illegible] po [illegible] ce of ac ie[illegible] i [illegible] [illegible] of co po [illegible] e o[illegible] ce [illegible] [illegible] i co[illegible] i e [illegible] o [illegible] o. e [illegible] [illegible] a ppie [illegible] e [illegible] [illegible] dpe [illegible] e o [illegible] e o[illegible] e a [illegible] i o [illegible] co[illegible] e of co po [illegible] e o[illegible] ce. e i ec o [illegible] e of e op[illegible] io [illegible] e [illegible] [illegible] [illegible] a [illegible] co[illegible] pie [illegible] i [illegible] eco[illegible] epo i i[illegible] e o [illegible] e o[illegible] e [illegible] e epo [illegible] [illegible] ! e i o [illegible] [illegible] p o e [illegible] e of i [illegible] [illegible] epo . e [illegible] [illegible] i co [illegible] e o e ie [illegible] [illegible] ce i co po [illegible] e o e [illegible] ce p [illegible] ice o [illegible] eco [illegible] pi [illegible] ce i e o[illegible] e.

e Boa[illegible]

Board Composition

e Boa[illegible] c [illegible] co [illegible] pi e [illegible] i ec o , [illegible] c [illegible] ee e ec i e i ec o , o [illegible] -e ec i e i ec o [illegible] ee [illegible] epe [illegible] [illegible] -e ec i e i ec o . e bief bio [illegible] ica [illegible] e [illegible] of e i ec o [illegible] e e o [illegible] e ec io [illegible] ea [illegible] e i ec o , S pe i o [illegible] Se io [illegible] [illegible] [illegible] of i [illegible] [illegible] epo . e o e [illegible] [illegible] [illegible] [illegible] pe i io [illegible] of e [illegible] ' ope [illegible] io [illegible] e f c io [illegible] of fo [illegible] [illegible] o e [illegible] b [illegible] e [illegible] e ie e e e [illegible] e Boa [illegible]. e e [illegible] of office of e i ec o [illegible] be effecti e f [illegible] e [illegible] e of ec o i [illegible] e io [illegible] [illegible] [illegible] o [illegible] [illegible] e [illegible] 1 A , [illegible] [illegible] e pi e [illegible] e [illegible] e of e pi io [illegible] of e i [illegible] e io [illegible] of e Boa [illegible].

[illegible] e epo [illegible] ! e i o [illegible] [illegible] p o e [illegible] e of i [illegible] [illegible] epo , e Boa [illegible] [illegible] e e e i [illegible] [illegible] of e 3.0 [illegible] 3.0 A of e [illegible] [illegible] [illegible] i [illegible] e e [illegible] o e [illegible] [illegible] [illegible] of [illegible] ea ee [illegible] epe [illegible] [illegible] -e ec i e i ec o i [illegible] ea [illegible] [illegible] e [illegible] epe [illegible] [illegible] -e ec i e i ec o po e [illegible] [illegible] [illegible] o pi [illegible] e p [illegible] o fe io [illegible] [illegible] ifica io [illegible] of acco [illegible] [illegible] o e [illegible] e [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] e pe i e [illegible] [illegible] e e i [illegible] [illegible] ea [illegible] e [illegible] epe [illegible] [illegible] -e ec i e i ec o ep e [illegible] ea [illegible] [illegible] e- i [illegible] of e Boa [illegible].

e [illegible] [illegible] a ecti e [illegible] [illegible] a co [illegible] [illegible] [illegible] o [illegible] epe [illegible] [illegible] ce f [illegible] ea c [illegible] epe [illegible] [illegible] -e ec i e i ec o p [illegible] [illegible] o e e i [illegible] [illegible] e e [illegible] [illegible] [illegible] e. e [illegible] co [illegible] i e [illegible] ea c [illegible] epe [illegible] [illegible] -e ec i e i ec o b [illegible] epe [illegible] [illegible] [illegible] acco [illegible] ce i [illegible] epe [illegible] ce i [illegible] e [illegible] e o [illegible] e 3.13 of e [illegible] [illegible] [illegible] e .

A i ec o , [illegible] c [illegible] [illegible] epe [illegible] [illegible] -e ec i e i ec o , [illegible] e b o [illegible] [illegible] i [illegible] pec [illegible] of [illegible] [illegible] b e b [illegible] e e pe i e [illegible] ce, [illegible] o e [illegible] e [illegible] [illegible] p o fe io [illegible] [illegible] o e Boa [illegible] fo i [illegible] effi [illegible] e [illegible] effec i e f c io [illegible] . [illegible] epe [illegible] [illegible] -e ec i e i ec o [illegible] [illegible] ei [illegible] ie [illegible] o e e [illegible] eA [illegible] [illegible] [illegible] i ee, e [illegible] [illegible] [illegible] i ee, e [illegible] [illegible] [illegible] i ee [illegible] [illegible] eS [illegible] e [illegible] [illegible] i [illegible] [illegible] [illegible] e [illegible] [illegible] i ee.

e [illegible] o e e ie e i ec o o [illegible] co e o e [illegible] [illegible] e [illegible] be [illegible] [illegible] [illegible] e of office e [illegible] [illegible] p bic co [illegible] [illegible] ie o o [illegible] i [illegible] [illegible] [illegible] o e i [illegible] ifica [illegible] co [illegible] [illegible] e [illegible] e [illegible] e [illegible] di [illegible] e [illegible] ie [illegible] [illegible] e [illegible] ei [illegible] o e [illegible]. e i ec o [illegible] e [illegible] ee [illegible] o [illegible] co e o e [illegible] [illegible] i o e co [illegible] [illegible] e [illegible] [illegible] e [illegible] [illegible] e.

Corporate Governance Report

oe a F ci of a ee aid b eBoa

eBoa i epoibefo a e ea po e fo e a ed a co c of eb ie of e o pa .
ee ae a -o- a a ed of e o pa o ee ec ie ieco a e eio a ed of e o pa
i e oio a co o a ea oi f e o eb eBoa . e ee ae f ci a epoibiiie
aepeio ica eie e b eBoa .

eBoa ee e fo i edi of a ajo a e of e o pa , ic : appo a a oi of a poic
a e , oe a aeie a b e , i e a co o a i e a ed e , aeia a acio (i pa ic a
oe a a i o eco ic of ee), i da fo aio , eco e aio fo appo ed of ieco a o e
i ifica i da a ope aio a e . Fo e a , pe e efe o eA ice .

a ii , eBoa a a o ee ae o eA i o i ee, e o ai o i ee, e e ai o
i ee a eS ae a i e a ed o i ee of e o pa aio epoibiiie a e o i e
epeci ie e of efe ce. F e e a of ee co i ee a e e o i a a epo .

A ieco a e a e ca o ie i oo ra , i co pia ce i appica be a a e ai , a
i ei ee of e o pa a eS a e o e a a e.

e o pa a a a e appo opia e iabii i ace oi e if i ieco i epec of e a acio a a
e .

ai a a ief E ec i e

. A dii a ee ec ie ieco a ec a a of eBoa , . A i a ei a ee ec ie ieco a
e e a a ae of e o pa , a . A o ei a ee ec ie ieco a ecief i da office of
e o pa . e ee of e a e epa a e oe.

e aio ip be ee ieco a ief E ec i e

. A dii e po e of . A i a e, a . A i a ei e i e of . A o e.
Sa e a i coe abo e, ee ae o i da, b i e , f ii a o o e a eia e aio ip a o o e e be of
eBoa .

Corporate Governance Report

Roles, Functions of the Board and Delegated Authorities

The Board is responsible for the overall corporate governance of the Company. The Board is responsible for the overall corporate governance of the Company, including formulating its strategies, monitoring the performance of the Company's business and operations, and overseeing the management of the Company's affairs. The Board has delegated certain functions to the Board committees. The Board has delegated to the Board committees certain functions in accordance with their respective terms of reference. The Board has delegated to the Board committees certain functions in accordance with their respective terms of reference, and the Board has delegated to the Board committees certain functions in accordance with their respective terms of reference.

Composition, Appointment, Removal and Retirement of Directors, Supervisors and Senior Executives

On December 18, 2020, the Company received a notice from Mr. Zhang Jianguo, a non-executive Director, tendering his resignation as a non-executive Director, a member of the Audit Committee and a member of the Nomination Committee of the Board, with effect from December 18, 2020. On December 18, 2020, the Company received a notice from Mr. Li Yuanqiang, a non-executive Director, tendering his resignation as a non-executive Director, a member of the Strategy Committee and a member of the Nomination Committee of the Board, with effect from December 18, 2020. On December 18, 2020, the Company received a notice from Mr. Li Yuanqiang, a non-executive Director, tendering his resignation as a non-executive Director, a member of the Strategy Committee and a member of the Nomination Committee of the Board, with effect from December 18, 2020. On December 18, 2020, the Company received a notice from Mr. Li Yuanqiang, a non-executive Director, tendering his resignation as a non-executive Director, a member of the Strategy Committee and a member of the Nomination Committee of the Board, with effect from December 18, 2020.

On December 18, 2020, the Company received a notice from Mr. Zhang Jianguo, a non-executive Director, tendering his resignation as a non-executive Director, a member of the Audit Committee and a member of the Nomination Committee of the Board, with effect from December 18, 2020. On December 18, 2020, the Company received a notice from Mr. Li Yuanqiang, a non-executive Director, tendering his resignation as a non-executive Director, a member of the Strategy Committee and a member of the Nomination Committee of the Board, with effect from December 18, 2020. On December 18, 2020, the Company received a notice from Mr. Li Yuanqiang, a non-executive Director, tendering his resignation as a non-executive Director, a member of the Strategy Committee and a member of the Nomination Committee of the Board, with effect from December 18, 2020.

On December 18, 2020, the Company received a notice from Mr. Zhang Jianguo, a non-executive Director, tendering his resignation as a non-executive Director, a member of the Audit Committee and a member of the Nomination Committee of the Board, with effect from December 18, 2020. On December 18, 2020, the Company received a notice from Mr. Li Yuanqiang, a non-executive Director, tendering his resignation as a non-executive Director, a member of the Strategy Committee and a member of the Nomination Committee of the Board, with effect from December 18, 2020. On December 18, 2020, the Company received a notice from Mr. Li Yuanqiang, a non-executive Director, tendering his resignation as a non-executive Director, a member of the Strategy Committee and a member of the Nomination Committee of the Board, with effect from December 18, 2020.

On December 18, 2020, the Company received a notice from Mr. Zhang Jianguo, a non-executive Director, tendering his resignation as a non-executive Director, a member of the Audit Committee and a member of the Nomination Committee of the Board, with effect from December 18, 2020. On December 18, 2020, the Company received a notice from Mr. Li Yuanqiang, a non-executive Director, tendering his resignation as a non-executive Director, a member of the Strategy Committee and a member of the Nomination Committee of the Board, with effect from December 18, 2020. On December 18, 2020, the Company received a notice from Mr. Li Yuanqiang, a non-executive Director, tendering his resignation as a non-executive Director, a member of the Strategy Committee and a member of the Nomination Committee of the Board, with effect from December 18, 2020.

Save as disclosed above, for the reporting period, there was no change in the composition of the Board, Supervisory Committee or Senior Executives of the Company.

Corporate Governance Report

[illegible]

Corporate Governance Report

Acco [illegible] S [illegible]

e [illegible] beed app [illegible] e [illegible] Acco [illegible] S [illegible] fo B [illegible] E epi e [illegible] ce e [illegible] d ea of 17, [illegible] co [illegible] ie i e i co e e i ed [illegible] e [illegible] ie [illegible] ce (e 622 of e of ( ) (e [illegible] ie [illegible] ce).

A ! ES

Accounting Policies

e [illegible] d a [illegible] ed a ep epa e [illegible] acco [illegible] ce i e Acco [illegible] S [illegible] fo B [illegible] E epi e Ba ic S [illegible], [illegible] e pedific acco [illegible] [illegible] e ee e io i e b e [illegible] of F [illegible] ce Feb 15, 2006 [illegible] be ed pei (ee e co eci e efe e o the Accounting Standards for Business Enterprises o CAS).

e [illegible] d a [illegible] ed a ep epa e [illegible] a [illegible] co ce bai .

e e ([illegible] [illegible] ie [illegible] ce bec [illegible] e effeci e [illegible] 3, 14. e [illegible] e a e [illegible] co e [illegible] e [illegible] d a [illegible] ed a e bee [illegible] co e acco [illegible] o e i ed of e ([illegible] [illegible] ie [illegible] ce.

Changes of Significant Accounting Policies

e c [illegible] e of i [illegible] ifica [illegible] acco [illegible] poide a e e o [illegible] oe o e F [illegible] d a S a ed Si [illegible] ifica [illegible] c [illegible] e [illegible] acco [illegible] poide of i [illegible] a epo .

A ed [illegible] ce a Boa [illegible] ee [illegible] [illegible] e a ee [illegible]

e [illegible] a a [illegible] ope ep acice of o [illegible] Boa [illegible] ee [illegible] fo a ea fo [illegible] e a ea a app o [illegible] a e [illegible] e a p [illegible] o co [illegible] e p o i i [illegible] A.1.1 of e o e. oice of o e [illegible] fo ed [illegible] a e i ed fo a e a Boa [illegible] ee [illegible] o p o i [illegible] e a i ec o i [illegible] oppo [illegible] i o a ed [illegible] p [illegible] o co [illegible] e p o i i [illegible] A.1.3 of e o [illegible] e [illegible] ee [illegible] [illegible] a e a ei [illegible] c [illegible] e [illegible] [illegible] ed [illegible] a of c [illegible] ee [illegible] .

Corporate Governance Report

[illegible] the [illegible], the Board [illegible] the attendance of the [illegible] Board [illegible] as follows:

Name of Directors	Number of Board meetings convened/attended
Executive Directors	
[illegible]	[illegible]
[illegible]	[illegible]
[illegible]	[illegible]
Non-executive Directors	
[illegible]	[illegible]
[illegible]	[illegible]
Independent Non-executive Directors	
[illegible] (elected on [illegible])	5/5
[illegible] (elected on [illegible])	5/5
[illegible] (elected on [illegible])	5/5
[illegible] (appointed on [illegible])	5/4
[illegible] (appointed on [illegible])	5/5
[illegible] (appointed on [illegible])	5/5

A [illegible] the [illegible] before the [illegible]. The [illegible] the [illegible] [illegible], [illegible], [illegible], [illegible] [illegible] [illegible].

[illegible] the [illegible] [illegible] by the [illegible] [illegible] [illegible]. [illegible] the [illegible] [illegible] [illegible]

Corporate Governance Report

In the year ended, the Board met [illegible] times and the attendance of the Directors was as follows:

Name of Directors	Number of general meetings convened/attended
Executive Directors	
[illegible]	2/2
[illegible]	2/2
[illegible]	2/2
Non-executive Directors	
[illegible]	2/2
[illegible]	2/2
Independent Non-executive Directors	
[illegible] (elected on June 18, 2020)	2/2
[illegible] (elected on June 18, 2020)	2/2
[illegible] (elected on June 18, 2020)	2/2
[illegible] (appointed on June 18, 2020)	0/0
[illegible] (appointed on June 18, 2020)	0/0
[illegible] (appointed on June 18, 2020)	0/0

Board Meeting

The Board has the responsibility for convening Board meetings, including the Annual Board meeting, and giving notice to the Shareholders. The Board convenes at least four regular Board meetings every year at approximately quarterly intervals. The Company Secretary assists the Board in preparing the agenda for meetings, and ensures that all applicable rules and regulations are complied with.

Annual General Meeting

The Company has held the Annual General Meeting in compliance with Rule 3.21 and Rule 3.22 of the Listing Rules, and has set out in the notice of the Annual General Meeting the procedures for voting by way of poll. The responsibilities of the Annual General Meeting are mainly to receive and consider the annual report and accounts; to declare dividends; to elect and re-elect Directors; to consider the remuneration of the Directors; to appoint or re-appoint auditors and authorize the Board to fix their remuneration; to grant mandates to issue shares; and to approve matters which are required by law to be dealt with by the Annual General Meeting.

Corporate Governance Report

A a e ae of i epo , eA i o i ee co i of o epe e o -e ec ie ieco , . (e a (c ai a of eA i o i ee) a . L , a o e o -e ec ie ieco , . A a . Si A i o i ee ee e e i e epo i eio o, a o e a e , eie a a e fo e ea 1 a i e e fo e ea 2 of e o .

e a e ce of e ieco a eA i o i ee ee e i e epo i eio a a fo o :

Directors	Number of meetings convened/ attended
. (e a (ai a)(appoi e o e 18,)	3/3
. L i (appoi e o e 18,)	3/3
. A a (appoi e o e 18,)	3/3
. (A i (ei e o e 18,)	3/3
. o e ei (ei e o e 18,)	3/3
. L ij (ei e o e 18,)	3/3

o i a io o i ee

e o pa a e abi e e o i a io o i ee i i ie e of efe ence i co pi ance i e ie of e o e a e ie a f cio ee a e o e o i a io o i ee b e Boa . e i a e po ibiii e of e o i a io o i ee a e p epa a e oce e a ci ei a fo ee i i ec a i a e fo ieco a e ei o a a e of e o pa a co c i pe i a eie of i ai ca io a ce ei ia , c i offei e Boa a ice o i ie a co poii o i acco ance i e o pa ' ope a i e , a e a a e o i c e; eie i e oce e a ci ei a fo ee i i e ca i a e fo ieco a e ea a a e of e o pa a i a po o a o e Boa ; oo i fo ai e ca i a e fo ieco a e ea a e; eie i a i a po o a o ec a i a e fo e ieco a e ea a e; eie i a i a po o a o ec a i a e fo o e ei o a a e c a ice ea a e , ec ea o e Boa a ci ef acco a ic ee obe eo e b e Boa ; o e a e a e Boa a a oi e i o ea i .

Acco i o e o i a io poic fo ieco , e o i a io o i ee a bi eco e a io a ee a a ei a of e ieco oi a ca i a e( ) o e Boa fo co i e aio , a e Boa i ed e e o po opo e c ca i a e( ) o e ea a ee i fo ee cio . o i a io b e o i a io o i ee a be ba e o ei a a io e ea fo e be ef of i e i of e Boa . e i a e ed io i be ba e o ei a co ib io a e ec e ca i a e( ) i b i o e o pa ' e eo e .

i e epo i eio , e o pa e-ee ec e e be of e Boa , fo ic e o i a io o i ee ac i e pe fo e i ie . i e jo effo of a pa ie , e e-ee cio o e be of e Boa a cce f co p e e .

Corporate Governance Report

e a e ce of e ec o a e e ea o o ee ee e e o o :

Directors	Number of meetings convened/attended
. A (a) (appo e e 18,)	0 0
. e a (appo e e 18,)	0 0
. (appo e e 18,)	0 0
. a e (ei e e 18,)	1/1
. A i (ei e e 18,)	1/1
. A a (ei e e 18,)	1/1

e a o of e o

Corporate Governance Report

e a e ce of e ie co a e S a e a ik a e o ee ee e in e epo ei o a a fo o :

Directors	Number of meetings convened/attended
. A ei (ai)	1/1
. (e a (appoi e o e 18,)	0
. j i (appoi e o e 18,)	0
. (A i (ei e o e 18,)	1/1
. A a (ei e o e 18,)	1/1

Boa i e i oic

e Boa a o e a Boa i e i poic a ic e a ea ab e objeci e e fo i e ai . e o pa eco ie a e b ace e bei of ai a ie e Boa i ie o a i effeci e a acie a a of co po a e o ce. e ea o o e a e Boa acie e a ba ce of i , e peie ce a i ei of pe peci e appo opia e o e ie e of e o pa ' b e . ee ecio of c i a e i be ba e o a e of i ei pe peci e, ic b o ie o e e, a e, c a e caio a back o , e id , pofe io a e peie ce, i , o e ea e of ice. e a e edio of a Boa appoi e i be ba e o ecapabii of e ee ec i a e a i o e poe ia co ib io o e Boa in ef e. A a i e o in e abebeo :

The Current Composition of the Board

Age	Gender	Years of service as Director
31 0 ea (3 pe o)	Fe a e (37.5%)	1 5 ea (4 pe o)
51 6 ea (4 pe o)		
61 ea a abo e (1 pe o)	a e (62.5%)	6 0 ea (4 pe o)

o po a e o e ce F cio

e Boa i e po ib efo pe fo in eco po a e o e ce ie ic b o ie o:

(a) o e ie e o pa ' co pi ce i e o e a i co ei eco po a e o e ce epo ;

(b) o e e op a ei e o pa ' poide a p ice of co po a e o e ce;

(c) o e e op, ei a o io eco e of co c appica e o po ee a ieco ;

(d) o e ie a o io e ain a co in o pofe io a e e op e of ieco , Spe i o a io a a e e ; a

(e) o e ie a o io e o pa ' poide a o in e o eco pi ce i ea a e a o e i e .

Corporate Governance Report

In e epo in 'eio', eBoa', o i pedia co'i ee, pe fo' e' e fo o in co po a e o e'a ce f'cio : (1) 'o'ide' eA ice in acco'a ce i e a o e i ed ; (2) ed ce' e a in fo ieco a' dio 'a a ed a' di po ofeio a 'e eo' ed ; (3) eie e' eco'e of co' c fo ieco , Spe io a' d' po ee; (4) co in o a e e' a' opi i e' co po a e o e'a ce a' pe fo' e' di ' ie in ic co' pia ce i a of e e i ed of co po a e o e'a ce; a' (5) eie in eco po a e o e'a ce epo .

ieco ' a' A 'i o' epo ibiii ie fo F' a da epo in in epec of F' a da S a e d

e ieco ac' o e' e di epo ibii fo pe a in eco oi' a e' in a da a ed fo e ea e' e' ece be 31, 2 ic i e a ea' fai ie of e a of e o' pa' a' e o pa' of e o p' e a' ca fo . e ieco a oac' o e' e di epo ibiiie oed e a eco oi' a e' in a da a ed of e o pa ep bi e' in a e' a e. e' a ed of e o' pa a poi' e o eBoa' c epa aio a' in fo aio a a e' ece a o abe eBoa' oca o a' in fo' e a e' ed of e o' pa ' co oi' a e' in a da a ed , ic a e B i e' o eBoa' fo app o a. e o' pa poi' e a' ed be of eBoa' i e a e' a eia of e o' pa ' e , a a' po opec .

e ieco ee' o a a eof a' ' a eia ' ce a' ie ea' o a' e o co' 'io ic' a ca a i' ifica i' f ce po e o p' abi i ocon' ea a o' co ce'.

e a ed epa e' b ea' i o of e o' pa e a' in di epo in epo ibiiie o eco oi' a e' in a da a ed of e o' pa i e o in eA 'i o' epo of i a' a epo .

i' a ed a' ' e a o o

eBoa' i epo ibe fo e i' a ed a' in e a co o ed a' eie in di effeci e o a' o o ba . Sc i' a ed a' in e a co o ed a e' eie' fo' a' in i' a e a' e' in a' e i' of fai o acie eb in e objeci e, a' ca o poi' e a' abe a' o abo e a ce a' a eia i ed o o .

A' e' in e' a ed c e a' poce i pedi e' in i of a oi a' epo ibiiie i e abi e' b e o' pa o afe a' a e a' ' a oi e' eo ' i poiio , a' a' pope acco in eco ' fo e poiio of eiabe in da in fo aio fo in e' a eo fo p bica io a' ec' pi ce of appicabe a , e a' e aio . A in e' a a i ' epa' ed a bee e abi e' b e o' pa ope fo e a in da a' ope aio a eie a' eco' e' acio ' ee' e o e ee a' ' a ed . ei e' a a i ' epa' ed ' obi o e ei e' a co o ' pope a' f'cio a in e' e. e e of ei e' a a i a' eie a e epo e' o eA ' o' i ee. e e opeco' e a' poe ia i' ifica i of e o p, e' ei' a e' ' epa' ed i i' if e i, a' e' a ed i a e ei a' co' i' ei in pac o eb in e a' ei ei oo' of e occ ce. Af e a e' ed , e' a ed i ' ee' in e a eie a' in e' a co o poce' e o a di ei a' pe ed in a' e in ef e.

Corporate Governance Report

e Boa e ie e effeci e e of e o p' i a e e a co o e e e e a e ai ie i e a e ac effeci e e of e e of i a e e a co o of e o fo e ea e ece be 31, 2 2 . ee e e o a e of aei a ce ce ea o ce, ope aio o co pia ce co o .

o e o oec S a e o e ' ee a e , e o p a e e ope a i a e e a co o e of co p e i e e , ce a ie ac ie a e a e abe job a oca io o ee i ee a e aei a e e i . eA i o i ee a e abi e e e Boa , i e o ibe fo e pe ii o of e a a i , e a io a e o p o e e of ei e a co o e , a i e a io of aei a e e e p ojec ope a e b e o pa . eS a e a i a e e o i eei e o ibe fo i a e o poi a ice o e o e e e op e a e a e aei a e e e edi io of e o pa a i a ope fo ee a io a co o of e oe a i e of e o pa . a ii o, e o pa a e abi e a i ai e ea e o e a e pa a io a i eA i o i ee o io e co pia ce of ee ea e, i o e o e a e e a e pa a io a i co o e i . e o pa a oe abi e a i ai e ea e o i i e fo io i co e. iffe e ope aio fo ei a e pe o of a po e ia i e fo io a i e ei a e pe o i ee e f e eca io a i co e a e ie . eS pe io o i ee o io e p e e io of e a co o b eBoa a i e a e e . A e e of o a co p e e a i e fo ce ea o e, poi pp o fo b e e op e a i a e e .

Se io a a e e ' e a io

e e a of e o pa ' e io a a e e a e e o e ecio e e ieco , S pe i o a Se io a a e e i i a a epo , oe e e a io ba fo e ea e e ece be 31, 2 2 i a beo :

Remuneration band (RMB)	Number of individuals
0 -5 0 Q00	4
5 0 Q0 1-1,00 Q00	2

A i o ' e e a io

Fo e ea e e ece be 31, 2 2 , e o p' a o a i o, i ice a e o e oope o i a LL, poi e a a i e ice. e ea e e ece be 31, 2 2 , e o a fee pai /pa abe e pec of a i a i e a - a i e ice poi e b e o p' a i o i e o beo :

A i e ice	B 0 Q00
o -a i e ice	B 4,0 0

Corporate Governance Report

[illegible] Sec e a ie

. [illegible] S [illegible], [illegible] [illegible] o ee of [illegible] e [illegible] e ice [illegible] o i e, S S o [illegible] o a e Se ice o [illegible] ([illegible] [illegible]) [illegible] i e, a bee [illegible] a e b e [illegible] [illegible] a [illegible] e of e jo [illegible] co [illegible] [illegible] ec e a ie. . ' [illegible] a co [illegible] ac [illegible] e [illegible] a e [illegible] [illegible] i . A i [illegible], e ec e a o e Boa [illegible] e o e jo [illegible] co [illegible] [illegible] ec e a .

[illegible] e e o [illegible] ! e i o [illegible] [illegible] o e [illegible] a e o , . a [illegible] e a [illegible] e o e [illegible] 15 o of e e [illegible] [illegible] o fe i o [illegible] a [illegible] [illegible] [illegible] co [illegible] pi [illegible] ce i e 3. [illegible] of e ([illegible] [illegible] [illegible] [illegible] e. . [illegible] a [illegible] e [illegible] ee [illegible] a [illegible] [illegible] o e oe, f [illegible] cio [illegible] [illegible] [illegible] ie of [illegible] eco of a i e [illegible] co [illegible] [illegible] [illegible] ([illegible] [illegible] [illegible] [illegible] [illegible] a f [illegible] [illegible] e o [illegible] e [illegible] e [illegible] i a [illegible] [illegible] a ei a [illegible] o i [illegible] e [illegible] b e e e [illegible] a a e [illegible] [illegible] e e o [illegible] ! e i o [illegible], [illegible] [illegible] e a a o [illegible] e a [illegible] e [illegible] o e [illegible] 15 o of e e [illegible] [illegible] o fe i o [illegible] a [illegible] [illegible] [illegible] co [illegible] pi [illegible] ce i e 3. [illegible] of e ([illegible] [illegible] [illegible] [illegible] e. e i co [illegible] e o a [illegible] e [illegible] ee [illegible] [illegible] o fe i o [illegible] a [illegible] [illegible] [illegible] co [illegible] pi [illegible] ce i e 3. [illegible] of e ([illegible] [illegible] [illegible] [illegible] e fo e ea [illegible] e [illegible] ece [illegible] be 31, [illegible] 21.

[illegible] ica io i S a e o e [illegible] e o e a io

e Boa [illegible] beie e a effeci e co [illegible] ica io i [illegible] e o i e [illegible] ia oe abi [illegible] [illegible] e o ' co [illegible] [illegible] ce [illegible] a ac [illegible] e [illegible] e o. e o [illegible] a o eco [illegible] e e [illegible] po [illegible] ce of [illegible] [illegible] a e c [illegible] [illegible] e [illegible] co e of co [illegible] o a e [illegible] fo [illegible] a io ic [illegible] abe [illegible] e o [illegible] [illegible] a e [illegible] o [illegible] fo [illegible] e [illegible] e [illegible] ed io.

e [illegible] e a [illegible] ee [illegible] of e [illegible] [illegible] [illegible] o i e [illegible] [illegible] po [illegible] c [illegible] [illegible] e fo co [illegible] ica io be ee e Boa [illegible] [illegible] e S a e o e. a [illegible] of e Boa [illegible], a e a c a [illegible] [illegible] of e fo Boa [illegible] co [illegible] i ee o, [illegible] i ab [illegible] ce, o e [illegible] be of e e peci e co [illegible] i ee [illegible] e e applicabe, e [illegible] epe [illegible] Boa [illegible] co [illegible] i ee, i be a i abe o [illegible] e e io a e [illegible] e a [illegible] ee [illegible] .

[illegible] e e o [illegible] ! e i o [illegible], o [illegible] e a [illegible] ee [illegible] e e e [illegible] b e [illegible] [illegible] . ! bi e [illegible] oc [illegible] [illegible] o e e i e a e co [illegible] o a e [illegible] fo [illegible] a io [illegible] [illegible] e a e a i abe [illegible] e [illegible] [illegible] ' ebi e a p:// [illegible] [illegible] o [illegible] . e o ca [illegible] o co [illegible] [illegible] ica e i e [illegible] [illegible] o [illegible] [illegible] a i @ [illegible] o [illegible] .

S a e o e ' i

Procedures for Shareholder(s) to Convene an Extraordinary General Meeting ("EGM")

S a e o e e e [illegible] e co [illegible] [illegible] of [illegible] E a [illegible] o cee [illegible] acco [illegible] [illegible] ce i e o ce e e fo be o :

S a e o e , [illegible] i [illegible] a o jo [illegible] o [illegible] o e [illegible] % of e S a e i o [illegible] i a e o o e [illegible] ee [illegible] , a e e i o e e e Boa [illegible] o co [illegible] e [illegible] E o a ca [illegible] ee [illegible] [illegible] i [illegible] . Acco [illegible] o a , a [illegible] i a i e e a io [illegible] e A ice, e Boa [illegible] a i e i e [illegible] fee [illegible] back o a ee o [illegible] a ee o co [illegible] e [illegible] E o e ca [illegible] ee [illegible] i [illegible] e [illegible] a [illegible] a e ece [illegible] c e e .

Corporate Governance Report

The Board has set up the Executive Committee, the Audit Committee, the Nomination Committee and the Remuneration Committee. The composition and the duties of each committee are described in the Board's report.

The Board's Executive Committee has a meeting once per month, or more frequently if necessary. The Executive Committee prepares matters for the Board's decision, and the Chief Executive Officer reports to the Executive Committee.

The Audit Committee has a meeting at least four times per year. The Audit Committee reviews the financial reporting, the internal control and the risk management. The Chief Executive Officer and the Chief Financial Officer participate in the meetings of the Audit Committee.

The Nomination Committee has a meeting at least once per year. The Nomination Committee prepares proposals for the Annual General Meeting regarding the election of Chairman of the Annual General Meeting, Chairman of the Board, other Board members, auditors, fees to the Board and auditors, and principles for the Nomination Committee. The Chief Executive Officer participates in the meetings of the Nomination Committee.

Corporate Governance Report

Procedures for Directing Shareholders' Enquiries to the Board

S a e o e a a e i ie co ce o e Bo a i o e ec e a o e Bo a .
e co ac e ai a e a fo o :

A e :
o.1 S j o a
(o ei e ia i ic
o , ej
e!
Fa : (86) 577 8878 117
E ai :i @ o .co

S a e o e a a o ee ie i e Bo a e e ee ee of e o pa .

ei o i io a oc e

e epo !eio , eA ice a e e ice.

e opo a a co i e e a app o e a e 2 e ao a e ee b a of a ed e o io o ac , 2 . Acco o e ee e i e of ep f o e S a e o d o a e ea o Appicabe e i e o A j e of oice!eio of e a ee co e b e ea i e o ie (《國務院關於調整適用在境外上市公司召開股東大會通知期限等事項規定的批覆》) i e b e S a e o d o cobe 17, 2 1 (o [2 1 o. 7), a ab o acco e ac a co i io of e o pa , e Bo a co i e e a app o e, o o e , e opo a ea io o e o eA ice. e ei e A ice bec e effeci e f o ac , 2 , a be p bi e o e ebi e of e (o o Soc E c e a e o pa . Fo e ai , pea e efe o e o pa ' o ce e a e a 22, 2 a ac , 2 .

e opo a a co i e e a app o e a e eco ee of e i ei of Bo a of e o pa o , 2 . e opo e e a a e o Bo a o ! a ep c a e (S a e a co i e e a app o e a e ao a e ee fo e ea 2 , e o ei c S a e o e ' a ee fo e ea 2 a e (S a e o e ' a ee fo e ea 2 of e o pa b a of a ed e o io o ac , 2 . Bo a co pee e pa ia ep c a e a ca ce aio of (S a e i e cope of a oi , a e e A ice acco . e ei e A ice bec e effeci e f o 2 , , a be p bi e o e ebi e of e (o o Soc E c e a e o pa . Fo e ai , pea e efe o e o pa ' o ce e a e a 22, , ac , a 2 , .

Corporate Governance Report

ii ic oic

e o pa fo ae i ii ic poic. ee e o pa i ib e i afe-a p of ec ea, i a ocae 0 % of ep of a e o pa ' a o co o ee e. e o pa a ae o oe ocaio o e acc ai eba ce of e o pa ' a o co o ee e acco fo oe 0 % of e o pa ' ei ee ca a. So e acc ai eba ce of e o pa ' a o co o ee e be ii ie o ae p fo e o e of e o pa of ep eio ea, ec ea' p of a i be e fo a p c o e befo e e a o co o ee ei a ocae acco o ep oiio of ep ece pa a ap. Af e e o pa a ocae e a o co o ee ef o e afe-a p of , i a ocae ai ceio a co o ee ef o e afe-a p of , po a e o io be a eb e e ea ee . Af e e o pa a ae p fo e o e a e a ocae a o co o ee e, i a i ib e e ea p of o e ae o e ba e o i ae o io, ece fo i ib io a ae o ba e o e ae o io a poi e in eA ice of A odaio. So e e ea ee i ib e ep of o e ae o e befo e e o e a be a ae p e a o co o ee e a be a ocae, io aio of ep oiio of ep ece pa a ap, ep of i ib e io aio of c poiio be e e o e o pa . op of a be i ib e epec of e ae of e o pa be e b e o pa .

e o pa a i ib e ii ic in deof efo o fo (o oe o fo in ao):

(1) ca ;

(2) ae;

(3) o e e o pe i e b a , ai i ai e e aio , epa ea e a e e aio , e e a o e of ep ace( ) of i .

e o pa a pa ca ii ic a o e pa e in B o eic S ae o e . Sc pa e a ae b e o pa o o e offod S ae a be e o ae a ec ae in B pai (. Sc (e ie fo e o pa ' pa e of ca ii ic a o e pa e o e o e offod S ae a be a e p a o e ee a poiio of e a i aio offod ec a eof eS ae.

e Boa a be a oi e b a of a o a e o io pa e b e e ea ee o o pe e e ii ic io ib io of e o pa .

Directors

Executive Directors

(管偉立
o e a_ b in e ope a_i on a_n d a_e ic p a_nin of e on pa_n . (e fo n d e d e on pa_n in Feb a_ 1_ 6 a_n d bec a_n e

a_n e e d a_ a_c in id a_n a_ e on o e on i/(o pi i/(溫州市精神病院
1_ 87 o ece_n be 1_ 3, e e e a_ p in a_i e pon ibe fo e_n e d ica_ ea_n e_n of p c i a_ ic p a_ie_n . . a_n
a_n d a_e f on e_n o e d ica_ ni e i (溫州醫科大學) (p e io in o n a_ e_n o e d ica_ o e e (溫州醫學
院
] È 9 [+ ...
i a_n e a_n d e b o e in - a_ of . A (on e a_n d . i.

Ms. WANG Lianyue (王蓮月), a_e d 52,i o e ec i e i ec o a_n d e e a_n a_n a_e . S ei p in a_i e pon ibe fo e
e e d a_ o e e a_n a_n a_e in ce Sa_e_n be 2011 a_n d o e ec i e i ec o in ce Ap i 2013. . a_n a_ a_pp oin e d
(o pi i/(溫州市精神病院), e e e a_ p in a_i e pon ibe fo e e a_ p a_ie_n ca_e. . a_n ec i e d o a_ od a_e
] È < Å } ª] È < ª ë))
in e o in ne 2004 a_n d e! a_ Sc oo of e o nid p a_ on i ee of e on ni! a_ of in a_/(中
共溫州市委黨校) in e o in ne 2002, e e e n a_ jo e d in n in a_n d eco n on ic a_n in i a_ion e pec i e . S e
a_n d a_e f on n in e E d ca_ion o e e of i'a_n i a_ o on ni e i (西安交通大學網絡教育學院), o on - i a_n ce
e d ca_ion, i a_ba_c e o ' e ee in a_ in 2007. S e a_ o co p e e d pa_ - in e/ o pi i a_n a_e e co e a_ e
in a_/E ope n e n a_ion i/B in e Sc oo (中歐國際工商學院
eco n d a_ p c o o ica_ co n a_n (二級心理諮詢師) b e in i of (n a_n e o ce a_n d Soci a_ Sa_ i of in a_/(人
力資源和社會保障部) in ece_n be 2004. . a_n i e po e of . A ei, e i e of . A (on e
a_n d e i e - in - a_ of . i.

Directors, Supervisors and Senior Management

Ms. WANG Hongyue (王紅月), a e 48, i o e ec i e ieco o c ief i d office. S ei p i e po ibefo e o e a i d a e e o c api a i e e of e o pa . S e jo e e o pa i a 6 o e i o ce epa e fo a 6 o ece be . S e bec e e ea of o ce epa e i a 000. a appoi e a e ec i e ieco i Api 13 a f e o pa a co e e i o a jo oc ie iabi co pa , e a appoi e a e ec i e ieco a a c ief i d office i Sep be 14. a o e e a S pe io fo Sep be 11 o Api 13. io o jo i e o pa , fo 4 o ece be 5, e o e i e ce epa e of o i i e ide e o e a e o pa of o a i ic (溫州市龍灣區康寧醫藥批發公司), ic e a e e ide e o e a eb e, e e e a e po ibefo acco i o. a a e fo e E ca io o ee of i' ia o ie i (西安交通大學網絡教育學院), o o -i ce e ca io, i a bac e o' e ee i acco i i 007. S e a e fo S a i ie i of H ce a Eco o ic i a e' e ee i E BA i a 17. i ei e of. A i e, e po e of. i e ie i - a of. A di.

Non-executive Directors

Mr. YANG Yang (楊揚), a e 65, i o -e ec i e ieco. ei p i e po ibefo o e ee e co po a e e eo e a eic p i of e o pa . e jo e e o pa i Api 15 a e e a o -e ec i e ieco ce e. Sce a 1, . a bee e i a a ieco of L i a E i a e e Lie, ee ei p i e po ibefo co po a e ope io a i e e. Sce a 0, . a a obee e i a a ieco of L a a e e (o o Lie (德福資本投資香港有限公司), a co pa e a i i pi a ee i e ice fo i e e b e, ee ei p i e po ibefo opi a a e e a e i e e. io o jo i e o pa , fo a 88 o ece be 0, . a e e a e e a e a e of Lo ice e ie Lie (長立實業有限公司), a co pa i o o e a i eb e of a i a e po oiio of i e e e ice, ee e a p i e po ibefo b e ee i o i i e e, fo e e a e a fac i. . a a e fo e a a o ee of e ee eope' ibe io A (中國人民解放軍海軍學院) i a j i a c 8, a jo i ope io a co a .

Directors, Supervisors and Senior Management

Mr. LIN Lijun (林利軍), a e 48, i o -e ec i e i ec o . ei a i e oo ibe o pe i a oi in e e j e oo Bo . . jo e e o pa in e 17 a e a o -e ec i e i ec o ce . Sce Ap 16, . a bee a i ec o of ec e e (o Li e (銀科投資控股有限公司), a co pa i e o e AS A Soc a e (ice bo: . S) a in e oiio of po e ice o b co o , e e ei a e oo ibe o oi o e a eic e eo e of co pa . Sce a c 16, e a bee a i ec o of A S(oba Foo o p (國際天食集團有限公司), a co pa i e o e (o o Soc E c a e (oc co e:0 3666.( ) a in e ope aio of i- o- i e ee ci e - e ice c a e a , e e ei a e oo ibe o oi o e a eic e eo e of co pa . Sce

Directors, Supervisors and Senior Management

ec o i o A odaio of a! ci a . Sce Api 14, e a bee e i a a ee o a c i a i e - ee Aca e of! c o e a . Sce a 1, e a bee e i a a ice c i a i ee A odaio fo e a (ea a e o a ec o i e! ofe io a o i ee of! c o e a a! cooica o aio . Sce Sep e be 14, e a bee e i a a ep ec o i ! c o o ic e ide B c , ee e ica A odaio . Sce o e be 1, e a bee e i a a ep ec o i ! c o o ic e ide ! ofe io a B c , ee e ica oco A odaio . . ao a e f o i ica i (fo e o a i ica oee) i a bac eo' e ee i e ide ei 1 83. A 1 88, e a e f o Sic i i (fo e o a e i a i of e ica Sde ce) i a e' e ee i e ide e. o be 1 3, e a e f o (d e be i e i i a oc o a e ee i e ide e.

Ms. ZHONG Wentang (鐘文堂), a e 32, a bee e i a a a e a e ep of o pi ce o aio, S a i ai o i o., . (上海信公企業管理諮詢有限公司) ce Feb a 1, a co pa e a i poi co aio e ice fo i e co pie, a i a epo ibefo b ie i co pi ce co aio. F Feb a 16 o Feb a 1, . o e e a a io co aio a e a co aio b ie ec o cce i e i S a i ai o i o., .,a epo ibefo b ie i co pi ce co aio. F c obe 12 o Feb a 16, e e e a a o a io a o cce i e i ice a e o e oope o i a A ie e o pa , a epo ibefo i ce a a i fo i e a co o. . o a e f o F a i e i S a i i a bac eo' e ee i odoo i e 12.

Mr. LIU Ning (劉寧), a e 5, a bee e i a e ice c i a of i i (ea ec oo o p o., . (a co pa i e o eS e S oc E c a e(oc co e: 00 253.S) i foc o e ica a ea i fo ai aio) ce Api 004, a epo ibefo e co pa ' o ea a a e . Sce Feb a 18, e a bee e i a ec i a of ea e ica ec oo (S a i) o., . (快享醫療科技(上海)有限公司), a epo ibefo e o ea a a e of co pa . Sce 18, e a bee e i a a e ec i e ec o of Bei i (ea ec oo o., . (北京衛寧健康科技有限公司), a epo ibefo e o ea a a e of co pa . Sce c obe 1, e a bee e i a a e ec i e ec o of S a i i ec oo o., . (上海衛心科技有限公司), a epo ibefo e o ea a a e of co pa . F Api 1, 1 o Api 004, e cce i e e e a a ec id of e ie S a e (e -ade a ((!) o pa a ec o a ice pei e of S a i i a i ea ica fo aio ec oo o., . (上海金仕達衛寧醫療信息技術有限公司). . i a e f o F a i e i S a i i e 1 85 i a bac eo' e ee i oie ec ic. (e a e f o F a i e i S a i i e 1 88 i a a e' e ee i oie a e ic. (e a aie fo o i io e ee a e a a e b e aifica io ei e o i ee fo Sio ! ofe io a ec ica ! oiio of S a i (i - ec Ac ie e e a fo aio of E i ee i Seie (上海市工程系列高新技術成果轉化類高級專業技術職務任職資格評審委員會) a 000 .

Directors, Supervisors and Senior Management

S ! E S S

Mr. SUN Fangjun (孫方俊), a e 4 Ø ,i c a of e S pe i o o i ee. [ei p a i e po ibe fo pe i o a ope aio a a e . . S jo e e o pa in a 2 11 e e a ice pei e of e o pa f o a 2 11 o Sep be 2 14. [e a appo e a c a of e S pe i o o i ee Sep be 2 14 a f e e o pa a co e e in o a jo oc i ie iabii co pa . ! io o jo in e o pa , f o Api 1, 6 o c obe 2 0 , . S o e a e [ea B ea of L c i ic, o (溫州市鹿城區衛生局) e e a p a i e po ibe fo e ica a i ai e a e . F o Api 1, 2 o Api 1, 6, e a e pei e of o [o i [o pi a (溫州市紅旗醫院), a oca o pi a o , e e a p a i e po ibe fo e o e a ope aio of e o pi a. F o A 1 88 o Api 1, 2, e e e a e ice pei e of e Ei ! eop e' [o pi a of o (溫州市第八人民醫院), a oca o pi a o , e e a p a i e po ibe fo a io e ica affai . . S a e f o i i e ica Sc oo in [i o jia ! o ce (黑龍江省雞西衛校) i a eco a oca io a ip o ain i i i , [i o jia ! o ce in A 1 74, e e ajo e in e i e. [e a acc e i e a cie p id in in e a e i e b o id a B ea of ! e o e (溫州市人事局) in a 1, 5.

Ms. HUANG Jingou (黃靖歐), a e 42, i o S pe i o. S ei p a i e po ibe fo pe i o a ope aio a a e . . [a jo e e o pa in Api 2 13 a e e a o S pe i o ce . S e a a appo e a S pe i o in Sep be 2 14 a f e e o pa a co e e in o a jo oc i ie iabii co pa . S ce o be 2 11, . [a a bee e in a ei e i ec o of L api a o p (德福資本), ic i a co pa a ain in pi a ee i in e i , e e ei p a i e po ibe fo in e i . ! io o jo in e o pa , f o A 20, o o be 2 11, e e e a e ojec i ec o of e in a e ica Boa (美國中華醫學基金會), ic i a fo a ain in e .S. foc in o i e ica c ai affai , e e a p a i e po ibe fo p ojec in pe a ain. F o e 20 3 o ece be 20 6, e a a o e a oo a Lee & Lo (胡關李羅律師行) e e a p a i e po ibe fo ain e a affai . . [a a a e f o S a -Se i e i (中山大學) in a o i a bac e o' e ee in a in 20 1.

Directors, Supervisors and Senior Management

Mr. CHEN Jian (陳建), a[illegible] 35, i[illegible] o[illegible] S[illegible] i[illegible] o. [illegible] p[illegible] a[illegible] e[illegible] ib[illegible] o[illegible] i[illegible] o[illegible] co[illegible] ce i[illegible] a[illegible] e[illegible] a[illegible] . [illegible] j[illegible] e[illegible] e[illegible] [illegible] e[illegible] a[illegible] o[illegible] S[illegible] i[illegible] ce [illegible]. Si[illegible] ce Ap[illegible] [illegible], [illegible] a[illegible] e[illegible] be of e[illegible] [illegible] of e[illegible] [illegible] Fo[illegible] a[illegible] (浙江省華福慈善基金). [illegible] e[illegible] ib[illegible] e[illegible] o[illegible] a[illegible] e[illegible] o[illegible] a[illegible] [illegible] o[illegible] peo[illegible] e o[illegible] j[illegible] [illegible] e[illegible] e[illegible] of[illegible] a[illegible] o[illegible]. Si[illegible] ce Feb [illegible] 16, e[illegible] a[illegible] e[illegible] ec[illegible] e[illegible] eco of[illegible] o[illegible] e[illegible] a[illegible] e[illegible] (S[illegible] a[illegible]) o., [illegible]. (九果投資管理(上海)有限公司) (a[illegible] co[illegible] a[illegible] e[illegible] [illegible] e[illegible] a[illegible] e[illegible] b[illegible] e[illegible] a[illegible] e[illegible] co[illegible]), a[illegible] e[illegible] ib[illegible] e[illegible] ea[illegible] c[illegible] a[illegible] ce[illegible] of[illegible] o[illegible] a[illegible] e[illegible] ojec[illegible] a[illegible] [illegible] o[illegible] i[illegible] e[illegible] o[illegible] ce. [illegible] e[illegible] bee[illegible] e[illegible] ec[illegible] e[illegible] eco of S[illegible] a[illegible] Sd[illegible] ce a[illegible] ec[illegible] oo (S[illegible] a[illegible]) o., [illegible]. (尚妍堂科技(上海)股份有限公司) (a[illegible] co[illegible] a[illegible] e[illegible] d[illegible] ce a[illegible] ec[illegible] oo p[illegible] o[illegible] a[illegible] a[illegible] e ice) [illegible] ce [illegible] 15. [illegible] e[illegible] a[illegible] e[illegible] ib[illegible] e[illegible] ea[illegible] a[illegible] e[illegible] o[illegible] p[illegible] o[illegible], e[illegible] a[illegible] [illegible] of d[illegible] ce a[illegible] ec[illegible] oo p[illegible] ojec[illegible]. [illegible] a[illegible] obee[illegible] e[illegible] [illegible] of oc[illegible] E[illegible] e[illegible] a[illegible] e[illegible] (S[illegible] a[illegible]) o., [illegible] (果創企業管理(上海)有限公司). (a[illegible] co[illegible] a[illegible] e[illegible] b[illegible] e[illegible] a[illegible] e[illegible] a[illegible] ec[illegible] oo [illegible] c ba[illegible] ope[illegible] a[illegible]) [illegible] ce Ap[illegible] [illegible] 15. [illegible] e[illegible] a[illegible] e[illegible] ib[illegible] e[illegible] pe[illegible] [illegible] i[illegible] e[illegible] a[illegible] e[illegible] co[illegible] ce ope[illegible] a[illegible] a[illegible] pa[illegible] id[illegible] a[illegible] [illegible] ep[illegible] epa[illegible] a[illegible] a[illegible] co[illegible] [illegible] ci[illegible] of off[illegible] e ec[illegible] oo [illegible] c ba[illegible] e a[illegible] i[illegible] e[illegible] S[illegible] a[illegible] a[illegible] F[illegible] ee a[illegible] e, coope[illegible] a[illegible] [illegible] e[illegible] o[illegible] [illegible] ci[illegible] of[illegible] e[illegible] ea[illegible] ec[illegible] oo p[illegible] ojec[illegible] b[illegible] ec[illegible] a[illegible] o.1 of e F[illegible] ee a[illegible] e de. [illegible] a[illegible] a[illegible] e[illegible] [illegible] [illegible] j[illegible] [illegible] e[illegible] e[illegible] of[illegible] o[illegible] [illegible] i[illegible] [illegible] (溫州大學甌江學院)[illegible] [illegible] e[illegible] 20[illegible], [illegible] a[illegible] ba[illegible] e[illegible] o'[illegible] e[illegible] ee[illegible] [illegible] [illegible] e[illegible] a[illegible] e, [illegible] a[illegible] [illegible] [illegible] [illegible] e[illegible] a[illegible] [illegible] e[illegible] a[illegible] e[illegible] [illegible] e.

Mr. QIAN Chengliang (錢成良), a[illegible] 68, i[illegible] o[illegible] S[illegible] i[illegible] o. [illegible] p[illegible] a[illegible] e[illegible] ib[illegible] e[illegible] o[illegible] i[illegible] o[illegible] co[illegible] ce i[illegible] a[illegible] e[illegible] a[illegible] . [illegible] a[illegible] j[illegible] e[illegible] e[illegible] [illegible] e[illegible] a[illegible] e[illegible] a[illegible] o[illegible] S[illegible] i[illegible] ce [illegible]. [illegible] io o[illegible] j[illegible] [illegible] e[illegible] [illegible], f[illegible] [illegible] a[illegible] 20 7 o[illegible] a[illegible] [illegible] 12, e[illegible] e[illegible] a[illegible] a[illegible] [illegible] office a[illegible] e S[illegible] a[illegible] [illegible] [illegible] i[illegible] ee of[illegible] [illegible] o[illegible] [illegible] id[illegible] a[illegible] [illegible] eo[illegible] e' [illegible] e (溫州市人大常委會). F[illegible] Feb [illegible] 20 3 o Ap[illegible] 20 7, e[illegible] e[illegible] a[illegible] a[illegible] ice[illegible] a[illegible] of[illegible] [illegible] o[illegible]. F[illegible] [illegible] cobe[illegible] 6 o[illegible] a[illegible] 20 3, e[illegible] e[illegible] a[illegible] a[illegible] [illegible] be of S[illegible] a[illegible] [illegible] [illegible] i[illegible] ee a[illegible] office of e[illegible] o a[illegible] i[illegible] [illegible] i[illegible] [illegible] i[illegible] [illegible] (麗水市委常委). F[illegible] [illegible] o[illegible] be[illegible] 5 o Sep[illegible] be[illegible] 6, e[illegible] e[illegible] a[illegible] e[illegible] ec[illegible] e[illegible] ep[illegible] office of e[illegible] o a[illegible] i[illegible] [illegible] i[illegible] [illegible] of e[illegible] [illegible] id[illegible] a[illegible] co[illegible] [illegible] i[illegible] ee of e[illegible] [illegible] [illegible] i[illegible] a[illegible] [illegible] e[illegible] o.

Mr. XIE Tiefan (謝鐵凡), a[illegible] 41, i[illegible] a S[illegible] e[illegible] i[illegible] o. [illegible] p[illegible] a[illegible] e[illegible] ib[illegible] e[illegible] o[illegible] i[illegible] o[illegible] co[illegible] ce i[illegible] a[illegible] e[illegible] a[illegible] . [illegible] ie j[illegible] e[illegible] e[illegible] [illegible] e[illegible] a[illegible] 200[illegible] [illegible] f[illegible] [illegible] a[illegible] 20[illegible] o Sep[illegible] be[illegible] 20 14, e[illegible] e[illegible] a[illegible] a[illegible] ie of po[illegible] i[illegible] [illegible] e[illegible] [illegible] e[illegible] [illegible] c[illegible] [illegible] e[illegible] ep[illegible] [illegible] ec[illegible] o of ei[illegible] [illegible] a[illegible] [illegible] ep[illegible] a[illegible] [illegible], e[illegible] ep[illegible] [illegible] ec[illegible] o of e[illegible] e i[illegible] [illegible] ep[illegible] a[illegible] [illegible], e[illegible] ec[illegible] o of ee i[illegible] [illegible] ep[illegible] a[illegible] [illegible] a[illegible] e[illegible] a[illegible] c a[illegible] ep[illegible] a[illegible] [illegible] a[illegible], ee[illegible] e a[illegible] [illegible] a[illegible] ib[illegible] e[illegible] o e i[illegible] [illegible] p c[illegible] a[illegible] e[illegible] a[illegible] [illegible] a[illegible] [illegible]. [illegible] e a[illegible] ppo[illegible] e[illegible] a[illegible] a[illegible] S[illegible] e[illegible] i[illegible] o[illegible] Sep[illegible] be[illegible] 20 14 a[illegible] e[illegible] e[illegible] [illegible] a[illegible] co[illegible] e[illegible] e[illegible] [illegible] o a[illegible] j[illegible] oc[illegible] [illegible] ie[illegible] ia[illegible] i[illegible] co[illegible] [illegible]. [illegible] ie a[illegible] a[illegible] [illegible] e[illegible] [illegible] e[illegible] [illegible] of [illegible] a[illegible] (中央廣播電視大學) i[illegible] a[illegible] od[illegible] a[illegible] e[illegible] ee[illegible] [illegible] a[illegible] ce[illegible] Bei[illegible] [illegible] ece[illegible] be[illegible] 20 4. [illegible] e a[illegible] a[illegible] e[illegible] [illegible] [illegible] a[illegible] [illegible] [illegible] i[illegible] [illegible] i[illegible] [illegible] i[illegible] o[illegible] ce (江西省井岡山大學) i[illegible] a[illegible] ba[illegible] e[illegible] o'[illegible] e[illegible] ee[illegible] bi[illegible] e[illegible] ca[illegible] [illegible] ee[illegible] [illegible] [illegible] a[illegible] [illegible] 16. [illegible] ie a[illegible] acce[illegible] e[illegible] a[illegible] a[illegible] [illegible] [illegible] ee b[illegible] e[illegible] [illegible] o [illegible] id[illegible] a[illegible] B[illegible] ea[illegible] of[illegible] e [illegible] e (溫州市人事局) [illegible] ece[illegible] be[illegible] 20 7.

Directors, Supervisors and Senior Management

SE A A E E

Mr. ZHOU Chaoyi (周朝毅), a e 5 ,i o ice e ea a e. ei a epo ibefo a i e ea a e ei f a c eof o pa . . o joi e e pa i Feb a 20 5 a e a o ice e ea a e ce e. e a appoi e a o ice e ea a e i Sep be 20 14 a af e e pa a co e e i o a joi oc i e iabii co pa .! io o joi i e pa , f o be 1 5 o ece be 20 4, . o e e a e icep ei e of e o a io ac a (溫州心血管醫院) ic i a oca o pi a i e o, ee e a pi epo ibefo oi ic. F o a 1 0 o cobe 1 5, . o e e a ea i a ope ei e a ecio cief (科長) of a eo ce a ec i ecio a e o a iio a i ee e ide e (溫州市中醫院) ic i a oca o pi a i e o, ee e a pi epo ibefo a eo ce a ec i . F o a a 1 86 o Api 1 0, . o e e a e a eo ce office a e office i eco- e a a e o i o S a oi (溫州市氣功療養院) i e o, ee e a pi epo ibefo a eo ce a o o o ai aio . . o co pee ea ce c a (高級研修班) fo o e ea a a a e e a ej a i ie i (a o, ej a ! oi ce i e 14. . o a acce i e a ai ooi b e o idpa B ea of (ea (溫州市衛生局) i ece be 1 8 a acce i e a cii ca a i a e ica p aciid e b ej a (ea B ea (浙江省衛生廳) i Api 200 . . o a acce i e a e io b i e ope a o b e o idpa (a eo ce a Soda Sec i B ea i o be 15.

Mr. YE Minjie (葉敏捷), a e 47,i o ice e ea a e. ei a epo ibefo a i e ea a e i e a e e of de ifc ee ac a ea c , i e aio a coope aio of e pa . (e joi e e pa i cobe 13 a e icep ei e . . e a appoi e a o ice e ea a e i Sep be 14 af e e pa a co e e i o a joi oc i e iabii co pa .! io o joi i e pa , f o 1 4 o Sep be 13, e a e ecio cief (科長) a e o e a (o pi a (溫州市精神病院), ic i a oca o pi a i e o, ee e a pi epo ibefo de ifc ee ac a ea c . . e a a e f o i ai e ica o e e (新鄉醫學院) i a a e' e ee i p cia a e e a ea i i ai , (e a ! oi ce i 20 7. (e a acce i e a cief p id i p cia b e (a eo ce a Soda Sec i B ea of ej a ! oi ce (浙江省人力資源和社會保障廳) i a a 14.

Mr. XU Yi (徐誼), a e 46,i o ice e ea a e. ei a epo ibefo a i e ea a e i e fadi a i fo ai ec oo of e pa . . joi e e pa i cobe 20 2 a e a ecio cief (科長) i e oi ic e pa e f o cobe 20 2 o a c 20 , ee e a pi epo ibe fo oi ic a e e . F o Api 20 , o Sep be 14, e e a o ice p ei e , ee e a pi epo ibefo a i e p ei i e oe a e e a oi ic of e pa . (e a appoi e a o ice e ea a e i Sep be 14 af e e pa a co e e i o a joi oc i e iabii co pa .! io o joi i e pa , f o Api 1 , o Sep be 20 2, e a a eac e a e! a Sc oo of e o idpa o i ee of e o i ! a of i a (中共溫州市委黨校), ee e a pi epo ibefo eac i i fo ai ec oo co e. . a a e f o e Bei i e of Eco o ic a e e (北京經濟管理職業學院) i a co e e ip o ai a e ei o o -i ace e caio i 20 5. . i e po e of . A (o e a e b o e i- a of . A ei a . A i a e.

Directors, Supervisors and Senior Management

Ms. ZHANG Feixue (章飛雪), age 51, is the Vice President and Secretary of the Board of the Company. She is responsible for the operation of the Board of the Company. She joined the Company in February 2004 and served as the Secretary of the Board in February 2004 and October 2007, and served as the Secretary of the Board in October 2007 to September 2011, and served as the Secretary of the Board and the Joint Company Secretary in September 2011 to October 2015. She has been responsible for the operation of the Board of the Company since October 2015. She graduated from Zhejiang Medical College (浙江醫科大學) in July 1990 with a bachelor's degree in medicine. She graduated from the Executive Master of Business Administration program of Zhejiang University (浙江大學) in January 2006.

Mr. WANG Jian (王健), age 36, is the Vice President and Chief Financial Officer of the Company. He is responsible for the financial management, investment, capital operation and asset management of the Company. He joined the Company in 2014 and served as the Secretary of the Board of the Company. He was appointed as the Secretary of the Board and the Joint Company Secretary in September 2014 and has been responsible for the operation of the Board since then. He was appointed as the Vice President in October 2017. He graduated from Zhejiang University (浙江大學) in July 2000 with a bachelor's degree in economics, and graduated from the Executive Master of Business Administration program of Zhejiang University (浙江大學) in January 2014. He was qualified as a Certified Public Accountant (註冊會計師) in October 2007, and was qualified as a Senior Accountant (高級會計師) in October 2013. He was qualified as a Certified Public Accountant (註冊會計師) in China in February 2008 and has been a practicing member of Ernst & Young Hua Ming LLP (安永華明會計師事務所(特殊普通合夥)) since March 2008. He was appointed as the Chief Financial Officer of the Company in February 2015. He graduated from Zhejiang University (浙江大學) in July 2005 with a bachelor's degree in economics, and graduated from the Executive Master of Business Administration program of Peking University (北京大學光華管理學院) in Beijing in January 2015. He is a non-practicing member of the Chinese Institute of Certified Public Accountants (註冊會計師非執業會員) and a member of the Association of International Certified Public Accountants. He has served as the Chief Financial Officer of the Company since December 2014.

Directors, Supervisors and Senior Management

Mr. JIN Weiguang (金偉光), a e 54, i o ice e e a a e. [ei p ai e po ibe fo e p ' fo i e e a a ai e a e . . jo e e p a 2015 a e e a ice e e a a e of S e i [o pa fo a 2015 o a 2017, ee e a p ai e po ibe fo ope io fu cio . . e e a ec ie e e office of e p a ce a 2017 a e a appo e a ice e e a a e of e p a o be 2018. ! io o jo e p a, fo A 87 o Ap i 2015, e e e i e o id a [ea B ea (溫州市衛生局), a e po ibe fo p a , ce, fi a c e, p ice, ai ic, e ip e , , co a be, odi e ica a e o e a e e o , co c e e i a ec o of e p a i ce e pa e e of e o id a [ea B ea fo Ap i 20 o Ap i 2015. F a c 2012 o a c 2015, e e e a e ea of office a e ea ec o of e p a i ce e pa e e of e o id a [ea B ea. . i a e e fo e o e po e ce o e e of e ! a Sc oo of e e a o i ee of ! (中央黨校函授學院) i ece be 1 7, a jo i eco o ic a e e . [e a e fo e ei a eco o ic po a e e co e of ej a o a ie i (浙江師範大學區域經濟研究生課程進修班) i A 2012. [e a e fo eA ai a i o e [ea A i ai (e ica ai a e e) (澳大利亞衛生行政管理 (醫療質量管理) 培訓班) i o be 2013. [e a o a e fo e ! bic A i ai Se i a of ej a ie i (浙江大學公共管理研修班) i o be 2014.

Sa e a ic o e in e fo o in ab e, in e epo in ! ei o, o e i eco , S pe i o o ei e a e of e p a ic o o a poii in a e be of e o p:

Directors/Senior Management	Members of the Group	Positions Held at Members of the Group	Term of Office
A ei	i i a i [o pa a	E ec i e ic o	F A 2011 o pe e
	a a i [o pa a	E ec i e ic o	F e 12 o pe e
	o ja a i [o pa a	E ec i e ic o	F ece be 12 o pe e
	e i a i [o pa a	E ec i e ic o	F Sep e be 13 o pe e
	S e i [o pa a	E ec i e ic o	F Sep e be 14 o pe e
	Bei i [o pa a	a i a	F A 2015 o pe e
	ei a ic [o pa a	E ec i e ic o	F o e be 2015 o pe e
	! i a i [o pa a	E ec i e ic o	F o e be 2015 o pe e
	S e i [o pa e ica e e o., L .	E ec i e ic o, e e a a i a	F Sep e be 2015 o pe e
	o [o pa a	a i a	F o e be 2015 o pe e
	e o L c [o pa a o., L .	a i a, e e a a e	F Ap i 2012 o pe e

Directors, Supervisors and Senior Management

Directors/Senior Management	Members of the Group	Positions Held at Members of the Group	Term of Office
A [illegible] e	i [illegible] [illegible] o., [illegible].	E ec i e ec o, [illegible]	F [illegible] [illegible] 17 ope
	[illegible] i [illegible] [illegible]	[illegible]	F [illegible] ece be 18 ope
	Bei [illegible]	i ec o	F [illegible] 1 ope
	ei [illegible] ! [illegible] ce ic	[illegible]	F [illegible] e 1 o Sep be 1
	[illegible] o [illegible] e Se ice o., [illegible].	E ec i e ec o, [illegible]	F [illegible] ece be [illegible] ope
A [illegible] e	[illegible] [illegible]	S pe i o	F [illegible] e 12 ope
	o [illegible]	i ec o	F [illegible] o be 15 ope
	[illegible] [illegible]	S pe i o	F [illegible] o be 15 ope
	ei [illegible] [illegible]	i ec o	Fo [illegible] A 16 ope
	[illegible] o o	i ec o	F [illegible] 16 ope
	[illegible] o [illegible]	S pe i o	F [illegible] o be 17 ope
	ei [illegible] [illegible] ec oo o., [illegible].	i ec o	F [illegible] o be 18 o Api 1
	ei [illegible] [illegible] ec oo o., [illegible].	E ec i e ec o	F [illegible] Api 1 ope
	ei [illegible] [illegible] ec oo o., [illegible].	[illegible]	F [illegible] Api 1 o [illegible]
	ei [illegible] ! [illegible] ce ic o., [illegible].	i ec o	F [illegible] e 1 ope
	[illegible] [illegible] [illegible] c [illegible] [illegible] ! c oo ic [illegible]	S pe i o [illegible]	F [illegible] e 1 ope F [illegible] ece be 1 ope
	[illegible] o [illegible] c [illegible] [illegible] o., [illegible].	S pe i o	F [illegible] Api [illegible] ope
	Bei [illegible] [illegible] o [illegible]	i ec o, [illegible] [illegible]	F [illegible] [illegible] ope F [illegible] e [illegible] o ece be [illegible]

Directors, Supervisors and Senior Management

Directors/Senior Management	Members of the Group	Positions Held at Members of the Group	Term of Office
i	i	S e i o	F A i 11 o e
	e	S e i o	F Se e be 13 o e
	S e	S e i o	F Se e be 14 o e
	e i c	S e i o	F o e be 15 o e
	Bei	S e i o	F A 15 o e
	S e e e i c e e	S e i o	F Se e be 15 o e
	o	S e i o	F o e be 15 o e
		S e i o	F ece be 15 o A
	e	F ece be o 1 o e 6	
o	i	F ece be 11 o e 7	e i o i

Directors, Supervisors and Senior Management

Directors/Senior Management	Members of the Group	Positions Held at Members of the Group	Term of Office
[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]

[illegible]

Auditor's Report



Auditor's Report

Key Audit Matters

Key audit matters are those matters that, in our professional judgment, are of most significance in our audit of the consolidated financial statements of the current period. These matters were addressed in the context of our audit of the consolidated financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

Key audit matters for the consolidated financial statements are as follows:

- Assessment for goodwill impairment of healthcare service
- Assessment for the impairment of contractual rights to provide management service

Auditor's Report

! S i (2 21) o. 100 8
(! e 3 of 8)

e A i e (co i e)

Key Audit Matter	How our audit addressed the Key Audit Matter
Assessment for goodwill impairment of healthcare service ef e o o e 2(18) p i e of o - e a e , o e 2(18)(a)(i) i i ca acco i e a e a e	

Auditor's Report

! S i (2 21) o. 1 0 8
(! a e 4 of 8)

e A i a e (co in e)

Key Audit Matter	How our audit addressed the Key Audit Matter
epai pedia a ei io o i a e beca e oo i a i ifica i pac o e co oi a e fi a cia a e , a e of oo i pai e i o e i ifica j e a e of f eca fo of ea ca e ice fo a e , ic i bjec o i e a ce a a pedia e i .	e a o co pa e ec e ea b e of ee opi a i ei ac a ope ai e o a e ee i ce of a a e bia e of ca fo fo eca . e eie e e iii a i o e abo e e a pio o a e ee o ic a ec a e e a pio , di e ii a o i a e a e, o pac e pai a o of oo i . ec ec e eca c ai acc ac of epe e a e off eca fo e pec e obe ei e fo eac a e o p. Ba e o e of abo e o pe fo e , efo a i ifica j e a e i o e e a e fo pai e of oo i a oca e o ea ca e ice a e ppo e b a ai abe a i ei ce.

Assessment for the impairment of contractual rights to provide management service

efe o o e 2(18) [o - e a e pai e , o e 2(28)(a)(i) iica acco in e a e a e a pio , a o e 4(13) a ibe a e o e a a cia a e . A a 31 ece be 2 2 , eca in a o of co ac a i opoi e a e ice b o a in [opi a o e o B , 3 3 0) 21. Fo e ea e e 31 ece be 2 2 , ea ac ope ai e of opi a e a e a e i o ee e b e , ic e e ee a a i ica io a co ac a i opoi e a e ice i be pai e, a e a ee oe e ie ope fo a pai e a e .	eob a e a e of ei e a co o a e a e a poce e ea e o ea e a e fo e pai e of co ac a i opoi e a e e ice a ope b a e , a a e ei e ie of i a e b a in o co i e ai o ee e of ce ai a o e in e ie fac o (e. . e co pe i a bjecii of e a e a a e bia a acco in e a e o e iii o i a e ai fo fa). ee a a e a e ei e a co o ea e o e pai e of co ac a i opoi e a e e ice in e o a in [opi a, inc in e co o oe e a e of a in e a pio b a e .

Auditor's Report

Key Audit Matter	How our audit addressed the Key Audit Matter

Auditor's Report

e fo a io

a a e of e o a (opi a i epo ibefo eo e fo a io. eo e fo a io co pie a of e fo a io c e a epo of e o a (opi a o e a e da a e a o' epo ee.

opi io of e da a e oe o co e eo e fo a io a e o o e pe a fo of a ce co c io ee.

connecio i o a i of e da a e , o epo ibii i o ea eo e fo a io a , in o o, co i e e eo e fo a io i ea ia co i e i e da a e o o o e eob a e in e a i o o e ie appea obe ea ia i ae. f, ba e d e o e a epe fo e, eco c e a eei a ea ia i a e of i o e fo a io, ea e ie o epo a fac.d b- .5(e o ea ce) 0 0 -1.556

Auditor's Report

Auditor's responsibilities for the Audit of the Financial Statements (continued)

As part of an audit in accordance with SA, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control.

- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.

- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the entity's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the entity to cease to continue as a going concern.

- Evaluate the overall presentation (including the disclosures), structure and content of the financial statements, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

- Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the Group to express an opinion on the consolidated financial statements. We are responsible for the direction, supervision and performance of the group audit. We remain solely responsible for our audit opinion.

We communicate with the Audit Committee regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Auditor's Report

Auditor's responsibilities for the audit of the financial statements (continued)

Because fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control, the ability to detect fraud is not as high as the ability to detect error. If we identify such misstatements in the financial statements, we are required to communicate with the governance bodies regarding the matters that we have identified during the audit that, in our professional judgment, are of most significance in the audit of the financial statements and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Practising certificate number: [illegible]	Signature: [illegible]	Chen Zhiming (Engagement partner)
Singapore, 26 January 2021	Signature: [illegible]	Chen Yi

Consolidated Balance Sheet

As at 31 December 2020
(Amounts in Bangladesh Taka)

ASSETS	Note	31 December 2020	31 December 2019
Current assets			
Cash in hand and with banks	4(1)	206,499,564	176,[illegible],[illegible]50
Investment in shares		–	[illegible],000,000
Accounts receivable	4(2)	321,407,965	30[illegible],52[illegible],612
Inter receivable	4(3)	63,435,813	63,317,366
Advance to supplier	4(4)	11,927,882	5,366,[illegible]2
Inventories	4(5)	37,508,471	[illegible]23,568,[illegible]236
Deposits for land development	4(6)	–	1[illegible],688,[illegible]74
Total current assets		640,779,695	6[illegible]21,[illegible]1,488
Non-current assets			
Long-term investment	4(7)	93,726,511	[illegible],[illegible]43,[illegible]13
Investment in subsidiary	4(8)	57,404,918	51,[illegible]281,86[illegible]
Property plant equipment	4(9)	107,804,936	10[illegible],856,000
Fixed asset	4(10)	533,743,384	55[illegible]2,[illegible]40,[illegible]8[illegible]2
Construction in progress	4(11)	134,941,286	7[illegible]2,18[illegible],60[illegible]
Right-of-use asset	4(12)	227,568,279	[illegible]235,31[illegible]2,14[illegible]
Intangible asset	4(13)	162,536,728	16[illegible],[illegible]8,1[illegible]28
Goodwill	4(14)	71,605,598	54,346,633
Long-term prepaid expense	4(15)	153,550,840	151[illegible]83,314
Deferred tax asset	4(16)	46,576,821	46,[illegible]275,[illegible]8
Investment in associate	4(17)	18,708,451	1,[illegible]7[illegible]1,68[illegible]
Total non-current assets		1,608,167,752	1,[illegible]4[illegible]5,86[illegible],367
TOTAL ASSETS		2,248,947,447	[illegible]2,117,351,855

Consolidated Balance Sheet

As at 31 December 2020
(Amounts in Bangladeshi Taka)

LIABILITIES AND SHAREHOLDERS' EQUITY	Note	31 December 2020	31 December 2019
Current liabilities			
Short-term borrowings	4(19)	312,500,000	250,000,000
Lease liabilities		36,080	
Accounts payable	4(20)	69,573,927	75,554,760
Other liabilities	4(21)	12,965,170	8,562,126
Employee benefit payable	4(22)	42,785,133	36,063,277
Tax payable	4(23)	49,046,555	33,480,760
Dividend payable	4(24)	76,603,400	133,348,712
Provision for non-current liabilities	4(25)	35,540,617	7,741,122
Total current liabilities			
Tn of non-current liabilities		8,680,000	

Company Balance Sheet

As at 31 December 2021
(Amounts in Bangladesh Currency)

ASSETS	Note	31 December 2020	31 December 2019
Current assets			
Cash in hand and at bank		118,136,805	101,128,086
Investment in shares		–	80,000,000
Accounts receivable	16(1)	78,544,241	99,[illegible]5,315
Advance, deposit and prepayment		1,931,488	781,172
Inter company receivable	16(2)	521,673,904	564,146,603
Inventories		10,374,364	8,401,212
Deferred tax assets-net		–	12,688,074
Total current assets		730,660,802	816,172,812
Non-current assets			
Investment in subsidiaries	4(8)	57,404,918	51,281,864
Long-term investments	16(3)	453,843,360	337,636,652
Fixed assets	16(4)	299,191,394	301,261,258
Capital work in progress		3,144,167	113,500
Right-of-use assets		–	80,963
Intangible assets	16(5)	22,383,643	21,255,734
Long-term prepaid expenses		17,188,510	18,875,432
Deferred tax assets		556,900	71,180
Security deposits		7,655,891	8,347,166
Total non-current assets		861,368,783	748,281,480
TOTAL ASSETS		1,592,029,585	1,565,254,292

Company Balance Sheet

As at 31 December 2020
(Amounts in Brunei Dollars)

LIABILITIES AND SHAREHOLDERS' EQUITY	Note	31 December 2020	31 December 2019
Current liabilities			
Short-term borrowings		310,000,000	250,000,000
Accounts payable		32,572,146	38,432,738
Other liabilities		3,480,240	2,806,872
Employee benefits payable		15,629,766	15,571,352
Lease payable		8,267,931	5,176,133
Tax payable		25,329,546	64,861,712
Amount owing to sub-consolidated entities		–	52,688,074
Total current liabilities		395,279,629	413,367,571
Non-current liabilities			
Long-term borrowings		38,000,000	
Lease liabilities		–	766,151
Provision		–	2,000,000
Deferred income tax		9,645,475	9,410,267
Deferred tax liabilities		1,607,649	76,887
Total non-current liabilities		49,253,124	12,253,305
Total liabilities		444,532,753	443,151,884
Shareholders' equity			
Share capital	4(a)	74,600,300	75,000,000
Capital reserve	16(7)	828,516,606	834,663,551
Less: treasury stock	9 (b)(1)	(23,311,144)	(21,721,144)
Statutory reserve	4(32)	36,593,229	33,181,321
Retained earnings	16(8)	231,097,841	220,462,672
Total shareholders' equity		1,147,496,832	1,122,604,408
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY		1,592,029,585	1,565,756,292

The accompanying notes form an integral part of these financial statements.

Lee Kheng Kiat:
Audit

Independent Auditor's Report:
Auditor

Year of Accounts Prepared:
Year

Consolidated Income Statement

Fo e ea e 31 ece be
(A o in B e o e ie a e)

Item	o e	2020	
1. Revenue	4(34)	1,031,283,760	1,7
Le : o of a e	4(34), 4(36)	(728,701,852)	(656,184,564)
a e c a e	4(35)	(5,413,866)	(5, 6,)
Se i ib i e e	4(36)	(8,072,345)	(7, 77,677)
e e a i ai ee e	4(36)	(125,062,445)	(1 3,338, 4)
ee a c e o e e	4(36)	(20,972,502)	(18, 7)
H d a e e	4(37)	(22,821,708)	(3,488,174)
c : ee e		(26,557,119)	(6,563, 6)
ee i co e		4,677,222	4,477,337
A : e i co e	4(38)	9,264,825	, , 548
e (o e) co e	4( )	(7,665,311)	4,336, 66
c : S a e of o e of a od a e		(7,727,019)	(3, 3,144)
f c e i fai a e	4( )	6,599,223	1, 17,46
i pai e o e	4(41)	(23,125,756)	(, 56,3 4)
A e pai e o e	4( )	(8,011,603)	
f i po a of a e		596,700	
2. Operating profit		97,897,120	45,847,348
A : o -ope a i co e	4(43)	909,040	, 388,5 7
Le : o -ope a i e e	4(44)	(10,901,945)	(1, 713) 68)
3. Total profit		87,904,215	55,5 2,8 7
Le : co e a e e	4(45)	(28,948,671)	(17, 5,18)

Consolidated Income Statement

For the year ended 31 December 2020
(Amounts in Brunei dollars)

Item	Note	2020	2019
4. Net profit		58,955,544	38,227,618
Attributable to:			
Equity holders of the parent		58,955,544	38,227,618
Non-controlling interests		–	
Attributable to equity holders of the parent:			
Continuing operations		70,000,134	57,288,234
Discontinued operations		(11,044,590)	(19,061,776)

Company Income Statement

Fo e ea_ ë *e* 31 ece be 2 2
(A o *i* B e o e i e a_e*)

Item	o e	2020	2 1
1. Revenue	16( )	417,163,187	384,6 6,64
Le : o of a_e	16( ), 16(11)	(2 5 ,115)	(2 3 ,7)
a_e * c a_e		(3,0 2 82)	(2 , 1,6)
Se i * i ib i e e	16(11)	(2,321,386)	(2,488,613)
e e a_ * a_ i ee e	16(11)	(54,661,422)	(62,554,461)
ee a_c * e o e	16(11)	(15,876,537)	(3,57 ,462)
H d a_e e e	16( )	(2,113,7 1)	(7,745 71)
c : ee e e		(16,578,8 5)	(57 76)
ee i co e		15 41,8 7	2,427,741
A *: e i co e		4,253,758	7,463 67
e ë (o e) co e	16(12)	(8 , 6 28)	755,472
c : S a_e of o e of a_ oda_e		(8,158,636)	(632 38)
a f c a e i fai a e		6,123 4	8 7,546
e i pai ë o e	16(13)	(7,4 3,1)	(14,531 28)
A e i pai ë o e	16(3)	(,847,8 8)	
2. Operating profit		47 , 7, 5	26,2 ,781
A *: o -ope a i co e		7 8,824	27,7 6,8 4
Le : o -ope a i e e		(4 62,518)	(11,4 8 85)
3. Total profit		44,733,411	42,5 8,6
Le : co e a_ e e	16(14)	(,6 4,334)	(,515,824)
4. Net profit		34 3 77	32 82,866
a i e* b co i i of ope a i			
e o f f co i i ope a i		34 3 77	32 82,866
e o f f i co i e* ope a i			
5. Total comprehensive income		34 3 77	32 82,866

e acco pa i o e fo a i e a_pa of ee fi a_ë d a_ a_ë ë .

Le a_ ep e ë a i e: A di

I i d pa_i c a_ e of acco i : A (d e

(ea* of acco i *epa_ ë : i a

Consolidated Cash Flow Statement

Fo e ea e e 31 ece be
(A o i B e o e i e e)

Item	o e	2020	

Consolidated Cash Flow Statement

Fo e ea e e 31 ece be 2 2
(A o in B e o e ie a e)

Item	o e	2020	2 1
3. Cash flows from financing activities			
a ece e f cai a co ib io		23,361,500	12,345,00
c : a ece e f cai a co ib io b non-co o in e o e of bi ia ie		21,771,500	12,345,00
a ece e f bo o in		406,492,970	270 00 00
a ece e ea in oo e in d ac i ii e		–	11, 60 00
Sub-total of cash inflows		429,854,470	4, 0 5,00
a ep a e of bo o in		(290,000,000)	(185,000 00)
a pa e fo i ib io of i i e o in ee e pe e		(17,109,612)	(0, 36,18)
a pai ea in oo e in d ac i ii e		(100,692,478)	(72, 7,242)
Sub-total of cash outflows		(407,802,090)	(286,543,431)
Net cash flows from financing activities		22,052,380	7,761,56
4. Effect of foreign exchange rate changes on cash and cash equivalents		(248,021)	(635,428)
5. Net increase/(decrease) in cash and cash equivalents		35,140,715	(22,114,744)
A : a ca e i a a e be in of e ea	4(47)(a)	164,951,950	187, 66, 4
6. Cash and cash equivalents at the end of the year	4(47)(a)( )	200,092,665	164, 51, 0

e acco pa in oe fo in e a pa of ee in d a a e .

e a ep e ai e: A di

I in d pa in c a e of acco in : A (o e

(ea of acco in ep a e : in a

Company Cash Flow Statement

For the year ended 31 December 2020
(Amounts in Brunei dollars)

Item	Note	2020	2019
1. Cash flows from operating activities			
Cash receipts from sale of goods and rendering of services		430,696,545	388,982,582
Cash receipts relating to operating activities		64,986,508	11,890,906
Sub-total of cash inflows		495,683,053	400,873,488
Cash paid for goods and services		(161,484,999)	(125,886,385)
Cash paid to and on behalf of employees		(135,403,738)	(124,557,846)
Income taxes and royalties paid		(9,282,581)	(18,265,441)
Cash paid relating to operating activities		(30,870,989)	(56,688,406)
Sub-total of cash outflows		(337,042,307)	(325,430,078)
Net cash flows used in operating activities		158,640,746	75,353,410
2. Cash flows from investing activities			
Cash receipts from disposal of investments		49,000,000	447,000,000
Cash receipts from investments		96,370	1,526,905
Cash receipts relating to investing activities		3,750,000	
Sub-total of cash inflows		52,846,370	1,973,600
Cash paid to acquire equity, intangibles and other non-current assets		(38,292,840)	(2,200,007,144)
Cash paid to investments		(158,247,608)	(230,750,000)
Cash paid relating to investing activities		(5,370,000)	
Sub-total of cash outflows		(201,910,448)	(2,432,757,144)
Net cash flows used in investing activities		(149,064,078)	(2,430,783,544)

Company Cash Flow Statement

Fo e ea d e 31 ece be
(A o in B e o e ie a e)

Item	oe	2020	1
3. Cash flows from financing activities			
a ecei e f o cap i a co ib io		1,590,000	
a ecei e f o bo o in		348,000,000	0 000 000
a ecei e ea in oo e in d ac i i ie		–	000 000
Sub-total of cash inflows		349,590,000	0 000 000
a ep a e of bo o in		(300,000,000)	(145 000 000)
a pa e fo i ib io of i ide o in ee e pe e		(16,486,881)	(18, 6,586)
a pai ea in oo e in d ac i i ie		(14,507,167)	(265,816)
Sub-total of cash outflows		(330,994,048)	(163,56 ,0)
Net cash flows from financing activities		18,595,952	6,437,5 8
4. Effect of foreign exchange rate changes on cash		(248,021)	(635,4 8)
5. Net increase/(decrease) in cash and cash equivalents		27,924,599	(5 ,6 7, 64)
A : a a ca e i a a e be in of e ea		90,212,206	14 ,80 ,10
6. Cash and cash equivalents at the end of the year		118,136,805	0 ,2 ,0 6

e acco pa in oe fo a in e a pa of ee in d a a e .

e a ep e i e: A di

I in d pa in c a e of acco in : A (d e

(ea of acco in ep a e : a

Consolidated Statement of Changes in Shareholders' Equity

For the year ended 31 December 20
(Amounts in Billions)

		Equity attributable to shareholders of the parent company						
	Note	Share capital	Capital surplus	Less: Treasury stock	Surplus reserve	Retained earnings	Non-controlling interests	Total shareholders' equity
Balance at 1 January 2020		75,500,000	824,715,445	(21,721,144)	33,189,321	252,800,715	97,024,925	1,261,509,262
Movements for the year ended 31 December 2020								
[illegible]		–	–	–	–	70,000,134	(11,044,590)	58,955,544
[illegible]		–	1,590,000	(1,590,000)	–	–	21,771,500	21,771,500
[illegible]	,	–	5,887,603	–	–	–	–	5,887,603
[illegible]	4(31)	–	(13,813,742)	–	–	–	(19,879,038)	(33,692,780)
[illegible]	4(31)	(899,700)	(13,624,556)	–	–	–	–	(14,524,256)
[illegible]	4(31)	–	(188,221)	–	–	–	–	(188,221)
[illegible]	5(1)	–	–	–	–	–	15,905,745	15,905,745
[illegible]		–	–	–	3,403,908	(3,403,908)	–	–
[illegible]	4(33)	–	–	–	–	–	(1,200,000)	(1,200,000)
Balance at 31 December 2020		74,600,300	804,566,529	(23,311,144)	36,593,229	319,396,941	102,578,542	1,314,424,397

[illegible] accompanying notes form an integral part of these financial statements.

		Equity attributable to owners of the Company						
	Note	Share capital	Share premium	Treasury shares	Special reserve	Retained earnings	Non-controlling interests	Total equity
Balance at 1 January 2019		75,000,000	827,337,886	(21350,000)	33,810,134	2,044,608	84,277,828	1,025,273,356
Movements for the year ended 31 December 2019								
Profit for the year						57,228,334	(1,061,776)	38,227,618
Acquisition of additional interest in a subsidiary from non-controlling interests							12,345,000	12,345,000
Share-based payments	9		5,102,526					5,102,526
Dividend paid to non-controlling interests of a subsidiary			(3,660,384)				(4,976,611)	(8,660,000)
Appropriation to statutory reserve			(188,856)	188,856				
Dividend			(4,075,722)				(2,152,086)	(6,857,808)
Business combinations under common control								
Deemed contribution from the controlling shareholder							26,585,570	26,585,570
Dividend paid								
Appropriation for property development					3,208,287	(3,208,287)		
Dividend to owners of the Company	4(33)					(11,325,000)		(11,325,000)
Balance at 31 December 2019		75,000,000	824,715,445	(21,721,144)	33,18,321	252,80,715	7,124,25	1,261,0,262

The accompanying notes form an integral part of these financial statements.

Director: Director: Date of approval:

Company Statement of Changes in Shareholders' Equity

For the year ended 31 December 2020
(Amounts in Brunei Dollars)

	Share capital	Capital surplus	Less: Treasury stock	Surplus reserve	Retained earnings	Total shareholders' equity
Balance at 1 January 2020	75,500,000	834,663,559	(21,721,144)			

Company Statement of Changes in Shareholders' Equity

Fo e ea e e 31 ece be 2 1
(A o in B e o e ie a e)

	o e S a ec a a	a p	e a oc	S p e e e	e e a	o a a e o e ' e i
Balance at 1 January 2019	75,00 ,000	828, 31,88	(21, 0 ,000)	, 81 ,34	182, 13 , 3	1 , 5,416 16
Movements for the year ended 31 December 2019						
o a co p e i e co e e p o					32 82,866	32 82,866
a a co ib io a i a a b a e o e						
a a i a a b a e o e		(188,856)	188,856			
S a e-b a e pa e c e a e o e ' e i		5, ,526				5, ,526
! o i ib io						
A pp opia io fo p ee e				3, 8,287	(3, 8,287)	
! o i ib io o a e o e					(11,32 ,000)	(11,32 ,000)
Balance at 31 December 2019	75,00 ,000	834,663,55	(21,721,144)	33,18 ,321	0 ,462,672	1,122 , 4, 8

e acco pa i oe fo a i e a pa of ee i a ia a e .

Le a ep e e a i e: ! i d pa i c a e of acco i : (ea of acco i ep a e :
A di A (o e i a

Notes to the Financial Statements

Fo e ea e 31 ece be 2 2
(A o i B e o e ie)

1 e e a i fo aio

e o pa a e abi e a ajo oc coope a i e e epie e e of o i ! c ia ic e abii aio [o i a (溫州市康寧精神康復醫院) e! o 7 Feb a 6. e a e of e o pa ' ei ee office S e jo oa, [a o ei e ia i ic, e o, eja , e! , a i ea a e i oca e i e o i , eja ! o ce, e! .

15 cobe 2 14, e o pa a co e e i o ajo oc ie iabii co pa a e a e o a i [o i a o., L . (溫州康寧醫院股弁皂蒂畾榣).

e i dpe acii ie of e o pa a i bi ia ie (e o p) a e ope a i p c ia ic o i a a poi i a a e ice o o i a i e! .

e o pa a i p a i i o e Soc E c a e of [o o ie o 2 o be 2 15.

i e epo i pei o, a affi ae o i a of e o p (o e 5) e e e a e off ope aio. ea ie, e o p co i e oi e i a oda e (o e 4(7)) a poi e a a e ice o o e o i a (o e 4(13)) oe pa i e ica e o .

! ea e efe o o e 5. a e i e co oi aio cope a o e 6. ee i o e iie fo e co oi aio cope a ec a e i e co oi aio cope fo e co oi ae i a da a e fo e c e ea.

e i da a e e ea oi e fo i eb e Boa of ie o of e o pa o 26 ac 2 21.

2 S a of i ifica acco i poide a acco i e i a e

e j e a ciica acco i e i a e a e a pio appie b e o p o e ee i aio of i ifica acco i poide a e e o i o e 2(28).

(1) Basis of preparation

e i da a e a e epa e i acco ce i e *Acco i S a fo B i e E epie Ba ic S a* , e edic acco i a a o e ee a e aio i e b e i of H ce o 15 Feb a 2006 a i be e pei o (ee e co eci e efe e o a e Acco i S a fo B i e E epie o AS).

e i da a e a e epa e o a o co ce ba i .

e e [o o o pa ie ce bec e effeci e o 3 ac 2 14. e a i co e i e i da a e a e bee a j e i acco ce i e i e e .

Notes to the Financial Statements

Fo e ea e 31 ece be 2 2
(A o in B e o e ie)

2 S a of ini ica acco in poide a acco in e a e (co in e)

(2) Statement of compliance with the Accounting Standards for Business Enterprises

e in da a e of e o pa fo e ea e 31 ece be 2 2 a ein co pi ce i e Acco in S a fo B ine E epie, a co pee pe e eco oi a a e co pa ' in da poiio of e o pa a 31 ece be 2 2 a i in da pe fo ce, ca fo a o e in fo aio fo e ea e e .

(3) Accounting year

e o pa ' acco in ea a o 1 a a e o 31 ece be .

(4) Recording currency

e o pa ' eco in c ci ein bi (B). e eco in c c of e o pa ' bi ie i e ein e ba e o ep a eco ic i e in ic e ope e. A e o pa ' bi ie ope e i in e a i eco in c ci B. e in da a e a epee e in B.

(5) Business combinations

B ine co bin aion in o in e epie o e co on co o

eco bin aion co a i e ina be e a e ob ine b e o pin ab ine co bin aion a ea e a fai a ea ea iiio a e. ee eco of eco bin aion ee ea ie' in ee in e fai a e of ea ie' ein ina be e a e , e iffe ce ei eco ie in p oi o o fo ec e peio . o ie a ib abe o eco bin aion a e in c e in p oi o o fo ec e peio in ic e a ein c e . a acio co a oda e i e i eo e i o eb ec iie fo eb ine co bin aion a ein c e in ei iia eco ie a o of ee i o eb ec iie .

Notes to the Financial Statements

Fo e ea e e 31 ece be 2 2
(A o in B e o e i e a e)

2 S a of i ifica acco in poide a acco in e a e (co in e)

(6) Preparation of consolidated financial statements

Notes to the Financial Statements

Fo e ea e 31 ece be 2 2
(A o in B e o e ie a e)

2 S a of i ifica acco in poide a acco in e a e (co in e)

(7) Cash and cash equivalents

a ca e i a e co pie ca o , epoi a ca be ea i a o e , o -e i i i e a e ea co e ibe o o a o of ca ic a e bjec o a in ifica i k of c e in a e.

(8) Foreign currency translation

Fo ei c e c acio

Fo ei c e c acio a e a e in o eco c e c in ee c e e a e pe ain a e a e of e acio .

A e ba ce ee a e, o e a i e e o in a e in fo ei c e de a e a e in o eco c e c in e po ec e a e o eba ce ee a e. E c e e iffe e ce ai in fo ee acio a e eco i e in p ofi o o fo ec e pei o, e cep fo o e a ib abe o fo ei c bo o in a e bee ab e o pedifica fo ac iii o co cio of aif in a e, ic a e ca i ai e a pa of eco of o e a e. o o e a i e e o in a e in fo ei c e de a e e ea e a i oica co a e a e a eba ce ee a e in e po ec e a e a e a e of e acio . e effec of e c e a ec e o ca i pe e e epa a e in eca fo a e .

(9) Financial instruments

A in d a in e i co ac a ie ie o a in d a e of e i a in d ia bii o e i in e of o e i . A in d a e o a in d ia bii i eco ie e e o p beco e a pa o eco ac a poiion of ei e .

(a) Hed a e

(i) a ifica io a e ea e

Ba e o eb ie o e fo a ain e in d a e a eco ac a ca fo c a ac ei ic of e in d a e , in d a e a e ca ifie a: (1) in d a e a o ie co ; (2) in d a e a fai a e o p ofi o o .

e in d a e a e ea e a fai a e a iii a eco iio . e a e a acio co a e a ib abe o e ac iii of e in d a e a ei c e in ei iia eco ie a o , ece fo e in d a e a fai a e o p ofi o o , e ea e a acio co of ic a e eco ie ie ec in p ofi o o fo ec e pei o. Acco ece abe o oe ece abe ain fo a e of po c o e ei of e ice (ec o i o ea oi ifica in d co po e) ei iia eco ie a eco i e aio ai i ie ob e c a e b e o p a e pec e .

Notes to the Financial Statements

Fo e ea e 31 ece be 2 2
(A o in B e o e ie a e)

2 S a of i ifica acco in poide a acco in e a e (co in e)

(9) Financial instruments (co in e)

(a) Ha dia a e (co in e)

(ii) Ha ed

Fo ha dia a e ea e a oi co c a acco ecei abe a o e ecei abe, e o p eco ie o poiio o eba i of e pec e ce i o e (E L).

i in co i e aio o ea o abe a ppo abei fo ai o pa e , c co i io a fo eca off eeco o ic co i io , a e a e efa i e i , e o p eco ie eE L a ep obabi i - i e a o of ep e a e of e ffe ce be ee eca fo ecei abe fo eco ac a eca fo e pec e oco ec.

A a ea ba a ce ee a e, eE L of ha dia Ve a ffe e a e a e ea e e pec i e . 12 o E L poiio i eco ie fo ha dia Ve in Sa e 1 a a e o a i ifica in ce ea e ce i i e in ce ii a eco ii o; ife eE L poiio i eco ie fo ha dia Ve in Sa e 2 a a e a i ifica in ce ea e ce i i e i o ce i Ha Ve in ce ii a eco ii o; a ife eE L poiio i eco ie fo ha dia in Ve in Sa e 3 a a e a ce i Ha Ve in ce ii a eco ii o.

Fo e ha dia Ve i o e ce i i e eba ce ee a e, e o p a Ve ee i o i ifica in ce ea e ce i i e in ce ii a eco ii o a eco ie e 12 o E L poiio.

Fo e ha dia Ve in Sa e 1, Sa e 2 a i o e ce i i e, e o p ca a e ei ee in co e b app in e effeci ei ee a e o e o ca in a o (befo e e cio of e Ha ed poiio). Fo e ha dia Ve in Sa e 3, ei ee in co e i ca a e b app in e effeci ei ee a e o e a oi co (afe e cio of e Ha ed poiio fo e o ca in a o).

Fo acco ecei abe, i pec i eof e e a i ifica in ha dia co po e ei , e o p Ve ea e e o poiio acco in oife eE L.

Notes to the Financial Statements

For the year ended 31 December 20XX
(Amounts in Brackets are Deficits)

2 Summary of significant accounting policies and accounting estimates (continued)

(9) Financial instruments (continued)

(a) Financial assets (continued)

(ii) Impairment (continued)

In case the Entity has financial assets that are measured at amortised cost, the respective carrying amount is reduced by the impairment loss directly for all financial assets with the exception of trade receivables, where the carrying amount is reduced through the use of an allowance account. When a trade receivable is uncollectible, it is written off against the allowance account. Subsequent recoveries of amounts previously written off are credited against the allowance account. Changes in the carrying amount of the allowance account are recognised in profit or loss.

Accounting policy

Financial instrument

The financial instrument

Loans or receivables

Amortised cost

The financial instrument

Financial assets

The financial instrument

Equity

The financial instrument

If, in a subsequent period, the amount of the impairment loss decreases and the decrease can be related objectively to an event occurring after the impairment was recognised (such as an improvement of the debtor's credit rating), the previously recognised impairment loss is reversed to the extent that the carrying amount of the asset does not exceed its amortised cost at the reversal date.

The loss is recognised in profit or loss.

Notes to the Financial Statements

Fo e ea e 31 ece be 2 2
(A o B e o e i e)

2 S a of i ifica acco i poide a acco i e a e (co i e)

(9) Financial instruments (co i e)

(a) H d a e (co i e)

(iii) e eco i i o

A d a e i e eco i e : (i) e co ac i o e ca fo f o e d a

Notes to the Financial Statements

Fo e ea e 31 ece be 2 2
(A o in B e o e ie)

2 S a of i ifica acco in poide a acco in e a e (co in e)

(11) Long-term equity investments

Lo -e e i in e ed co pie e op' o -e e i in e ed in i bi iaie, e op' o -e e i in e ed in i a odae.

S bi iaie ae ein e ee oe ic e op i abe oeed eco o. A a odaei ein e ee oe ic e op a i ifica if ence b aidpain in ein da e ope ain poic edio .

e ed in bi iaie aepeed e in e op' ind da aed in eco e o, e ae aj e o ee i e o ein p epain eco oi ae ind da aed . e ed in a odae ae acco e fo in ee i e o.

(a) e e ina io of in e ed co

Fo o -e e i in e ed ac ie o ab in e co bina io in o in epie o e co d co o, ein e ed co a be eco bina io co .

Fo o -e e i in e ed ac ie o o ab in e co bina io: fo o -e e i in e ed ac ie b pa ed in ca , einii ain e ed co a be ep c aepice ac a pai; fo o -e e i in e ed ac ie bi in e i ec iie, einii ain e ed co a be efai a eof ee i ec iiei e.

(b) S be e ea ed e eco ii io of p oi o o

Lo -e e i in e ed acco e fo in eco e o ae ea e aiii ain e ed co . a i ie o p oi ib io ec ae b ein e ee i eco ie ain e ed in co ein p oi o o fo ec e peio.

Fo o -e e i in e ed a ae acco e fo in ee i e o, ee einii a in e ed co ecee e op' ae of efai a eof ein e ee' ie inabe e ae a e e of ac iiio, ein e ed i ii a ea e a co . ee einii ain e ed co i e e op' ae of efai a eof ein e ee' ie inabe e ae a e e of ac iiio, e iffe ence i c e in p oi o o fo ec e peio e eco of e o -e e i in e ed i a j e p a acco in .

Notes to the Financial Statements

Fo e ea e e 31 ece be 2 2
(A o in B e o e ie a e)

2 S a of i ifica acco in poide a acco in e a e (co in e)

(12) Investment properties

e e p ope ie, c a e ea bee ea e o , bi a e e fo e
p po e of ea a bi a e bee co c e o e e ope fo f e c0 ce of e, a of f e0 30 00 e

Notes to the Financial Statements

For the year ended 31 December 2022
(Amounts in Brazilian Reais)

2 Summary of significant accounting policies and accounting estimates (continued)

(13) Fixed assets

(a) Recognition and initial measurement of assets

Fixed assets comprise buildings, vehicles, computer equipment, electronic equipment and other equipment.

Fixed assets are recognised initially at acquisition cost. Fixed assets are carried at acquisition cost less accumulated depreciation and accumulated impairment losses.

Notes to the Financial Statements

Fo e ea e e 31 ece be
(A o i B e o e i e e)

Notes to the Financial Statements

For the year ended 31 December 2022
(Amounts in Brunei Dollars)

2 Summary of significant accounting policies and accounting estimates (continued)

(15) Borrowing costs (continued)

For specific borrowings obtained for the purpose of obtaining a qualifying asset, actual borrowing costs incurred during the period on the specific borrowings less any investment income earned from the temporary investment of those borrowings are capitalised.

For general borrowings used for obtaining a qualifying asset, capitalisation rate of the borrowings is applied to the weighted average of the expenditures on that asset to determine the amount of borrowing costs eligible for capitalisation. The weighted average carrying amount of an asset during a period includes borrowing costs previously capitalised. All other borrowing costs are recognised in profit or loss in the period in which they are incurred.

(16) Intangible assets

Intangible assets are measured at cost, including any directly attributable expenditure on making the asset ready for its intended use and net of accumulated amortisation and accumulated impairment losses.

(i) Land use rights

Land use rights are amortised over the shorter of the lease period of 60 years. If the title deed conferring the land use rights does not specify the lease period, the land use rights are amortised over the estimated useful life of the asset.

(ii) Software

Software are amortised over their estimated useful life of 5 years.

Notes to the Financial Statements

Fo e ea ed e 31 ece be
(A o I B e o e ie ae)

2 S a of i ifica acco I poide a acco I e a e (co I e)

(16) Intangible assets (co I e)

(iii) o ac a i o oi e a ed e ice

o ac a i o oi e a ed e ice ae ei o a ea o ia, ic e be ea e a co (e o pai o ac ie c i) e acc a e a oi aio a acc a e pai e o e.

o ac a i o oi e a ed e ice ae o ie o a ai -ie bai o e e co ac a e a beo :

	o ac a e
! ja (a fe ! cia ic(o ia (! ja (o ia)	ea
a (a fe a e(o ia (a (o ia)	ea
i e a(ea e e(i (ea e e)	ea

(i) ice ce

ice ce ac ie o a e ac iiio a b ie co bi aio a e eco ie a fai a e a e a e of a e ac iiio. e eice ce a e ie ef ife a a e be ea e a co e

Notes to the Financial Statements

For the year ended 31 December 20[illegible]
(Amounts in Brunei dollars)

2 Summary of significant accounting policies and accounting estimates (continued)

(16) Intangible assets (continued)

(ii) Research and development

Expenditure on internal research and development projects is charged to profit or loss when incurred unless development costs are capitalised if the following conditions are satisfied: the project is clearly defined and the expenditure attributable to the project can be identified separately and measured reliably; the technical feasibility of the project can be demonstrated; the intangible asset will be used or sold; adequate resources exist to complete the project; and there is an intention to complete the project.

Expenditure not meeting the criteria for capitalisation is expensed as incurred. Capitalised development costs are recorded as intangible assets and amortised from the point at which the asset is ready for use on a straight-line basis over the period of expected future benefits. During the period of development, the asset is tested for impairment annually.

Notes to the Financial Statements

Fo e ea e 31 ece be 20
(A o in B e o e ie a e)

2 S a of i ifica acco in poide a acco in e a e (co in e)

(17) Long-term prepaid expenses

Lo -e pepai e pe e c e ee pe i e fo po e o f e a e e e ope a in ea e, a o ee pe i e a ebe c e b o be eco ie a e pe e oe oe a de ea in ec e ea a be e peio . Lo -e pepai e pe e ae a oie o e a -e ba i oe ee pec e be efi da peio a e pe e a ac a e pe i e e of acc a e a o i aio .

(18) Impairment of long-term assets

H e a e, co cio in po e, i -of- ea e, in a ibea e i ie ef ie a o -e e i in e e in bi ia ie a odae a e e fo pai e if ee i a ica io a ea e a be pai e a eba ce ee a e. f ee of e pai e e ica e a e eco e abe a o of a a ei e a i ca in a o, a poiio fo pai e a a e pai e o a e eco ie fo e a o b ic ea e' ca in a o ecee i eco e abe a o. e eco e abe a o i ei e of a a e' fai a ee co o e a epee a e of ef eca fo epece obe ei e fo ea e. ! oiio fo a e pai e i ee ine a eco ie e ei ii a e, e eco e abe a o of a o pofa e o ic ea e be e i ee ine. A o pofa e i e a e o pofa e ai abe o de ea ei epe e ca info .

oo i a i epa a e pee e in efi da a e e i e ea a a fo pai e, i epeci e of e ee ei a ica io ai a be pai e. n co cio ee, eca in a e of oo i i a oca e o ee a e a e o po o p of a e o p ic a ee pece obe efi fo e ie ie of eb ine co bi aio. f ee of e e ica e a e eco e abe a o of a a e o po a o p of a e o p, inc in e a oca e oo i, i o e a i ca in a o, e co epo in pai e o i eco ie. e pai e o i if e ce fo eca in a o of oo i a i a oca e o ea e o po o p of a e o p, a e ce fo eca in a o of o e a e i in ea e o po o p of a e o p in popoio o eca in a o of a e o e a oo i .

ce e abo e a e pai e o i eco ie, i i o be e e fo e a e eco ee in e be e peio .

(19) Employee benefits

E po ee be efi efe o a fo of co i e aio o co pe aio i e b e o pin ec a efo e ice e e b e po ee o fo e in aio of e po e aio ip, ic inc e o -e e po ee be efi , po -e po e be efi , e in aio be efi a o e o -e e po ee be efi .

(a) S o -e e po ee be efi

S o -e e po ee be efi inc e a e o a ie, bo , a o ce a bi ie, aff efe, pe i o co ib io o e ica in ce, o in j in ce a e a i in ce, o in f , io in co a e po ee e caio co , o -e pai abe ce a ec. e o -e e po ee be efi ac a occ e a e eco ie a aiabi in e acco in peio in ic e ei ce e e b e po ee, i a co epo in c a e o epo o fo e c e peio o eco of ee a e . o o ea be efi a e ea e a fai a e.

Notes to the Financial Statements

For the year ended 31 December 2012
(Amounts in Brunei Dollars unless otherwise stated)

2 Summary of significant accounting policies and accounting estimates (continued)

(19) Employee benefits (continued)

(b) Post-employment benefits

The operating post-employment benefit plans are either defined contribution plans or defined benefit plans. A defined contribution plan is a post-employment benefit plan under which the Company pays fixed contributions into a separate entity and will have no obligation to pay further contributions; a defined benefit plan is a post-employment benefit plan other than a defined contribution plan. In the normal circumstances, the operating post-employment benefit plans are funded by contributions to insurance companies, as determined by actuaries.

(c) Participation

The Company participates in the statutory pension plan as mandated by the Government of Brunei Darussalam. Such pension plan is accounted for as defined contribution plan. Accordingly, the Company's obligations are limited to the amount contributed and expensed in the year.

(20) Dividend distribution

A final dividend is recognised as a liability in the period in which the final dividend is approved by the shareholders.

(21) Provisions

Provisions are recognised when the Company has a present obligation as a result of a past event, it is probable that an outflow of economic benefits will be required to settle the obligation, and a reliable estimate can be made of the amount of the obligation.

Provisions are measured at the best estimate of the expenditure required to settle the present obligation. Factors surrounding uncertainty, risk, time value of money, and future events are taken into account in the best estimate of provisions. The effect of the time value of money, when material, is calculated by discounting the expected future cash flows at a pre-tax rate that reflects current market assessments of the time value of money and the risks specific to the liability.

Reimbursement from a third party of provisions is recognised as a separate asset only when it is virtually certain that reimbursement will be received if the Company settles the liability.

Provisions are not recognised for future operating losses.

Provisions are reviewed at each balance sheet date and adjusted to reflect the current best estimate.

Notes to the Financial Statements

Fo e ea e e 31 ece be 0 0
(A o in B e o e ie)

2 S a of i ifica acco in poide acco in e a e (co in e)

(22) Share-based payments

(a) e pe of a e-ba e pa e

A a e-ba e pa e i a ac io ic e o p e i e o a e iabiie a a e ee e ba e o e i e , ec e fo ice e ee b e po ee o o e pa ie. E i e c e ee i e inve e o e o p , o o e acco in iie i e e o p. S a e-ba e pa e a e i e in oe i - e e a e-ba e pa e ca - e e a e-ba e pa e . Fo e ea e e 31 ece be 0 0 , e o p i o o ca - e e a e-ba e pa e .

e o pa ' e ice a ei ce i e p i e i - e e a e-ba e pa e fo ec e eof e ice e ee b e po ee, i ea e a efai a eof e e ice a e a e a e. Fo a e-ba e pa e a a e o e ed abe i e ice i e e i pei o a e co pee, a ea ba ce ee a e i e e i pei o, e e ice ob a e in ec e pei o a , ba e o e be e a e of e be of e e e i e , be c e in e ee co o e pe e a efai a eof ee i e a e a e, i ca a ee ea acco .

(b) e o o ee e efai a eofe i e

efai a eof e ice a ei ee e ba e o e ffe ce be ee efai a e e ice of e o p' e ice a e a e a e.

(c) Bai fo ee e ebe e a eofe ed abee i e

Notes to the Financial Statements

For the year ended 31 December 2022

(All amounts in Brazilian reais)

2 Summary of significant accounting policies and accounting estimates (continued)

(23) Revenue recognition

Notes to the Financial Statements

For the year ended 31 December 2022
(Amounts in Brunei Dollars)

2 Summary of significant accounting policies and accounting estimates (continued)

(24) Government grants

Government grants refer to the assistance provided by the government in the form of transfer of resources to the Company, including tax refunds, subsidies, etc.

Government grants are recognised when there is reasonable assurance that the Company will comply with the conditions attached to them. Government grants that compensate the Company for expenses incurred are recognised as income on a systematic basis in the periods in which the expenses are recognised. Government grants that compensate the Company for the cost of an asset are deducted from the carrying amount of the asset and consequently are effectively recognised in profit or loss over the useful life of the asset.

Government grants are recognised in profit or loss on a systematic basis over the periods in which the Company recognises as expenses the related costs for which the grants are intended to compensate. Specifically, government grants whose primary condition is that the Company should purchase, construct or otherwise acquire non-current assets are recognised as deferred income in the statement of financial position and transferred to profit or loss on a systematic and rational basis over the useful lives of the related assets.

Government grants that are receivable as compensation for expenses or losses already incurred or for the purpose of giving immediate financial support to the Company with no future related costs are recognised in profit or loss in the period in which they become receivable.

Notes to the Financial Statements

For the year ended 31 December 20
(Amounts in Brunei Dollars)

2 Summary of significant accounting policies and accounting estimates (continued)

(25) Deferred tax assets and deferred tax liabilities (continued)

Deferred tax liabilities are recognised for taxable temporary differences arising from investments in subsidiaries, associates and joint ventures, except where the timing of the reversal of the temporary difference is controlled by the Group and it is probable that the temporary difference will not reverse in the foreseeable future. Deferred tax assets arising from deductible temporary differences associated with such investments and interests are only recognised to the extent that it is probable that sufficient taxable profits will be available against which the temporary differences can be utilised, and they are expected to reverse in the foreseeable future.

Deferred tax assets and deferred tax liabilities are offset when:

- the deferred taxes are related to the same tax payer within the Group and the same taxation authority; and,
- that tax payer within the Group has a legally enforceable right to offset current tax assets against current tax liabilities.

(26) Leases

At commencement, or on reassessment of a contract that contains a lease component, the Group allocates the consideration in the contract to each lease component on the basis of their relative stand-alone prices.

The Group as lessee

At the commencement date, the Group recognises right-of-use assets and lease liabilities in the statement of financial position. Lease payments included in the measurement of the lease liability comprise fixed payments, variable lease payments that depend on an index or a rate, amounts expected to be payable by the Group under residual value guarantees, the exercise price of a purchase option if the Group is reasonably certain to exercise that option, and payments of penalties for terminating the lease, if the lease term reflects the Group exercising that option. Variable lease payments that do not depend on an index or a rate are recognised as expenses (unless they are incurred to produce inventories) in the period in which the event or condition that triggers those payments occurs.

In calculating the present value of lease payments, the Group uses its incremental borrowing rate at the lease commencement date because the interest rate implicit in the lease is not readily determinable. After the commencement date, the amount of lease liabilities is increased to reflect the accretion of interest and reduced for the lease payments made. In addition, the carrying amount of lease liabilities is remeasured if there is a modification, a change in the lease term, a lease payment change or a change in the assessment of an option to purchase the underlying asset.

For short-term leases (lease terms of 12 months or less) and leases of low-value assets, the Group recognises the lease payments as an operating expense on a straight-line basis over the lease term.

Notes to the Financial Statements

Fo e ea e 31 ece be 2 2
(A o in B e o e ie a e)

2 S a of i ifica acco in poide a acco in e a e (co in e)

(26) Leases (co in e)

e o a ee ee (co in e)

e o a a acco fo a ea e o ifica io a a epa a e ea eif bo : (1) e o ifica io in ce ea e e cope of e ea e b a in e i o e eo oe e in a e ; (2) eco i e a io fo e ea e in ce ea e b a a o co e a e i e a -a epice fo ei ce ea ei cope a a app opia e a j e o a a -a epice o efec e d c ce of eco ac .

Fo a ea e o ifica io a i o acco e fo a a epa a e ea e, e o p a e ee e e ea e a e effec i e a e of e ea e o ifica io, a e ea e e ea e iabii b i co in e ei e ea e pa e in a ei e i co a e, ece p a eco ac c a e i ec e in f -1 a e acco e fo b app in e p acica e pe ie . Fo a ea e o ifica io ic ec ea e e cope of e ea e o o e ea e e, e o p ec ea e eca in a o of ei -of- ea e, a eco i e in p of o o a a o o ea in o epa ia o f e in aio of e ea e. Fo o e ea e ic ea o e ea ea e of ea e iabiiie, e o p co epo in j eca in a o of ei -of- ea e.

Fo e a ai e a a e of -1 a fo epeio e e B e 21 , e o p appie e p acica e pe ie a eco e i co e ai e in p of o o e ea ee i eac e o i i eoi in a pa e obi aio i co epo in j e of ea e iabiiie.

e o a ee o

A ea ei c a ifie a a ce ea eifi a fe b ia a ei e a e d a oo e ip of a e in a e. A ope a ea ei a ea e o e a a ce ea e.

e o p acco fo a ea e o ifica io a a e ea e f e effec i e a e of e o ifica io, a co i e a ea e pa e ecei e in a ce a ecei abe e a o e ea e bef e o ifica io a ecei abe of e e ea e.

(a) pe a ea e

e e o p ea e o ef-o e bi , ac in e a e i , a oo ei ce e ope a ea e, e a co e e ef i eco i e e a ai -in e bai o e ea e e . aiabe a a i in e o ace a pe ce a e of a e i eco i e in a co e a in c e .

(b) H ce ea e

A e co ce e a e, e o p eco i e ea e pa e ecei abe e a ce ea e a e eco i e ee a e . ea e pa e ecei abe e a ce ea e a e p e e a o -e ecei abe; ea e pa e ecei abe e a ce ea e e i in de ea (c ie) a f eba ce ee a e a ei c e in ec e poi of d -c e a e .

Notes to the Financial Statements

For the year ended 31 December 2012
(Amounts in Brunei Dollars)

2 Summary of significant accounting policies and accounting estimates (continued)

(27) Segment information

For operating purposes, the Group is organised into business units based on their products and services, and has two reportable operating segments as follows:

The operating segments is a component of the Group that engages in business activities; (2) its operating results are reviewed regularly by the Group's chief operating decision maker to make decisions about resources to be allocated to the segment and to assess its performance, and (3) for which discrete information is available, operating segments are aggregated or disaggregated if the products and services within each reportable segment have similar economic characteristics and are similar in each of the following respects:

(28) Critical accounting estimates and judgements

The Group makes estimates and assumptions concerning the future. The resulting accounting estimates will, by definition, seldom equal the related actual results. The estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year are discussed below:

(a) Critical accounting estimates and assumptions

Key sources of estimation uncertainty at the reporting date, that have a significant risk of causing an adjustment to the carrying amounts of assets and liabilities within the next financial year, are discussed below:

(i) Allowance for impairment of trade receivables

At 31 December 2012, gross amount of trade receivables was B$ 3,230,121 (31 December 2011: B$ 1,162,735). Allowance for impairment losses of trade receivables are made based on an assessment of the recoverability of trade receivables. The assessment is based on the credit history, existing market conditions as well as forward looking estimates at the end of each reporting period. The assessment of the likelihood of the allowance for impairment losses of trade receivables requires the use of judgement and estimates. Where the expectation is different from the original estimate, such difference will impact the carrying value of trade receivables and allowance for impairment losses of trade receivables in the period in which such estimate has been changed.

The Group makes estimates and assumptions concerning the future. The resulting accounting estimates will, by definition, seldom equal the related actual results. The estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year are discussed below:

Notes to the Financial Statements

Fo e ea_ ed *e* 31 ece be 2 2
(A o in B e o e ie a_e*)

2 S a of i ifica acco in poide a* acco in e a_e (co in e*)

(28) Critical accounting estimates and judgements (co in e*)

(a) iica acco in e a_e a e a pio (co in e*)*

(i) A e ed fo e pai ed of co ac a i o oi*e a_ed e ice (co in e*)

2 2 2, e a pio a* ope* o eco ie eco e abe* o of co ac a i o oi*e a_ed e ice* a inc *e:

	Yiwu Health Centre	Pujiang Hospital
A e a_e be of in-pai be* in ope aio*	362	274
A e a_e in-pai pe in pe *a pe be**	266	247
o a in*	6%	16 %
e-a *i co a_e	2 .11%	1 .5 %
o a_e in e abe peio*	2.5%	2.5%

2 2 1, e a pio a* ope* o eco ie eco e abe* o of co ac a i o oi*e a_ed e ice* a inc *e:

	Yiwu Health Centre	Pujiang Hospital and Chun'an Hospital
A e a_e be of in-pai be* in ope aio*	373	233
A e a_e in-pai pe in pe *a pe be**	283	2 4
o a in*	6%	33%
e-a *i co a_e	1 .37%	1 , 4%
o a_e in e abe peio*	3%	3%

* ep e ea_e a_e in be in pco in fi e ea .

2 2 , e o p*ee in e* o a_e a* o a in ba_e* o pa e pei ce a* fo eca_ o f e a_e *e e o , a* a*o e* ep e- a in ee a_e a ef ec e i pedic o eco ac a i o oi*e a_ed e ice a e i co a_e. o a_e in e abe peio*i e i e* a_e a_e o a_e o ie* b e o p oe o a_e ca_ fo be o* e fi e- ea_ fo eca_ peio*, ic i co i i a_e in a_e* in e* ep , a* *oe o e cee* e o -e* a_e a_e o a_e of eac p o* c . Fo ea_ ed *e* 31 ece be 2 2, o p oii fo in pai ed a a*e ba_e* o a_ed e ' e of in pai ed e .

Notes to the Financial Statements

For the year ended 31 December 20[illegible]
(Amounts in Brunei Dollars)

2 Summary of significant accounting policies and accounting estimates (continued)

(28) Critical accounting estimates and judgements (continued)

(a) Critical accounting estimates and assumptions (continued)

Notes to the Financial Statements

2 S a of i ifica acco i poide a acco i e a e (co i e)

(28) Critical accounting estimates and judgements (co i e)

(a) iica acco i e a e a e a io (co i e)

(iii) e e i aio of efai a eo i e e p ope ie

e e p ope ie (oe 4( )) a e b e e ea e efai a e i ei co e app oac . ei p ai i c e a, a e a e/ca i ai aio a e, ac c a e, e c.

e ea e i fo aio of fai a e ea e i a fo o :

	Fair value as at 31 December 2020	Valuation technique	Significant unobservable inputs Name	Weighted average	Relationship with fair value	Observable/ Unobservable
a e of B i e e ei (i e E ca io a e	42,628) 66	co e app oac	a e a e/ ca i ai aio a e o e a 380 (B o) ac c a e	5.0 % 48.51 2.74%	(a)	ob e abe
a e of B i e e ei (i e E ca io a e	65,176,80	co e app oac	a e a e/ ca i ai aio a e o e a 0 .5 (B o) ac c a ei)	00 % 0 33	(a)	ob e abe
	0 7,0 4, 36					

i) Acco o e i e ea e, e ac c a e of e p ope i 0 i efo ec a pe io .

(a) e a io ip be ee e ob e abe i p e efai a e:

- the higher the ultimate return rate/capitalisation rate is, the lower the fair value is;
- the higher the estimated vacancy rate is, the lower the fair value is;
- the higher the monthly rental is, the higher the fair value is.

Notes to the Financial Statements

For the year ended 31 December 2022
(All amounts in Brunei Dollars unless otherwise stated)

2 Summary of significant accounting policies and accounting estimates (cont'd)

(28) Critical accounting estimates and judgements (cont'd)

(a) Critical accounting estimates and assumptions (cont'd)

(i) Accounting estimates and assumptions of cost

The cost of an asset is affected by estimates and assumptions of the expected useful life of the asset and expected residual value at the end of its useful life. Such estimates are determined after taking into consideration the expected usage of the asset, expected physical wear and tear, technological or commercial obsolescence and legal or similar limits to the use of the asset. See also the relevant accounting policies (note 4(14)).

The cost of the Group's right-of-use assets and lease liabilities, operating lease commitments and non-lease components of contracts are affected by estimates and assumptions of the Group's incremental borrowing rate for discounting. The existence and terms of extension and termination options, the assessment of whether the Group is reasonably certain to exercise such options and the estimation of expected useful lives of right-of-use assets are affected by estimates and assumptions.

Provisions and contingent liabilities are affected by estimates and assumptions of the likelihood of outflow of economic benefits, and the amount of provision or contingent liability. The likelihood of outflow of economic benefits and the amount of provision or contingent liability are assessed at each reporting date, but the actual outflow of economic benefits in future periods may vary from those estimated.

Provisions for restoration costs are affected by estimates and assumptions of the timing and amount of future expenditures, and the discount rate used. These estimates and assumptions are reviewed at each reporting date and changes in these estimates and assumptions are reflected in the cost of the related asset.

Provisions for warranties are affected by estimates and assumptions of the timing and amount of future expenditures, and the discount rate used. These estimates and assumptions are reviewed at each reporting date and changes in these estimates and assumptions are reflected in the profit or loss.

Notes to the Financial Statements

Fo e ea e 31 ece be 2 2
(A o in B e o e ie a e)

2 S a of i ifica acco in poide a acco in e a e (co in e)

(28) Critical accounting estimates and judgements (co in e)

(a) iica acco in e a e a e a ion (co in e)

( ) co e a a ef e in co e a

e o i bjec oi co e a e in eo j i cio . ee a e o e a io a e ed fo ic e a e a ee ai io i ce a in eo a co e of b e . Si ifica j e a i e ie f o e o in ee ai e po oiio fo in co e a e in ea c of ee j i icio . ee e a a o co e of ee a e i ffe d f o e a o a ee iii a eco e , c ffe ce i pac ei co e a a ef e a poiio in epeio in ic c ee ai io i a e.

ef e a a e a e eco i e fo e e cibe a o e a ca be ca ie fo a o be e ea o ee e a i pobabe a abe p oi i be a abei ef e a ic e e cibe a o e ca be ii e. a abe p oi a i be a abei e f ei c e e a abe p oi a i be ea ie o o a ope aio a e a abe p oi a i be ce a e pod e ee a of a abe e po a ffe ce in c e in pio peio . e e a e a e e ie o ee ie e e a o of a abe p oi in ef e. A ffe ce be ee e ea a ee a e a a j e o e ca in a o of ef e a a e .

(b) iica j e e in app in e acco in poide

(i) e e e o p a co o o e e o i a p oi e a a e e ice

e o p e ee o a ee e i ee a o i a in ec a ef o co ac a i o p oi e a a e e ice o c o i a a ob a a e e ice fee e in e peio .

Af e a e in e po e of c o i a 'in e a ed io a ei bo ie a co i ee o i ai ope aio -e a e acii ie a e po e a e o e o p o a idpa e in e o i a 'ai ope aio -e a e acii ie, a a e e beie e a e o p e jo e i of o in ai pa in ee ed io a ei bo ie a co i ee, b oe o ob a ed io a ei po e o ea e e o i a 'ai ope aio -e a e acii ie. ea ie, e o p a o co i e e a ia be e o ob a e b bo pa ie o eco ac. e o p

Notes to the Financial Statements

For the year ended 31 December 2022
(All amounts in Brunei Dollar unless otherwise stated)

2 Summary of significant accounting policies and accounting estimates (continued)

(28) Critical accounting estimates and judgements (continued)

(b) Critical judgements in applying accounting policies (continued)

(ii) Determination of significant increase in credit risk

Determination of the appropriate significant increase in credit risk criteria and basis of measurement for the expected credit loss, including the definition of default, the significant increase in credit risk criteria and the selection of appropriate forward looking information, etc.

Determination of the appropriate economic scenarios and their probability weightings and basis of measurement for the expected credit loss (i.e., unbiased and probability-weighted amount), including the identification of forward looking information and the assessment of multiple economic scenarios: whether the identified forward looking information is relevant, and the weightings assigned to the

Notes to the Financial Statements

For the year ended 31 December 2022
(All amounts in Brunei Dollar thousands)

3 Taxation

The major categories of the applicable corporate income tax are:

Category	Tax rate	Tax base
Enterprise income tax (a)	15%, 20% to 25%	Taxable income
Withholding tax ("WHT") (b)	1%, 3%, 5%, 6% to 13%	Gross
Interest and guarantee commission	7%	Amount of WHT being paid
Technical service	3%	Amount of WHT being paid
Local technical service	2%	Amount of WHT being paid
Income tax (c)	18% to 18%	70% of statutory income of corporate income
Branch tax (d)	BND5 million	Amount repatriated
Land tax	0%-0%	Amount of rental

(a) On 1 December 2022, the Government announced the reduction of the Enterprise Income Tax ("EIT") rate, effective for the year of assessment 2023 (income year 2022). The Act 28 of the *Enterprise income tax (amendment) order* reduces the income tax rate applicable to the EIT rate from 18% to 15%.

In accordance to the *Enterprise income tax (amendment) order* and the Notice of the Minister of Finance and Economy on Enterprise Income Tax (Amendment) Order 2022, effective from 1 January 2022, the Company's subsidiaries, Brunei Fluor Ltd. ("BFL") and Brunei Fluor Industrial Estate Sdn. Bhd. ("BFIE") are subject to the EIT rate of 20%.

Notes to the Financial Statements

For the year ended 31 December 2016
(All amounts in Brunei Dollars unless otherwise stated)

3 Summary of significant accounting policies (continued)

(b) Investments in subsidiaries, associates and joint ventures

Investments in subsidiaries, associates and joint ventures are accounted for at cost less impairment in the Company's statement of financial position. On disposal of such investments, the difference between net disposal proceeds and their carrying amounts is included in profit or loss.

Investments in subsidiaries are stated at cost less impairment losses, if any. On disposal of investments in subsidiaries, the difference between net disposal proceeds and the carrying amounts of the investments are included in profit or loss.

Investments in associates are stated at cost less impairment losses, if any. On disposal of investments in associates, the difference between net disposal proceeds and the carrying amounts of the investments are included in profit or loss.

Investments in joint ventures are stated at cost less impairment losses, if any. On disposal of investments in joint ventures, the difference between net disposal proceeds and the carrying amounts of the investments are included in profit or loss.

Investments in subsidiaries, associates and joint ventures are derecognised when the Company loses control, significant influence or joint control. If the retained equity interest in the former subsidiary, associate or joint venture is an investment in an associate, joint venture or financial asset, the retained equity interest is measured at fair value at that date, and the fair value is regarded as its cost on initial measurement as an investment in an associate, joint venture or financial asset. The difference between the fair value of any retained equity interest and any proceeds from disposing the interest in the former subsidiary, associate or joint venture, and the carrying amount of the investment at the date when control, significant influence or joint control is lost is included in profit or loss for the year.

Investments in subsidiaries, associates and joint ventures are classified as non-current assets unless they are expected to be realised within 12 months after the reporting period, or are held for trading.

Investments in subsidiaries, associates and joint ventures are tested for impairment when there is any indication that the investments may be impaired. For the purpose of impairment testing, the recoverable amount (i.e. the higher of the fair value less costs to sell and the value-in-use) is determined for an individual investment, unless the investment does not generate cash flows that are largely independent of those from other assets. If this is the case, the recoverable amount is determined for the cash-generating unit to which the investment belongs.

In assessing value-in-use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the investment for which the estimates of future cash flows have not been adjusted.

If the recoverable amount of an investment is estimated to be less than its carrying amount, the carrying amount of the investment is reduced to its recoverable amount. An impairment loss is recognised in profit or loss immediately, unless the investment is carried at revalued amount in accordance with another standard (e.g. in accordance with the revaluation model in FRS 16), in which case the impairment loss is treated as a revaluation decrease under that standard.

Where an impairment loss subsequently reverses, the carrying amount of the investment is increased to the revised estimate of its recoverable amount, but so that the increased carrying amount does not exceed the carrying amount that would have been determined had no impairment loss been recognised for the investment in prior years. A reversal of an impairment loss is recognised in profit or loss immediately, unless the investment is carried at revalued amount in accordance with another standard (e.g. in accordance with the revaluation model in FRS 16), in which case the reversal of the impairment loss is treated as a revaluation increase under that standard.

Notes to the Financial Statements

Fo e ea e 31 ece be
(A o in B e o e ie ae)

3 a aio (co in e)

(b) (co in e)

! o e Ano ce e o e a e-A e a loide o Sppo in e e pio of o B ine of ii a ia e d a o e o (Ano ce e o. 13) e Ano ce e o E e e Appicabe e o of e loide fo e cio E pio of a e-a e a o Sa -ca e a pe (Ano ce e o. 24) join i e b e ini of Hi ce e Sa e a aio Ai ini aio, abe ae e e of a -ca e a pe in o e po ce, o o eio i idpaie iec e ece a oe e ec (bei o ce bjec o A a e ae of 3% befo e a be bjec o A a ep efe e ia ae of 1%. e e f o e ei of a ae e co in e ice of e o pa ' bi ie a bjec o A a ep efe e ia ae of 1% f 1 ac o 31 ece be .

! o Ano ce e o ee a loide fo eedin a e-A e a efo (. 3 of F, S A A) join i e b e ini of Hi ce, e Sa e a aio Ai ini aio e e a Ai ini aio of o e ee e aio , e o pa ' bi ie, e o in o e o., . (e o in o e) e ej e e ica o., . (ej e e ica) ee bjec o A fo a e of p a ce ica po c e ie a e appicabe a ae of 13% f 1 Apii , ie e appicabe a ae a 16% befo e .

(c) ! o e oice o aio Affai (in i S i o (17 o.) e (in i S i o (17 o. 31) i e b in o Loca a B ea a B c o 13 Apii 17, in a in (o ia a e e e f o pope a fo 3 ea ce 1 16.

! o A ice 0 of e ic a of e ini of Hi ce e Sa e aio Ai ini aio o in e ep e aio e e o iio o So e Spec ific e o ce ea E a e ' e ep e aio e e o iio o So e Spec ific e o ce ei ce e e a ' (i S i i i[86 o. 8), i e a oo e -occ pie' pope ie of aio o ia ope a e b e epie, pope a a bee e pe' i efe ce oo e -occ pie' pope ie in ce b e ini of Hi ce. e o pa ' bi ie, in in (o ia, a e e pe' f o pope a fo 3 ea ce 1 17.

( ) ! o e pe e aio i o A j e of ba a e a loic in e o i o! o oe a e ' e ie e ii aio i e b e o idpa! eope' o e e ffice o, a 16 e oice o aio Affai (e i S i o ii o 16 o. 173 e i S i (17 o. 40 68) i e b e o Loca a aio B ea c e a B c o 16 e 13 a a 17, e o pa e jo e 00 % e e pio o ba e a fo e ea of 17, 18 e .

! o A ice 7 of e edio of e Sa e o d o A e e e aio of e! eope' ep bic of ina i e o a e (e o.483 of e Sa e o d of e! eope' ep bic of ina e ic a of e ini of Hi ce e Sa e a aio Ai ini aio o a loide of e ica e / ea i io (i S i 000 o. 42), e o pa e i bi ie, in in (o ia, in ia in (o ia e jo e 00 % e e pio o ba e a fo e ea of .

Notes to the Financial Statements

For the year ended 31 December 2020
(Amounts in Brunei Dollars unless otherwise stated)

4 Notes to consolidated financial statements

(1) Cash at bank and on hand

	31 December 2020	31 December 2019
Cash on hand	374,287	45,334
Cash at bank	206,125,277	175,377,544
Time deposits	–	1,300,000
	206,499,564	176,722,878

As at 31 December 2020, the Group's cash at bank of B$6,046,824 were held under Escrow Accounts for construction projects of certain subsidiaries (see note 8(5)(a)).

As at 31 December 2019, the Group's time deposits of B$100,000, the Group's cash of B$119,468,600 were pledged as security for banking facilities granted to the Group (see note 8(5)(a)).

(2) Accounts receivable

	31 December 2020	31 December 2019
Receivables from related parties (note 8(5)(a))	7,250,000	8,250,000
Trade receivables	348,065,571	330,174,215
Subtotal	355,315,571	338,424,215
Less: provision for bad debts	(33,907,606)	(27,723,603)
	321,407,965	310,700,612

Accounts receivable are non-interest bearing and are generally on terms of 30 days.

Notes to the Financial Statements

Fo e ea_ e e 31 ece be 2 2
(A o i B e o e ie a_e)

4 o e o eco oi a_e fi a d a_ a_e e (co i e)

(2) Accounts receivable (co i e)

(a) e a_d a_ i of acco ecei abe ba_e o e bi i a_ei a_ fo o :

	31 December 2020	31 ece be 2 1
i 1 ea_	276,029,265	266, 32, 53
1 2 ea_	59,715,117	57, 88,0 7
2 3 ea_	19,442,357	13 8,00 1
e 3 ea_	128,832	413,854
	355,315,571	338,424,215

2 2 , e o p a o acco ecei abe e eco i e e o a fe of fi a d a_ a_e .

(b) I o i io fo ba e eb

e o p ea_ e e o a_o a ce of acco ecei abe a_ a o e a_ o e ife e E L, e a e e of e e e co a a i i ifica fi a d co po e .

A a_ 31 ece be 2 2 , e e e o acco ecei abe fo ic e e a_e p o i io fo ba e eb a_p o i e o ei i i a_ ba_i (31 ece be 2 1 : B1,88 ,254).

Notes to the Financial Statements

For the year ended 31 December 2020
(All amounts in RMB unless otherwise stated)

4 Notes to consolidated financial statements (continued)

(2) Accounts receivable (continued)

(b) Provision for bad debts (continued)

(i) Accounts receivable for which lifetime expected credit loss provision is recognised on an individual basis:

	31 December 2020			31 December 2019		
	Book value	Provision for bad debts		Book value	Provision for bad debts	
		Lifetime			Lifetime	
	Amount	ECL rate	Amount	Amount	ECL rate	Amount
Not yet due	29,027,823	1%	290,278	23,314,108	1%	233,148
Past due within 30 days	169,414,663	4%	6,776,587	151,536,144	5%	7,576,807
31 to 180 days	77,586,779	4%	3,103,471	109,282,664	6%	5,465,508
181 to 365 days	59,715,117	20%	11,943,024	57,614,783	11%	6,337,626
1 to 3 years	19,442,357	60%	11,665,414	11,662,708	50%	5,831,354
Over 3 years	128,832	100%	128,832	413,854	100%	413,854
Total	355,315,571		33,907,606	336,534,561		26,014,347

(ii) The amount of provision for bad debts made in the current year is RMB23,414,275 (2019: RMB20,616,274), and the amount of RMB72,787 was recovered (2019: RMB25,800).

The book balance of accounts receivable with a cumulative amount of RMB17,337,485, and the provision for bad debts with a cumulative amount of RMB17,337,485, were written off during the current year.

Notes to the Financial Statements

For the year ended 31 December 2020
(Amounts in Brackets are for the previous year)

4 Other receivables and prepayments (continued)

(3) Other receivables

	31 December 2020	31 December 2019
Loans to third parties (i)	11,623,500	21,283,500

Notes to the Financial Statements

For the year ended 31 December 2020
(All amounts in Brunei Dollars unless otherwise stated)

4 Other receivables (continued)

(3) Other receivables (continued)

(a) Ageing of other receivables after provision for bad debts:

	31 December 2020	31 December 2019
Within 1 year	20,302,805	21,336,124
1 to 2 years	18,699,660	19,781,947
2 to 3 years	4,964,193	5,365,316
Over 3 years	24,282,668	28,982,514
	68,249,326	75,465,781

(b) Movements for other receivables book value and provision:

	Stage 1 12-month ECL (on the grouping basis)		Stage 3 Lifetime ECL (credit-impaired)		Total
	Book value	Provision for bad debts	Book value	Provision for bad debts	Provision for bad debts
31 December 2019	65,440,476	3,111,215	5,975,285	5,037,200	12,148,415
Increase in current year	15,334,712	5,410,977		488,428	1,489,405
Write off in current year					

Notes to the Financial Statements

Fo e ea e 31 ece be 2 2
(A o in B e o e ie a e)

4 o e o eco oi a e in a d a a e e (co in e)

(3) Other receivables (co in e)

(b) ! o i io fo o e c a e in book a e a e (co in e)

(i) A a 31 ece be 2 2 , fo o e ecl abe a Sa e 1, e ea e o i io fo ba eb a a e be o :

	Book value	12-month ECL rate	Provision for bad debts
! o i e o e o ba i :			
o i pa ie	11,623,800	7%	813,645
A ce	8, 75,352	7%	628,275
ecl abe fo e a e pa ie	26,113,638	5%	1,0 5,682
epoi a a ee	8,682,0 6	3%	260 ,46
e	0 ,6 8,415	1%	0 6, 84
	60 , 3,211		3,115 55

(ii) A a 31 ece be 2 2 , e o i o a e o e ecl abe a Sa e 2.

(iii) A a 31 ece be 2 2 , fo o e ecl abe a Sa e 3, e ea e o i io fo ba eb a a e be o :

	Book value	Lifetime ECL rate	Provision for bad debts
! o i e o e i a ba i :			
io o i in (o e i)	2,156,115	7 %	1,6 8,458

i) e o a o e e a pa i b e o i epo io ea . e o e e e e o e in a e eco ac a e e o e pa o e e a pa i . A a 31 ece be 2 2 , e a i a i in e ia poce in eco . e o a e oi a in e eco dia io pa i e o e pa . Ba e o e a e e e e o e , a a e e a e a o io fo ba eb a 7 % fo e acco ecl abe.

(c) 2 2 , e o e fe a jao F e (o i a a ac a eco e e a B 0 000 . e o of B7,11 ,1 fe a jao F e (o i a a i e off in ce a a e e e a e o a ific o be eco e e acco in o e e of ej e e .

Notes to the Financial Statements

For the year ended 31 December 2020
(Amounts in Brunei dollars)

4 Notes to consolidated financial statements (continued)

(4) Advances to suppliers

(a) Ageing of prepayments is as below:

	31 December 2020		31 December 2019	
	Amount	% of total balance	Amount	% of total balance
Within 1 year	11,747,540	98%	5,258,821	98%
1 to 2 years	93,133	1%	20,553	
2 to 3 years	20,209	–	54,646	1%
Over 3 years	67,000	1%	32,000	1%
	11,927,882	100%	5,366,020	100%

(5) Inventories

(a) Inventories are analysed by category as follows:

	31 December 2020	31 December 2019
Land held for development	28,767,481	17,38 ,132
Completed properties	6,165,704	3,0 3,818
Properties held for sale (i)	2,575,286	2,575,286
	37,508,471	23,568,236

As at 31 December 2020 and 31 December 2019, all of the properties are pledged to banks for banking facilities.

In 2020, there was no capitalisation of interest in inventories (2019: Nil).

(i) Properties held for sale

Project Name	Expected Start Date	Expected Completion Date	Balance as at 31 December 2019	Transfer from Inventories	Transfer to Inventories	31 December 2020
Phase of Bungalow Development in Mukim Kilanas	October 2012	December 2017	173,0 7,5 4	2,575,286		2,575,286

As at 31 December 2020, the properties held for sale are pledged to banks.

Notes to the Financial Statements

Fo e ea e 31 ece be 2 2
(A o in B e o e ie a e)

4 o e o eco oi a e in ad a a e e (co in e)

(5) Inventories (co in e)

(b) e in ebook a eo in e oie fo ec e ea a e a e a fo o :

	31 ece be 2 1	B in e co b aid in o in e epie o in e co o (oe 5(1)(c))	c ea ei ec e ea	ec ea ei ec e ea	31 December 2020
! a ace ica in oc	17,38 ,132	81 ,6 3	214,63 2,2 0	(2 4) 73,5 24)	28,767,481
d e be	3,6 3,818	223, 76	58 , 6) 57	(56,658,147)	6,165,704
! ope ie e fo a e	2,575,286				2,575,286
	23,568,236	10 43,57	273,6 8,3 7	(20 ,731,671)	37,508,471

(6) Current portion of non-current assets

	31 December 2020	31 ece be 2 1
epoi eci be (i)	–	12,688,7 4

(i) ep e e e epoi pai b e d pa o e o e o ce e eco cio a epa io p oec of e (opi a a ee in ep oject co cio co ac i e i e i -pa co ac o. S c epoi o be eco e e af e eco pei o of ep oject e e e of p oject fee. 8 a 2 , e opa ie i e a eco di a io a ee e , co fi in a e pa e epoi ee ea e a off e epe fo ce a ee poi e b eco ac in pa o e d pa , a d e pa a e ie e o e e abo e epoi o eo e pa .

(7) Long-term equity investments

	31 December 2020	31 ece be 2 1
A od a e (a)	93,726,511	8 , 43,1 3
Le : ! oii fo in pai e of d -e e i in e e	–	
	93,726,511	8 , 43,1 3

ee i o i ifica e icio d a e of d -e e i in e e e b e o p.

Notes to the Financial Statements

For the year ended 31 December 20XX
(Amounts in Bahraini Dinars)

4 Summary of significant accounting policies (continued)

Notes to the Financial Statements

For the year ended 31 December 2020
(All amounts in Brunei dollars unless otherwise stated)

4 Notes to consolidated financial statements (continued)

(10) Fixed assets

	Buildings	Medical equipment	Motor vehicles	Electronic equipment and other equipment	Total
Cost					
At 31 December 2019	523,768,640	106,225,602	6,728,107	50,237,867	687,030,217
Increase through business combination of entities under common control (note 5(1)(c))		2,094,411	128,233	148,247	3,370,891
Additions	17,006,946	15,923,876	1,078,208	4,335,688	38,344,720
Increase through disposal of a subsidiary		(1,448,170)	(2,644,135)	(2,673,603)	(6,765,908)
Transfer (i)	(14,899,787)				(14,899,787)
At 31 December 2020	525,875,799	122,795,719	5,290,548	52,047,199	705,809,233
Accumulated depreciation					
At 31 December 2019	44,000,443	47,772,003	3,064,572	34,766,263	129,603,281
Increase through business combination of entities under common control		1,771,433	854,652	1,126,907	3,753,012
Additions	15,265,160	16,790,918	854,652	8,126,907	41,037,637
Increase through disposal of a subsidiary		(1,356,088)	(2,515,574)	(2,143,684)	(6,015,346)
At 31 December 2020	59,274,559	63,206,184	1,403,702	35,452,886	159,337,331
Net book value					
At 31 December 2020	462,501,240	49,817,985	3,886,846	17,537,313	533,743,384
At 31 December 2019	479,768,197	58,453,599	3,664,535	15,471,604	557,357,935

(i) For the purpose of the presentation of project assets in the balance sheet as at 31 December 2020, the Group has reclassified certain buildings with net book value of B$14,899,787 from property, plant and equipment to investment properties. The reclassification was made in accordance with the Group's policy on investment properties as disclosed in note 2(10). Accordingly, the depreciation expense of these buildings, amounting to B$1,489,979, is reclassified from cost of sales to cost of investment properties in the income statement.

Notes to the Financial Statements

For the year ended 31 December 2020
(Amounts in Brunei Dollars)

4 Notes to the consolidated financial statements (continued)

(10) Fixed assets (continued)

(a) The movement of cost of land, leasehold land improvements, leasehold properties and equipment during the financial year:

	2020	2019
Cost of land	34,129,808	26,587,185
Leasehold land improvements	6,525,635	7,767,122
Leasehold properties and equipment		

Notes to the Financial Statements

For the year ended 31 December 20XX

(Amounts in Bahraini Dinars)

Notes to the Financial Statements

For the year ended 31 December 2020
(Amounts in Brunei Dollars unless otherwise stated)

4 Other operating expenses (continued)

(13) Intangible assets

	Land use rights	Software	Contractual right to provide management services	Licences	Trademark rights	Total
Cost						
At 31 December 2019	36,45[illegible]	[illegible],253,061	51,[illegible]0 7,413	55,837,000		153,457,414
Increase due to business combination	27,0 7,000	10,538,446			2,8[illegible],386	31,574,832
Effect of movements in exchange rates		537,11[illegible]		27,000,000		27,537,11[illegible]
Decrease due to disposal (note 5(1)(c))			(14,[illegible]33,544)			(14,[illegible]33,544)
Decrease due to disposal (i)						
At 31 December 2020	64,166,940	10,828,626	36,973,869	82,837,000	2,829,386	197,635,821
Accumulated amortisation						
At 31 December 2019	30,[illegible],7[illegible]7	5,15[illegible],[illegible]1	6,744,678	6,157,30[illegible]		23,15[illegible],286
Increase due to business combination	10,75,774	1,66[illegible],348	20,68,111	[illegible],23[illegible],[illegible]8	4[illegible],[illegible]7	14,[illegible]1,748
Decrease due to disposal (i)			(2,161,[illegible]41)			(2,161,[illegible]41)
At 31 December 2020	6,173,771	6,828,639	6,650,848	15,396,628	49,207	35,099,093
Net book value						
At 31 December 2020	57,993,169	3,999,987	30,323,021	67,440,372	2,780,179	162,536,728
At 31 December 2019	31,361,[illegible]43	40[illegible],3,70[illegible]	45,16[illegible]2,735	[illegible],67[illegible],68[illegible]		1[illegible],[illegible]8,128

[illegible] 2020, [illegible]operation of [illegible]ibe[illegible]e [illegible]o[illegible]e[illegible]o B14,[illegible]1,748 (2019: B[illegible],874,756). [illegible] 2020, [illegible]on of [illegible]epe[illegible]ciation [illegible]pe[illegible] [illegible]c[illegible]e[illegible] o[illegible]co[illegible]of [illegible]e, [illegible]e[illegible]a[illegible]e[illegible] [illegible]i[illegible]i[illegible]ee [illegible]pe[illegible]e [illegible]e[illegible] [illegible]i[illegible]ib[illegible]io[illegible]e[illegible]pe[illegible]e[illegible]ee B11,65[illegible],616, B[illegible],385[illegible]23 [illegible] B57,[illegible]0[illegible], [illegible]ecie[illegible] (2019: B[illegible]00[illegible],[illegible]03, B1,865,353 [illegible] [illegible]).

(i) [illegible]e [illegible]o[illegible]pe[illegible]ee[illegible]i[illegible]o[illegible]e[illegible] [illegible]e[illegible]a[illegible]e[illegible]e[illegible] [illegible]e[illegible]ice[illegible]a[illegible]ee[illegible]e[illegible] in [illegible]ac[illegible] 16. [illegible]e[illegible] [illegible]e[illegible]a[illegible]e[illegible]e[illegible] [illegible]e[illegible]ice[illegible]pe[illegible]io[illegible]i[illegible]o[illegible] [illegible]ac[illegible] 15 o[illegible] Feb[illegible] [illegible] 46. [illegible]in [illegible]e[illegible]a[illegible]ee[illegible]e[illegible] [illegible]pe[illegible]io[illegible], [illegible]e [illegible]o[illegible]pp[illegible]o[illegible]i[illegible]e[illegible] [illegible]a[illegible]e[illegible]e[illegible] [illegible]e[illegible]ice [illegible]o [illegible]'[illegible] [illegible](o[illegible]i[illegible]a[illegible]e[illegible] co[illegible]ec[illegible] [illegible]a[illegible]e[illegible]e[illegible] [illegible]e[illegible]ice[illegible]ee. Acco[illegible]in[illegible] [illegible]o [illegible]e[illegible]a[illegible]ee[illegible]e[illegible], [illegible]e [illegible]o[illegible]pe[illegible]eco[illegible]i[illegible]e [illegible]e[illegible]co[illegible]ac[illegible]a[illegible]i [illegible]o[illegible]pe[illegible]o[illegible]i[illegible]e[illegible] [illegible]a[illegible]e[illegible]e[illegible] [illegible]"

Notes to the Financial Statements

For the year ended 31 December 2021
(All amounts in Brunei Dollars unless otherwise stated)

4 Notes to consolidated financial statements (continued)

(14) Goodwill

	31 December 2019	Increase/(decrease)	31 December 2020
Cost			
Arising on acquisition	8,533,389		8,533,389
Arising on acquisition	7,784,850		7,784,850
Arising on acquisition	9,271,800		9,271,800
Beginning balance	22,987,331		22,987,331
Arising on acquisition	5,068,960		5,068,960
Arising on acquisition	6,843,289		6,843,289
Arising on acquisition		11,822,030	11,822,030
Arising on acquisition		13,448,538	13,448,538
Exchange	2,390,403		2,390,403
Sub-total	88,150,590	25,270,568	88,150,590
Less: Impairment loss recognised			
Arising on acquisition	(8,533,389)		(8,533,389)
Beginning balance		(8,011,603)	(8,011,603)
Sub-total	(8,533,389)	(8,011,603)	(16,544,992)
	54,346,633	17,258,965	71,605,598

Notes to the Financial Statements

Fo e ea_ e e 31 ece be
(A o in B e o e ie a_e)

4 o e o eco oi a_e in adia a_e e (co in e)

(14) Goodwill (co in e)

(a) A oo i of e o a_ bed a_oca_e o e ea_e a_ e o o of a_ e o o e a_ of c a_e i o c e of eco a_oca_io of oo i , ic i a_i e b ope a_in e e a_fo o :

	31 December 2020	31 ece be
(ea_ ca_e e ice e e		
in in (o i a_	9,271,800	9,271,800
e in a_fa (o i a_	7,784,850	7,784,850
Bei in in (o i a_	22,987,331	22,987,331
(a_ a_ 85 (ea_ ca_e e ice e e)	(1,530,682,030)	(1,488,820,030)
'		

Notes to the Financial Statements

For the year ended 31 December 20XX
(Amounts in Bahraini Dinars)

4 Summary of significant accounting policies (continued)

Notes to the Financial Statements

For the year ended 31 December 2020
(All amounts in RMB unless otherwise stated)

4 Notes to consolidated financial statements (continued)

(16) Deferred tax assets and deferred tax liabilities

(a) Deferred tax assets

	31 December 2020	
	Deductible temporary differences and deductible losses	Deferred tax assets
Provisions	122,695,044	30,673,761
Unpaid interest	38,721,119	9,680,280
Share-based payments	16,899,060	4,224,765
Advance received for operating lease	126,654	31,664
Depreciation of right-of-use assets and amortization of intangible assets	7,865,404	1,966,351
	186,307,281	46,576,821
Including:		
Expected to be recovered in more than one year		9,680,280
Expected to be recovered after one year		36,896,541
		46,576,821

	31 December 2019	
	Deductible temporary differences and deductible losses	Deferred tax assets
Provisions	126,45 ,168	31,614,7 2
Unpaid interest	40 5 0 18	10 13 0 6
Share-based payments	11,11 ,5 0	2,77 ,80
Advance received for operating lease	126,654	31,664
Depreciation of right-of-use assets and amortization of intangible assets	5,346,351	1,336,588
Unpaid	2,000 000	50 000
	185,0 3,711	46,275, 8
Including:		
Expected to be recovered in more than one year		10 ,5 0 ,467
Expected to be recovered after one year		35,755,463
		46,275, 8

Notes to the Financial Statements

For the year ended 31 December 2020
(All amounts in RMB unless otherwise stated)

4 Notes to consolidated financial statements (continued)

(16) Deferred tax assets and deferred tax liabilities (continued)

(b) Deferred tax liabilities

	31 December 2020	
	Taxable temporary differences	Deferred tax liabilities
Appreciation of the fair value arising from business combination not under common control	91,613,072	22,903,268
Changes in fair value of financial assets	8,516,685	2,129,171
	100,129,757	25,032,439
Including:		
Expected to be settled in one year (inclusive)		2,572,269
Expected to be settled after one year		22,460,170
		25,032,439

	31 December 2019	
	Taxable temporary difference	Deferred tax liabilities
Appreciation of the fair value arising from business combination not under common control	82,57 ,0 12	20,644,753
Changes in fair value of financial assets	1 , 17,462	47 ,365
	84,4 6,474	21,124,118
Including:		
Expected to be settled in one year (inclusive)		2,4 5,167
Expected to be settled after one year		18,628, 51
		21,124,118

(c) Deferred tax assets or deferred tax liabilities presented on a net basis after offsetting

	31 December 2020	31 December 2019
Deferred tax assets	51,245,123	33,454,884

Notes to the Financial Statements

Fo e ea e e 31 ece be 2 2
(A o i B e o e ie a e)

4 o e o eco oi a e i a d a e e (co ie)

(16) Deferred tax assets and deferred tax liabilities (co ie)

( ) e cibe o e fo ic o e e a a e a eco ie i e pie a fo o :

	31 December 2020	31 ece be 2 1
2 2	–	8,646, 75
2 21	8,766,673	5,838,726
2 22	11,852,360	6, 37,80
2 23	651,018	1,6 2,585
2 24	9,667,426	0 ,338,718
2 25	20,307,646	
	51,245,123	33,454,884

(17) Other non-current assets

	31 December 2020	31 ece be 2 1
! epa e fo fi e a e a p ojec	4,708,451	1,7 1,68
e epoi (i)	14,000,000	
	18,708,451	1,7 1,68

(i) A a 31 ece be 2 2 , e ba ce of e epoi o e o B14,000,000 i a e f o 15 Apil 2 2 o 15 Apil 2 22. e ba ce 1ie ic e ca , ie ie e e epoi of e p ojec co p ci o a e e co ac of a bi ia of e o p, e o L ce (o ia o., L . (L ce (o ia).

Notes to the Financial Statements

For the year ended 31 December 2020
(All amounts in RMB unless otherwise stated)

4 Notes to consolidated financial statements (continued)

(18) Provision for asset impairment and losses

	31 December 2019	Increase in current year	Decrease in current year: Reversal	Decrease in current year: Write-off	31 December 2020
Provision for bad debts of accounts receivable	27,203,613	23,414,275	(72,787)	(17,337,485)	33,907,606
Provision for bad debts of other receivable	12,148,415	1,48[illegible],05	(1,645,237)	(7,11[illegible],170)	4,813,513
Provision for impairment of goodwill	8,533,38[illegible]	80,11[illegible],603			16,544,992
	48,585,407	32,855,383	(1,718,024)	(24,456,655)	55,266,111

(19) Short-term borrowings

	31 December 2020	31 December 2019
Guaranteed borrowings (Note 8(4)(i)) (i)	312,500,000	250,000,000

(i) As at 31 December 2020, the guaranteed borrowings of RMB62,500,000 (guaranteed by the Company and Mr. [illegible] (the controlling shareholder of the Company); the guaranteed borrowings of RMB50,000,000 (guaranteed by Mr. [illegible]; the guaranteed borrowings of RMB200,000,000 (guaranteed by Mr. [illegible] and Mr. [illegible].

As at 31 December 2020 and 31 December 2019, the interest rates of short-term borrowings ranged from 4.05%-5.22% and 4.35%-5.22% per annum, respectively.

(20) Accounts payable

Details of accounts payable by nature are as follows:

	31 December 2020	31 December 2019
Within 3 months	54,689,668	65,881,555
3 to 6 months	9,659,122	7,47[illegible],5
6 to 12 months	4,105,307	1,381,01[illegible]
1 to 2 years	571,326	[illegible]6,88[illegible]
2 to 3 years	252,094	[illegible],4,816
Over 3 years	296,410	[illegible]0,613
	69,573,927	75,554,[illegible]0

Notes to the Financial Statements

Fo e ea_ ë ^e 31 ece^ be 2 2
(A ^o^ in B ^ e o e ie a_e^)

4 oe o ecoⁿ oi^a_e^ in^ di a_ a_ë ë (coⁿ in e^)

(21) Contract liabilities

	31 December 2020	31 ece^ be 2 1
A^ ^ce f o^ oo^ ^ e ice	12,965,170	8,562,126

2 2 , ecoⁿ ac iabii of B8,562,126 c ^e^in eca_ in ^o^ a_ be in in of epeio^ a_ ^fe e^ o eope_in in coⁿ e, ^ in c ^in ^e^ca_ e ice in coⁿ e.

(22) Employee benefits payable

	31 December 2020	31 ece^ be 2 1
S o -e^ ë^ p o ee be ei^ pa_ abe (a)	41,593,360	34,4 ,60
ei^ e^ co^ ib io^ p ^ pa_ abe (b)	1,191,773	1, 2,587
	42,785,133	36 63,277

*(a) S o -e^ ë^ p o ee be ei^*

	31 ece^ be 2 1	B in e co^ b^ ai o^ in o in e^ p i e ^o ^e co^ ^ co^ o (oe 5(1)(c))	c e_ei^ ec ë ea	ec e_ei^ ec ë ea	31 December 2020
a_e ^ a_ie , bo^ , a_o ^ce ^ bi^ie	33, 6,48	7 8, 28	8 8, 26,122	(8 1,577,68)	40,453,010
S ff e f_e	45		6, 21, 25	(6,64 , 5)	17,470
Sod_in ^ce co^ ib io^	813,536	1, 271	, 838,145	(,555,516)	1,115,436
c ^in : e^ca_in ^ce	716,324	1,0 2	, 624,221	(, 55,863)	1,103,684
o^ ^j in ^ce	2, 25	26	1, 8	(2 2, 82)	10,420
a_e^i in ^ce	76,287		2,616	(7,571)	1,332
(o in f^ ^	5,615		14,35 ,645	(14, ,816)	7,444
La_bo ^io^ f^ ^ ^ë p o ee e^ ca_io^ f^ ^			653, 5	(653, 5)	–
e o -e^ ë^ p o ee be ei^			143,716	(143,716)	–
	34,4 ,60	817,	3 ,235, 58	(3 3, ,587)	41,593,360

Notes to the Financial Statements

For the year ended 31 December 2020
(Amounts in Brunei Dollars unless otherwise stated)

4 Other operating liabilities (continued)

(22) Employee benefits payable (continued)

(b) Retirement contribution plan

	31 December 2019	Business combination (Note 5(1)(c))	Increase during the year	Decrease during the year	31 December 2020
Basic pension	1,553,011	17,132	8,612,089	(8,015,343)	1,166,779
Welfare fund	3,576	612	233,074	(248,268)	24,994
	1,556,587	17,744	8,845,163	(8,263,611)	1,191,773

(c) Termination benefits payable

For the year ended 31 December 2020, the Group has no termination benefits incurred for termination of employment contracts.

(23) Taxes payable

	31 December 2020	31 December 2019
Withholding tax payable	22,692,620	12,348,641
Income tax payable	4,826,592	623,037
Value added tax payable	1,990,173	582,601
Stamp duty payable	18,110,608	18,402,751
Others	1,426,562	1,454,173
	49,046,555	33,409,603

Notes to the Financial Statements

For the year ended 31 December 2020
(Amounts in Brazilian Reais)

4 Other obligations, provisions and contingencies (continued)

(24) Other payables

	31 December 2020	31 December 2019
Liabilities for projects (i)	27,016,438	55,0 1,768
Liabilities on lease operations (see note 8(5)(b))	12,870,241	28,4 1,713
0 1 .44 0	(28,4 1,713)	j-42.87 - other
640 0	j--4.44 6,713)	j-42. Lease repo i

Notes to the Financial Statements

Fo e ea d e 31 ece be 2 0
(A o in B e o e ie a e)

4 oe o eco oi a e in ad a e e (co in e)

(26) Long-term borrowings

	31 December 2020	31 ece be 2 1
B k a ee bo o in (a)	95,992,970	6 000 000
B k pe e oa (b)	18,000,000	
Le : e po io of - e bo o in (oe 4(25))		
a ee bo o in	(3,000,000)	(4 000 000)
	110,992,970	2 000 000

(a) A a 31 ece be 2 0 , e pa ' ba k a ee bo o in o e o B 5 2 0 , d ic B2 000 000 a a ee b di, i e a e a e o e of e pa (oe 8(4)(i)). e oa e a f 16 Ap i 2 0 o 16 Ap i 2 23. e a ee bo o in o in o B8 000 000 e e a ee b di, i e a e a e o e of e pa , i, a e a e o e (oe 8(4)(i)). e oa e a f 31 ece be 2 1 o 31 ece be 2 24, e pi idpa i be epa a in f 2 22. e a ee bo o in o in o B45 000 000 e e a ee b di, i e a e a e o e of e pa , i, a e a e o e (oe 8(4)(i)). e oa e a f 2 A 2 1 o 2 A 2 , e pi idpa i be epa a in f 2 21. e a ee bo o in o in o B 2 0 e e a ee b d , -co o in a e o e of a bi ia of e o p (oe 8(4)(i)). e oa e a f 11 o be 2 0 o 11 o be 2 22.

(b) A a 31 ece be 2 0 , e ba ce of e pa ' ba k pe e oa o in o B18 000 000 a pe e b 53.33% e i of e o in (opi a i a o a o of B8 000 000 , e a a ee b di i e a e o e of e pa (oe 8(4)(i)). e oa e a f 8 e 2 0 o 8 e 2 27.

(c) A a 31 ece be 2 0 , ei e e a e of - e bo o in a ie f 4.35% o 7.2 % a a (31 ece be 2 1 : 4.75% o 5.15%).

(27) Lease liabilities

	31 December 2020	31 ece be 2 1
Lea e ia bi i ie	222,341,901	2 ,861,36
Le : e po io of ea e ia bi i ie (oe 4(25))	(32,540,617)	(27 53,218)
	189,801,284	183,8 8,151

A a 31 ece be 2 0 , e o p a oi e a ee o in c e in ea e ia bi i ie b o ea o po e ia ca o f o in ef e.

A a 31 ece be 2 0 , e o p a o ea e pa e of ea e co ac a a bee i e b a o e bee pe fo e.

Notes to the Financial Statements

Fo e ea e 31 ece be 2 2
(A o in B e o e ie a e)

4 oe o eco oi a e in adia a e e (co in e)

(28) Provisions

	31 ece be 2 1	c ea ei ec e ea	ec ea ei ec e ea	31 December 2020
e in ii aio (i)	2,000,000		(2,000,000)	–

(i) A a 31 ece be 2 1, ei ii aio of e o pa a jo F e (o ia (oe 4(13)) a i e ia. e o p o pa B2,000,000 o jo F e (o ia ba e o be e a e. A a 31 ece be 2 2, e ma j e e of i ii aio co c e a e o p o pa B2 , 3,87 o jo F e (o ia.

(29) Deferred income

	31 December 2020	31 ece be 2 1
o e e	9,645,475	, , 4 ,267

o e e p ojec	31 ece be 2 1	A o c a e oo e in co e in ec e ea	31 December 2020	A e - e a e / co e - e a e
E pa io p ojec of e in pai bi (i)	, , 4 ,267	(3 3,7 2)	9,645,475	A e - e a e

(i) e efe e in co e ea e o a e i e o e e of B0 ,632,800 fo e eco cio a e pa io p ojec of ei pai bi eci e f o e o Ri ce B ea in 2 13. e o pa eco i e efe e in co e e eci in e a a e oca e e o e e ef ife of e a e e o a i -i e bai a e eco e in op of o o fo ec e pei o af e i co pei o in 2 17.

(30) Share capital

	31 ece be 2 1	o e e fo ec e ea ep c a e of a e	31 December 2020
S a e capi a (i)	75,000,000	(8 , ,700)	74,600,300

(i) 2 2 , e o p ep c a e 8 , ,700 a e of e o pa ' oc . A a o of B14,52 ,256 a pai fo e ep c a e, in c in B8 , ,700 e ce a a e capi a a e ce a a e ie .

Notes to the Financial Statements

For the year ended 31 December 2021
(Amounts in Brunei dollars)

4 Other reserves and retained earnings (continued)

(31) Capital surplus

	31 December 2021	Increase during the year	Decrease during the year	31 December 2020
Share premium (i)	775,683,317	1,680,163	(27,438,398)	749,889,082
Share-based payment reserve (note 32)	10,903,663	5,887,603	(1,080,163)	16,710,203
Others (ii)	38,155,465		(188,221)	37,967,244
	824,715,445	7,585,666	(27,734,582)	804,566,529

(i) The increase during the year relates to the issuance of 16,433,333 new shares pursuant to the exercise of options granted under the Employee Share Option Scheme. The total proceeds received from the exercise of options amounted to B$1,680,163 which comprised B$1,150,000 contributed by employees and recognised in share premium.

The decrease during the year relates to the repurchase of shares in 2021 as part of the Company's non-compliance with the minimum public float requirement. As at 31 December 2021, the Company's public float was 8% of the Company's total number of issued shares (excluding treasury shares). The repurchase of shares (as disclosed in note 29) resulted in a reduction of B$27,682,775. The difference between the consideration paid for the repurchase of the shares and the

Notes to the Financial Statements

For the year ended 31 December 2020
(Amounts in Brazilian Reais unless otherwise stated)

4 Notes to consolidated financial statements (continued)

(32) Surplus reserve

	31 December 2019	Appropriation in current year	Decrease in current year	31 December 2020
Statutory surplus reserve	33,188,321	3,404,908		36,593,229

According to the Company Law of the People's Republic of China and the Articles of Association of the Company, the Company is required to appropriate 10% of the profit for the year to statutory surplus reserve, and the Company can cease appropriation when the balance of statutory surplus reserve accounts for 50% of the registered capital. The statutory surplus reserve can be used to offset previous years' losses or increase registered capital upon approval.

(33) Retained earnings

	2020	2019

Notes to the Financial Statements

For the year ended 31 December 2020
(All amounts in Brunei dollars unless otherwise stated)

4 Revenue and cost of sales (continued)

(34) Revenue and cost of sales

	2020	
	Revenue	Cost
Sale of goods	978,466,160	701,039,798
Rendering of services	52,817,600	27,662,054
	1,031,283,760	728,701,852

	2019	
	Restated	Original
Sale of goods	743,483,663	616,183,633
Rendering of services	67,200,166	39,000,931
	810,683,829	656,184,564

(a) Revenue and cost of sales for sale of goods

	2020	
	Revenue	Cost
Industrial sale	222,586,930	194,543,819
Retail and wholesale trade	755,879,230	506,495,979
	978,466,160	701,039,798

	2019	
	Restated	Original
Industrial sale	155,615,871	174,317,815
Retail and wholesale trade	587,873,792	441,785,818
	743,489,663	616,183,633

(i) The Group's revenue for industrial sale and retail and wholesale trade is recognised upon delivery.

Notes to the Financial Statements

For the year ended 31 December 20XX
(Amounts in Brackets are Omitted)

Notes to the Financial Statements

For the year ended 31 December 2020
(All amounts in Brunei Dollars unless otherwise stated)

4 Operating profit after charging (continued)

(36) Expenses by nature

Operating profit after charging, in addition to those expenses disclosed elsewhere in the financial statements, the following expenses by nature:

	2020	2019
Employee benefits	339,081,062	288,688,273
Purchases of goods and consumables	260,283,959	225,0[illegible] 1,256
Operating leases	3,339,117	28[illegible] 68,4[illegible] 8
Depreciation of property, plant and equipment	41,037,075	34,8[illegible] 70, 48
Depreciation of right-of-use assets	33,116,519	[illegible] ,85[illegible] ,52[illegible]1
Amortisation of intangible assets	14,101,748	[illegible] ,874,756
Amortisation of deferred expenditure	35,549,405	34,[illegible] 8,665
Foreign exchange gain on operating activities	4,382,432	[illegible] 3,5[illegible]0
Allowance for impairment	44,513,962	35[illegible] [illegible] ,416
Utilities	19,138,805	18,58[illegible] 00 5
Food and beverages	14,146,526	16,[illegible] 8[illegible] 41
Printing and stationery	24,081,462	17,3[illegible]25,[illegible]
Other employee benefits	6,622,267	[illegible] ,44[illegible]2,6[illegible] 3
Auditors' remuneration		
Audit service	800,000	[illegible],60[illegible] 000
Non-audit service	24,500	[illegible]6,[illegible]00
Loss on disposal of property, plant and equipment	2,914,695	3[illegible] 33,565
Rental of premises	4,170,744	6,[illegible]42,376
Office expenses	5,256,718	5,8[illegible]10, 43
Share-based payment (note)	5,887,603	5[illegible] [illegible] ,52[illegible]6
Others	24,360,545	16,688,[illegible]
	882,809,144	[illegible] 3,51[illegible] ,[illegible]0

Notes to the Financial Statements

For the year ended 31 December 2020
(All amounts in Brunei Dollars unless otherwise stated)

4 Other income and other gains (continued)

(37) Financial expenses – net

	2020	2019
Bank borrowings interest expense	20,173,820	17,231,667
Less: interest income capitalised (Note 4(a))	(13,820,000)	(13,820,000)
	6,353,820	3,411,667

Notes to the Financial Statements

For the year ended 31 December 2020
(All amounts in Brunei dollars unless otherwise stated)

4 Other income and gains (continued)

(38) Other income (continued)

(i) According to the notice of the Sultan in Council regarding the Income Tax (Amendment) Order 2020 published in the Government Gazette dated 30 April 2020, certain income derived from Financial Institutions (Exemption) Order, 2016, namely, interest income, dividend income and gains from disposal of financial assets, amounting to B$1,200,000, B$80,000 and B$80,000 respectively, are exempted from Income Tax for the year of assessment 2020, 2021 and 2022, respectively.

(ii) In addition to the exemption granted under Section 16(1)(zm) of the Income Tax Act (Cap. 35), certain income amounting to B$1,000,000 derived from qualifying-activity bonds is exempted from income tax for the year of assessment 2020.

(iii) According to the Exemption of Interest Income of Financial Institutions from Income Tax Act and Exemption of Interest Income of Financial Institutions from Income Tax Act (Amendment) Order 2020 published in the Government Gazette dated 30 April 2020, interest income derived by Financial Institutions from loans granted to Brunei Economic Development Board pursuant to the Exemption of Interest Income of Financial Institutions from Income Tax Act (Cap. 35), interest income derived by financial

Notes to the Financial Statements

For the year ended 31 December 2020
(All amounts in RMB unless otherwise stated)

4 Notes to consolidated financial statements (continued)

(40) Gains from changes in fair value

	2020	2019
Investment properties measured at fair value (Note 14)	476,174	1,630,116
Financial assets at fair value through profit or loss (Note 4(8))	6,123,049	8,487,346
	6,599,223	10,117,462

(41) Credit impairment losses

	2020	2019
Loss on bad debts of accounts receivable	23,341,488	12,356,414
Loss on bad debts of other receivables	(215,732)	8,899,910
Total	23,125,756	21,256,324

(42) Assets impairment losses

	2020	2019
Goodwill impairment	8,011,603	

(43) Non-operating income

	2020	2019
Other	59,275	2,750,243
Gain from the reconciliation of consideration arising from business combination	–	25,666,158
Others	849,765	971,326
	909,040	29,388,527

Notes to the Financial Statements

For the year ended 31 December 2020
(Amounts in Brunei Dollars unless otherwise stated)

4 Other operating income and expenses (continued)

(44) Non-operating expenses

	2020	2019
Donation paid	8,537,428	2,587,277
Provision for impairment	1,518,692	10,055,380
Impairment of non-financial assets	–	8,418,374
Impairment of construction in progress	–	4,822,111
Provision for litigation (Note 28)	–	2,000,000
Others	845,825	4,830,826
	10,901,945	32,713,968

(45) Income tax expenses

	2020	2019
Current income tax charge based on the results for the year	31,485,064	23,040,066
Deferred income tax	(2,536,393)	(6,113,877)
	28,948,671	17,926,189

The reconciliation of income tax charge based on applicable tax rate of the Group to income tax expense at effective tax rate is as follows:

	2020	2019
Profit before tax	87,904,215	55,522,807
Income tax expense at statutory rate of 25%	21,976,054	13,880,702
Effect of tax rate change	(391,588)	
Non-deductible expenses for tax purposes	4,889,834	2,741,475
Different tax rate for other jurisdiction	(1,722,889)	
Additional tax deduction for research and development	(2,071,323)	(1,036,088)
Tax exempt income	10,127,644	8,337,400
Utilisation of tax exempt income	(3,859,061)	
Deferred tax asset not recognised	–	(6,624,800)
Income tax expense	28,948,671	17,926,189

Notes to the Financial Statements

Fo e ea e e 31 ece be 2 2
(A o in B e o e ie a e)

4 o e o eco oi a e in a di a a e (co in e)

(46) Earnings per share

(a) Baic ea in pe a e

	2020	2 1
o oi a e e p oft a ib e o eo a a e o e of e pa d co pa (B)	70,000,134	57,28 ,3 4
d e a e a e be of o in o a a e of e o pa (be of a e)(i)	72,452,438	730 0 000
Baic ea in pe a e(B)	0.97	0 .78

(i) A a e in o e , fo o in e app o a b e a e o e a e d ea ee in o 13 e 2 18, e o pa i e 2,46 000 o a a e fo a a e in ce i e p . A e e oc a e e a e a ea oc , acco o e p e a io of Acco in S a a fo B ine E e p i e o. 7i e b e i of H ce, e o pa e ce 2,46 000 e ice a e fo eo in a e d cac a in e baic ea in pe a e in 2 . 2 , e o pa ep c a e a o a of 8 ,Ø0 a e f o e a e a e, e eo in o a a e e o bjec o e pac of e ep c a e d id e abo e.

(b) i e ea in pe a e

i e ea in pe a e i cac a e b eco oi a e e p oft a ib e o eo a a e o e of e pa d co pa a j e b e i e po d i a o a a e i i e b e a j e d e a e a e be of o in o a a e . Fo e ea e e 31 ece be 2 , eco oi a e e p oft a ib e o eo a a e o e of e pa d co pa a j e b e i e po d i a o a a e a BØ 000 ,134. e a j e d e a e a e be of o in o a a e a 72,82 4,553. e i e ea in pe a e a B 6. Fo e ea e e 31 ece be 2 , eco oi a e e p oft a ib e o eo a a e o e of e pa d co pa a j e b e i e po d i a o a a e a B57,28 ,3 4. e a j e d e a e a e be of o in o a a e a 73 270 66. e i e ea in pe a e a B .77.

Notes to the Financial Statements

For the year ended 31 December 2020
(All amounts in Brunei dollars unless otherwise stated)

4 Notes to consolidated financial statements (continued)

(47) Supplementary information to the cash flow statement

(a) Supplemental information on cash flow statement

Reconciliation from profit before tax to net cash flow from operating activities

	2020	2019
Profit before tax	58,955,544	38,227,618
Add: Amortisation of prepaid lease payments	8,011,603	
Depreciation of property, plant and equipment	23,125,756	24,256,324
Depreciation of right-of-use assets	41,037,075	34,870,148
Depreciation of investment properties	33,116,519	24,854,521
Amortisation of intangible assets	14,101,748	10,874,756
Amortisation of other prepaid lease payments	35,549,405	34,248,665
(Gain)/Loss on disposal of property, plant and equipment, net	(692,250)	(3,585,518)
Net foreign exchange gain	(6,599,223)	(1,217,462)
Net gain on derecognition of contract assets upon modification of lease agreement from operating to finance	–	(25,666,158)
Loss on disposal of other prepaid lease payments	–	13,240,243
Provision for employee benefits	26,805,140	27,148,834
Net fair value gain/(loss)	7,665,311	(24,336,266)
Share-based payments expense	5,887,603	5,120,526
Decrease in deferred income	(303,792)	(803,712)
Decrease/(increase) in deferred tax assets	305,286	(5,052,876)
Decrease in deferred tax liabilities	(2,841,679)	(611,001)
Increase in inventories	(12,896,656)	(1,636,053)
Increase in operating receivables	(19,356,716)	(24,652,100)
Decrease in operating payables	(12,214,682)	(24,124,174)
Cash flow from operating activities	199,655,992	111,248,775

Notes to the Financial Statements

Fo e ea_ e e 31 ece be 2 2
(A o in B e o e ie a_e)

4 o e o eco oi a_e in di a_ a_e e (co in e)

(47) Supplementary information to the cash flow statement (co in e)

(a) S e e a_ in fo ai o eca_ fo a_e (co in e)

Si ifica_ no -ca_ ac io in ea_io oi e in in di ac i ie.

Fo e ea_ e e 31 ece be 2 2 , i ifica_ no -ca_ ac io in ea_io oi e in in di ac i ie ee i e a_ fo o :

	2020	2 1
i -of- ea_ e in ce a_e in ec e pei o (o e 4(12))	33,603,772	234, 63, 17

e o e in ca_

	2020	2 1
a_ a_ e e of e ea_	200,092,665	164, 51, 0
e : a_ a_ e be in in of e ea_	(164,951,950)	(187) 66,6 4)
e in c ea_e/(ec ea_e) in ca_	35,140,715	(22,1 0, d0 1.S , 562

Notes to the Financial Statements

For the year ended 31 December 2020
(Amounts in Brunei dollars unless otherwise stated)

4 Notes to the consolidated financial statements (continued)

(47) Supplementary information to the cash flow statement (continued)

(c) Reconciliation of net debt for the year 2020

	2020
Cash	20,665,561
Non-cash	45,528,115
Cash liabilities	(25,888,096)
Non-cash liabilities	(6,750,000)

(i) Analysis of cash and cash equivalents

	31 December 2020	31 December 2019
Comprise: Amounts due from banks	374,287	45,334
Amounts due from banks that can be classified as cash and cash equivalents	199,718,378	164,836,340
Time deposits that can be classified as cash and cash equivalents	–	1,343,222
Total cash and cash equivalents	200,092,665	166,224,896

Notes to the Financial Statements

Fo e ea e 31 ece be 2
(A o in B e o e ie a e)

5 e in eco oi aio co e

e o -o e bi a in e a ea E-(o ia (e o) o., L . a e b ej in (ea ec oo o., L . (ej in (ea) (a bi a of e o) 0 ac 2 i a ei ee ca i a of B5 000 000 .

ej in (ea , a bi a of e o , e a o -o e bi a e o in oe 22 a a 2 , i a ei ee ca i a of B50 000 .

2 Ap i 2 , e o a e o e E e pie a e o., L . (e o e) jo e p L c in (o ia i a ei ee ca i a of B50 000 000 , of ic B0 000 000 a bcibe b e o a e B2 000 000 a bcibe b e o e .

25 a 2 , e o a e ee in o e i a fe a ee e i in i io a e o e , in bo ei B o e! o A ea a e a e e a e ! a e ip (ie [iabiiie ! a e ip) (a e) in bo ei B o e! o A ea a e a e o., L . (a e e). e a ee e ip a e a e o a ac ie 52, 5% a 0 .38% e i f o a e a e e a co i e aio of B ,780 000 a B22 000 e peci e . A o a of B0 000 000 a pai fo ee i a fe. Af e a , e o a o a o a of 53.33% e i of e o in (o ia .

ej in (a fe (o ia a e o., L ., a bi a of e o , e abi e ' a in (o ia 2 i 00 % a e o in . 31 A 2 , ' a in (o ia ac ie eb in e of ' (o ia . ' (o ia a ca ce a fe eb in co bi aio .

Notes to the Financial Statements

For the year ended 31 December 2020
(All amounts in RMB unless otherwise stated)

5 Business combination and consolidated financial statements (continued)

(1) Business combination involving enterprises not under common control

(a) Business combinations in the current period not under common control

Acquiree	Date of acquisition	Purchase consideration	% of equity interest	Date of purchase	Basis for determination of date of acquisition	Revenue of the acquiree from the date of purchase to the end of the year	Net profit of the acquiree from the date of purchase to the end of the year	Cash flows from operating activities of the acquiree from the date of purchase to the end of the year	Net cash flows of the acquiree from the date of purchase to the end of the year
[illegible]	31 [illegible]	[illegible]	53.33%	31 [illegible]	[illegible]	18,[illegible]	1,[illegible]	(1[illegible])	1,[illegible]
[illegible]	31 [illegible]	1[illegible]	100%	31 [illegible]	[illegible]	7,[illegible]	[illegible]	([illegible])	1,[illegible]

(b) Consideration and goodwill in current period are as follows:

	[illegible]	[illegible]
Consideration		
Cash	[illegible]	
Fair value of previously held non-current equity investment (note 4(13))(1)		1[illegible]
Total consideration	[illegible]	1[illegible]
Less: Share of fair value of identifiable net assets acquired	(18,[illegible])	[illegible]
Goodwill	11,[illegible]	13,448,538

Notes to the Financial Statements

Fo e ea ed e 31 ece be 2 2
(A o in B e o e ie a e)

5 a e in e co oi ai o cope (co in e)

(1) Business combination involving enterprises not under common control (co in e)

(c) e a e a iabiiie of eac iee a e ae of p c ae 2 2 eei e a be o :

(i) e o in (opi a

	Fai a ea e ae of p c ae	a in o a e ae of p c ae	a in o a a 31 ece be 2 1
a a ba e a d a	4,4 6,4 0	4,4 6,4 0	7,8 ,, 5
eci ab e	6 3 47	6 3 47	4 8 ,244
e oie	842,5 6	842,5 6	1,1 0 38
epa e			31,483
Fi e a e	2,25 67	2,25 67	2,356,833
a ibe a e	27,514 1	514 1	576,46
-e p epa e pe e	3,1 6,867	3,1 6,867	3,4 3,757
e eci ab e	325,5 6	325,5 6	1 ,354
e fe e a a e	6 6,177	6 6,177	
e pa ab e	(36,8)	(36,8)	(3,6 1,277)
Acco pa ab e	(2.557 7))	(2.557 7))	(3,614,442)
a ac iabiiie	(442,4 8)	(442,4 8)	(477 , 5)
E p o ee be e pa ab e	(4 2,3)	(4 2,3)	(581,572)
e iabiiie	(2.873)	(2.873)	(31 82)
e fe e a iabiiie	(6,75 000)		
e a e	34 83,715	13,833,715	11,2 3,7 5
e : a -co o in ee	(15 5,745)	(6,456,1 5)	(5,228,76)
e a e ob a e	18,177 7	7,377,52	5 74 36

e o pe ee e e fai a e of a e a iabiiie of e o in (opi a a e ae of p c a e b in a ia ec i e. e a ia app oac e a be a pi a of a io a e a ei e a be o :

e a ia app oac of in a ibe a e i co e app oac . e a pi e a in c e a e a e be of in -pai be in ope ai , a e a ei -pai pe in pe a pe be , o a in , i co a e af e a a pe pe i o a e.

Notes to the Financial Statements

For the year ended 31 December 2022
(All amounts in Brazilian Real unless otherwise stated)

5 Business combination and consolidation scope (continued)

(1) Business combination involving enterprises not under common control (continued)

Notes to the Financial Statements

Fo e ea e e 31 ece be 2 2
(A o i B e o e i e e)

6 ee o e ii e

(1) Interest in subsidiaries

(a) S c e of e o

Name of the subsidiaries/units	Type of entity	Major business location

Notes to the Financial Statements

For the year ended 31 December 2020
(All amounts in Brunei Dollars unless otherwise stated)

6 Investments in subsidiaries (continued)

(1) Interest in subsidiaries (continued)

(a) Scope of group (continued)

Name of the subsidiaries/units	Type of entity	Major business location	Place of registration	Nature of business	Shareholding (%) as at 31 December 2020		Method of acquisition
					Direct	Indirect	
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]		75.00 %	Acquisition
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]		51.00 %	Incorporation
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]		100.00 %	Incorporation
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]		100.00 %	Incorporation
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]		100.00 %	Incorporation
Bdr [illegible]	[illegible]	Bdr	Bdr	[illegible]		51.00 %	Acquisition
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]		100.00 %	Acquisition
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]		95.00 %	Acquisition
[illegible]	[illegible]	[illegible]	[illegible]	Software information [illegible]		100.00 %	Incorporation
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]		66.00 %	Incorporation
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]		51.00 %	Establishment
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]		65.38%	Establishment
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]		51.00 %	Establishment
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]		90.00 %	Establishment
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]		64.55%	Acquisition
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]		63.00 %	Incorporation
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	60.00 %		Incorporation
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	53.33%		Establishment
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]		100.00 %	Incorporation
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]		100.00 %	Incorporation
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]		100.00 %	Incorporation

Notes to the Financial Statements

Fo e ea e 31 ece be 2 2
(A o in B e o e ie a e)

6 ee in o e ii ie (co in e)

(1) Interest in subsidiaries (co in e)

(b) o -co o in ee

	31 December 2020	31 ece be 2 1
L ce in (o i a	19,893,809	
o in (o i a	7,703,174	8,465,4 6
S e in (o i a	6,994,726	11,64 Q0 6
e o o a e e	15,159,737	14,224,263
ej (fe o., L .	11,764,309	0 , 8 ,338
Bei in (o i a	9,845,907	16 55,477
(e e in (o i a	11,262,400	12,666 64
e	19,954,480	22, 84,371
o a	102,578,542	, 7 24, 25

(c) S bi ia ie i i ifica o -co o in ee

Name of subsidiaries	Shareholding of non-controlling shareholders (%)	Profit or loss attributed to non-controlling shareholders as at 31 December 2020	Dividends distributed to non-controlling shareholder as at 31 December 2020	Non-controlling interests as at 31 December 2020
L ce in (o i a	40%	(106,191)	–	19,893,809
e o o a e e	25%	935,474	–	15,159,737
ej (fe o., L .	34%	783,971	–	11,764,309
(e e in (o i a	49%	(1,403,664)	–	11,262,400
		209,590	–	58,080,255

Notes to the Financial Statements

For the year ended 31 December 2020
(All amounts in Brunei Dollars unless otherwise stated)

6 Investments in subsidiaries (continued)

(1) Interest in subsidiaries (continued)

(c) Subsidiaries with significant non-controlling interests (continued)

Summarised financial information of significant non-wholly-owned subsidiaries of the Company before inter-company eliminations:

	31 December 2020					
	Current assets	Non-current assets	Total assets	Current liabilities	Non-current liabilities	Total liabilities
[illegible]	11,379,262	41,840,261	53,219,523	3,485,000	–	3,485,000
[illegible]	11,872,301	133,946,018	145,818,319	77,661,341	7,518,031	85,179,372
[illegible]	33,174,567	18,979,615	52,154,182	17,553,274	–	17,553,274
[illegible]	15,275,548	36,143,566	51,419,114	18,756,949	9,677,675	28,434,624
	71,701,678	230,909,460	302,611,138	117,456,564	17,195,706	134,652,270

	2020			
	Revenue	Net (loss)/profit	Total comprehensive (losses)/income	Cash flows from operating activities
[illegible]	–	(265,477)	(265,477)	5,014,560
[illegible]	11,033,761	3,741,896	3,741,896	5,826,841
[illegible]	4,214,044	2,305,796	2,305,796	7,499,276
[illegible]	13,882,909	(2,864,620)	(2,864,620)	(1,705,998)
	29,130,714	2,917,595	2,917,595	16,634,679

Notes to the Financial Statements

For the year ended 31 December 2012
(All amounts in Brunei dollars unless otherwise stated)

6 Investments in subsidiaries (continued)

(1) Interest in subsidiaries (continued)

(c) Significant non-controlling interests

Information relating to significant non-controlling interests of the Company is set out below (continued):

	31 December 2012					
	Principal place of business	Non-controlling interests	Ownership interests	Profit allocated to non-controlling interests	Non-controlling interests
Name of subsidiary					
Brunei Oxygen Limited	Brunei	30,652	55,857,078	7,158,360	6,661,720	37,890,155	44,511,875
Brunei Industrial Gases Sdn. Bhd.	Brunei	42,847,241	9,525,512	51,823,533	21,845,521		21,845,521
Other non-controlling interests		11,366,013	3,483,413	51,265,426	15,228,118	10,182,114	25,410,312
Balance at 31 December		18,213,778	38,860,141	56,873,919	2,412,723	21,631,741	24,132,540
Total non-controlling interests		6,715,714	86,183,136	9,265,810	17,438,226	66,553,532	84,031,758
		78,113,496	373,871,870	475,412,536	144,445,057	145,176,188	289,621,245

	2012			
	Revenue	Profit/(loss) after tax	Total comprehensive income/(loss)	Net cash flows from operating activities
Name of subsidiary				
Brunei Oxygen Limited	73,418,154	22,447,814	22,447,814	27,630,527
Subsidiaries with non-controlling interests	14,527,860	(11,424,025)	(11,424,025)	(8,730,268)
Brunei Industrial Gases Sdn. Bhd.	3,825,018	(100,658)	(100,658)	3,842,343
Other non-controlling interests	14,644,462	(3,263,285)	(3,263,285)	4,311,374
Balance at 31 December	160,444,812	(4,018,170)	(4,018,170)	(184,041)
Total non-controlling interests	18,710,248	1800 1467B1	Total comprehensive income	

Notes to the Financial Statements

For the year ended 31 December 2020
(Amounts in RMB unless otherwise stated)

6 Investments in associates (continued)

(2) Interests in associates

(a) Summary information of individually immaterial associates

	Major business location	Place of registration	Nature of business	Whether strategic to the Group's activities	Shareholding (%)	
					Direct	Indirect
Hangzhou Anken Information Technology Co., Ltd.	Hangzhou	Hangzhou	Internet medical service	Yes	–	24%
Chengdu Yining Hospital	Chengdu	Chengdu	Hospital management	Yes	–	49%
Shanxi Shanda	Taiyuan	Taiyuan	Hospital management	Yes	–	49%

The Group has elected to measure its investments in associates at fair value.

(b) Aggregate information of individually immaterial associates

	31 December 2020 Hangzhou Anken Information Technology	31 December 2020 Chengdu Yining Hospital	31 December 2020 Shanxi Shanda
Current assets	21,843,683	14,877,237	27,742,224
Non-current assets	19,898,732	53,502,689	63,554,292
Total assets	41,742,415	68,379,926	91,296,516
Total liabilities	12,872,701	34,928,640	21,027,505
Equity attributable to shareholders of the investee company	27,809,556	33,451,286	70,269,011
Share of the associate's net assets at the acquisition (i)	8,055,177	8,028,309	21,080,703
Adjustments			
Goodwill	–	5,024,000	4,494,286
Others	4,500,000	99,975	–

Notes to the Financial Statements

Fo e ea ed e 31 ece be 2020
(A o in B e o e ie a e)

6 ee in o e ed ie (co in e)

(2) Interests in associates (co in e)

(b) aio in id a in fo ai o i nifica a od a e (co in e)

	2020 Hangzhou Anken Information Technology	2020 Chengdu Yining Hospital	2020 Shanxi Shanda
e ed e	37,414,435	10,078,842	19,503,386
o a co p e ed i e o	(14,409,474)	(3,877,172)	1,491,929

(i) e o pca c a e a e of a e b a e o in aio ba e d o e a o a ib abe o e p a ed co pa in e a od a e' co oi a e in id a a ed . e a o of a od a e d e co oi a e in id a a ed a be in o acco e fai a e of e i ed in ab e a e a iabiii e of e a od a e d ac in ei e ed a effec of i in acco in poide .

(c) S a ie in fo ai o i nifica a od a e

e e of e a od a e of e o p a e a e a in o e 4(7).

	2020	2019
A e a e ca in o of e ed	42,444,061	8,732,7
A e a e o of efo o in i e in p opo io e o (i)	(2,841,799)	(2,, , 17)
o a co p e ed i e o	(2,841,799)	(2,, , 17)

(i) e e o a abe in o e acco e fai a e of e i ed in ab e a e a iabiii e of e a od a e d ac in ei e ed a effec of i in acco in poide .

7 Se e in fo ai o

e epo abe e e of e o p a e eb in e i a p oi e iffe p o c o e ice, o ope a e in e iffe a ea. iffe b in e e o a ea e ie iffe ec oo ie a e a be in a e ie. e o p, e efo e, in e epo in e a e ep o cio a ope aio of ea epo abe e e a e a e ope ai e , in o e o abe ed io abo e o ce o be a oca e o e e e e a o a e pe fo a ce.

2020, a ep opo io of e e e, e p o a o a e of e o o a e e e in e o p'

Notes to the Financial Statements

Fo e ea e e 31 ece be 2 2
(A o in B e o e ie a e)

8 e a e pa ie a e pa a acio (co in e)

(4) Related party transactions

(a) id poide

e ice of poiio of e ice a pa e of a o e a e pa ie a e e ine e ba e o e oiaio .

(b) oiio of e ica a a e e ice

	2020	2 1
i ea e e	3,000,000	3000 000
e a e in i i a	629,767	572,743
	3,629,767	3,572,743

(c) ea e

i -of- e a e ince e in ec e peio e e o pa a e ee:

e of e o	pe of ea e a e	2020	2 1
ej a ia	B i in	–	6,65 ,40

e ea eiabii in ee e pe e a a e abe b e o pa a e ee

	2020	2 1
ej a ia	299,117	0 , 372

( ) a e o be a of e a e pa ie

	2020	2 1
o -po o i aio e abi e b e o p	3,360	
e in o pi a	514,369	, 0 , 7
e	–	0 ,41
	517,729	, 81,3 8

Notes to the Financial Statements

For the year ended 31 December 2020
(All amounts in Brunei dollars unless otherwise stated)

8 Related parties and related party transactions (continued)

(4) Related party transactions (continued)

(e) Advance paid on behalf of related parties

	2020	2019
Joint venture	2,726,131	

(f) Disposal of related parties

	2020	2019
Sale of Advanced Information Technology	–	15,274,000
Sale of Investment	–	2,800,000
	–	18,074,000

(g) Key management personnel

	2020	2019
Sale of Advanced Information Technology	4,000,000	

(h) Remuneration of directors

	2020	2019
Salaries and bonus	5,041,695	4,580,381
Share-based payment	490,634	453,432
	5,532,329	5,033,813

Notes to the Financial Statements

For the year ended 31 December 2020
(All amounts in Brunei Dollars unless otherwise stated)

8 Related parties and related party transactions (continued)

(4) Related party transactions (continued)

(i) Acceptance of guarantees by the group

	2020	2019
Immediate holding company	18,000,000	
Immediate holding company and fellow subsidiaries	280,000,000	340,000,000
Immediate holding company and fellow subsidiaries and associates	50,000,000	
Ultimate parent company and immediate holding company	2,500,000	
Ultimate parent company and immediate holding company and fellow subsidiaries	75,000,000	20,000,000
Other related parties	992,970	
	426,492,970	360,000,000

(j) Purchase of assets

	2020	2019
Assets held for sale	–	1,021,278

Refer to note 15 for assets held for sale, purchase agreement.

(k) Board fees for key management personnel

	2020	2019
Board Fees	–	16,000

Notes to the Financial Statements

For the year ended 31 December 2020
(All amounts in Brunei dollar unless otherwise stated)

8 Related party balances and transactions (continued)

(5) Receivables from and payables to related parties (continued)

(b) Balances of related parties

		31 December 2020	31 December 2019
Non-trade payables	Shareholder	–	1,760,000
	Associate	–	490,000
		–	2,250,000
Trade payables	Entity with significant influence over the Group		
	Ultimate holding company	–	15,500,421
	Associate	4,074,900	4,232,754
	Joint venture	–	1,610,115
	Shareholder	5,844,383	3,412,644
	Director	–	490,000
	Key management personnel	2,917,717	
	Other related parties under common control	–	2,490,000
	Associate	23,252	241,185
	Joint venture	9,989	2,866
		12,870,241	28,541,713
Lease liabilities	Associate	5,665,172	6,754,366

Notes to the Financial Statements

For the year ended 31 December 2022
(All amounts in Brunei Dollars unless otherwise stated)

8 Related party disclosures (continued)

(6) Equity and interest of directors

(a) Emoluments of executive directors

The emoluments of executive directors, during the year are as follows:

Name	Emoluments	Salaries and subsidies	Contributions to pension plans	Bonus	Other welfare	Total
Executive directors (i)						
[illegible]	–	398,454	18,205	89,291	34,180	540,130
[illegible]	–	326,454	–	128,611	28,212	483,277
[illegible]	–	184,330	8,335	105,865	41,798	340,328
Non-executive directors (i)						
[illegible]	–	–	–	–	–	–
[illegible]	–	–	–	–	–	–
Independent directors						
[illegible]	35,000	–	–	–	–	35,000
[illegible]	35,000	–	–	–	–	35,000
[illegible]	35,000	–	–	–	–	35,000
[illegible]	35,000	–	–	–	–	35,000
[illegible]	35,000	–	–	–	–	35,000
[illegible]	35,000	–	–	–	–	35,000
Supervisors						
[illegible]	–	–	–	–	–	–
[illegible]	–	71,074	8,722	68,526	17,723	166,045
[illegible]	–	–	–	–	–	–
[illegible]	–	–	–	–	–	–
[illegible]	–	–	–	–	–	–
Total	210,000	980,312	35,262	392,293	121,913	1,739,780

Notes to the Financial Statements

For the year ended 31 December 2022
(All amounts in Bahraini Dinars unless otherwise stated)

8 Related party balances and transactions (continued)

(6) Equity and interest of directors (continued)

(a) Equity of directors and their interest (continued)

The equity of each director, and their interest are as follows:

Name	Equity	Ordinary shares	Saving shares	Options	Bonds	Preference shares

Notes to the Financial Statements

For the year ended 31 December 2020
(Amounts in Brunei Dollars unless otherwise stated)

8 Related party relationship and transaction (continued)

(6) Equity and interest of directors (continued)

(a) Emoluments of directors' service (continued)

	2020	
	Provision of director service to the Company or the subsidiaries	Provision of other services to the Company or the subsidiaries	Total
Emoluments of directors	–	1,363,735	1,363,735

	2019	
	Provision of director service to the Company or the subsidiaries	Provision of other services to the Company or the subsidiaries	Total
Emoluments of directors		1,[illegible]7,840	1,[illegible]7,840

(i) Receivable from directors

Remuneration in form of, etc.

(7) The five individuals whose emoluments were the highest

For the year ended 31 December 2020 included in the [illegible] (2019: [illegible]) individuals whose emoluments are reflected above. The emoluments of the [illegible] (2019: five) are as follows:

	2020	2019
Basic salaries, bonus, other benefits	4,449,720	3,[illegible]4,21[illegible]
Employer's provident fund	305,924	152,553
	4,755,644	3,[illegible]46,772

		Headcount	
		2020	2019
Range:			
B$[illegible]00,000	B$1,000,000	3	5
B$1,000,000	B$1,[illegible]00,000	2	
		5	5

Notes to the Financial Statements

Fo e ea e 31 ece be 2 2
(A o in B e e o e ie a e)

S a e-ba e pa e

(a) The restricted share incentive plan I

(1) e e a in fo ai o

Fo o in e eibe ai o of e 3 e io of e Bo a of i ec o ' ee in of e o pa o 4 2 14 e e a e o e ee in in e ea of 2 14 o 21 2 14, e o pa o e E i ce ie! a of e o a in (o ia o., L . of i e ice a e in ce i e a , ee ie iabii pa e ip (LL) e e abi e , a e in bo d ai a in e e a e ! a e ip (ie ! a e ip) (d ai a in), in bo Bd a in e e a e ! a e ip (ie ! a e ip) (Bd a in) a in bo in i a in e e a e ! a e ip (ie ! a e ip) (in i a in). e e e a pa e of d ai a in a Bd a in i . a Bi (e ea ie of ea a co o in pe o a e e o ee of e o pa); e e e a pa e of in i a in i . a (o e. e ai e e o ee pa id pa in e e ice a e a co ib e ecai a a e a pice a beco e ie pa e of e LL . Af e ee abi e of e LL e io e abo e, eoi in a e o e of e o pa , a di a (o e, a fe e d a e cai a of B1,12 , 5 (4% of ee i of e o pa) o e abo e ee LL a co i e ai o of B18.684 pe a e.

Sce e a e of beco in e pa e of e LL , o e pa id pa in e o ee o co ib e e cai a o e B12 Q00 (c i e) e eco i e o e in e o pa fo 36 o ie o e co ib e beo B12 Q00 fo 12 o f o e a e e o pa a i e in a oc ec e. e o o ei in i pei o. f a e o ee ei befo e e of e ei e ice pei o eb S af e e a e of e o pa i e in e oc ec e, efo o in e i be a pie :

(i) e e o ee i 12 o e in pei o ei in befo e ee i ai o of e ei e ice pei o o a e o i a f o e LL b d e i i f o e. Af e ee i ai o of e ei e ice pei o, e e e a pa e o e i pa ei a e b e e e a pa e ac ie d e i a e.

(ii) e e o ee i 36 o e in pei o ei in i in 12 o af e ei , e a e a abo e i be a pie . f ei in be ee 12 o a 36 o , e e e a pa e o e i pa ei a e b e e e a pa e ac ie ee i a e. ep c a epicei e a 0 % of e a e a e oc pice of 2 a acio a ece in e a e of a o a fo e ei ai o.

A a 31 ece be 2 2 , e o pa eci e in e e d of B2 , 44Q00 . e o pa i o a e a ep c a e a a e d o co i e i e LL o e e o ee.

e abo e a acio a co i e e a e i - e a e-ba e pa e d o e o ee in ec a efo d e ice. efai a e of e o pa ' a e a e o e o ee o a pa e, 21 2 14, a e e in e b e ffe d ce be ee efai a e of ee i a fe e (e e in e b a o fe io a a ai o i) a cai a co ib io b in ce i e a e , a B5,86 Q00 .

Notes to the Financial Statements

For the year ended 31 December 2018
(All amounts in Brunei dollars unless otherwise stated)

2. Share-based payments (continued)

(b) The restricted share incentive plan II

(1) General information

On 13 December 2018, the Company's shareholders approved the Company's Restricted Share Incentive Plan II on 13 December 2018, which is administered by the Board of Directors of the Company (the "Board"). The Board of Directors of the Company may grant awards to selected employees of the Company and its subsidiaries (the "Eligible Employees"), including executive directors of the Company and its subsidiaries (the "Executive Directors"), senior management of the Company and its subsidiaries (the "Senior Management"), and other employees of the Company and its subsidiaries (the "Other Employees") of up to 2,460,000 ordinary shares (accounting for 3.37% of the total issued share capital as at the date of the Prospectus) at a price of B$0.47 per share. As at 31 December 2018, there were B$3,311,144, of the B$2,460,000 shares granted remaining unissued (B$2,851,144 in carrying amount).

The vesting period of the restricted shares granted is set out in the relevant grant notice. For the purpose of the restricted shares granted to employees, the vesting date shall be the last day of the vesting period set out in the relevant grant notice; the number of the restricted shares to be vested on the vesting date shall be the number of restricted shares granted multiplied by the vesting percentage; the restricted shares granted to the employees shall be vested on the vesting date; and the purchase price of the restricted shares granted to the employees shall be the nominal value.

The restricted shares granted to employees shall be subject to a vesting period of

Notes to the Financial Statements

For the year ended 31 December 2020
(Amounts in Brackets are expressed)

13 Financial risk

The Group's activities expose it to a variety of financial risks: market risk (principally foreign exchange risk and interest rate), credit risk and liquidity risk. The Group's overall risk management policy focuses on the unpredictability of financial markets and seeks to minimise potential adverse effects on the Group's financial performance.

(1) Market risk

(a) Foreign exchange risk

The Group's principal operations are transacted in Hong Kong dollars which is the functional currency of the Company and its subsidiaries in Hong Kong. The Group is exposed to foreign exchange risk arising from various currency exposures, primarily with respect to United States dollars ("USD"). The Group manages foreign exchange risk by performing regular reviews of the Group's net foreign exchange exposure.

As at 31 December 2020 and 31 December 2019, each category of the Group's financial instruments denominated in foreign currencies are set out below:

	31 December 2020		
	HKD	USD	Total
Cash and bank balances	69,340	2,109,936	2,179,276

	31 December 2019		
	HKD	USD	Total
Cash and bank balances	3,333,874	8,143,081	11,476,955

As at 31 December 2020, for the Group's monetary assets denominated in USD, if the HKD strengthened/weakened by 3% against the USD while all other variables were held constant, the Group's profit for the year would have decreased/increased by approximately HK$40,034 (31 December 2019: HK$258,231) mainly as a result.

Notes to the Financial Statements

For the year ended 31 December 2022
(Amounts in Brunei Dollars unless otherwise stated)

13 Financial risk (continued)

(1) Market risk (continued)

(b) Price risk

The Group's price risk arises from investments in equity securities that are classified as fair value through profit or loss. Financial instruments are subject to price risk arising from uncertainties about future prices of the instruments. The Group's investments in equity securities are publicly traded on the Brunei Darussalam Securities Exchange. As at 31 December 2022, the investments in equity securities amounted to B$8,2 0 (31 December 2 1 :

Notes to the Financial Statements

For the year ended 31 December 20XX
(All amounts in Brazilian reais)

13 Financial risk (continued)

(2) Credit risk (continued)

The credit risk in relation to trade receivables, contract assets, lease receivables, derivative financial instruments and deposits with banks arises from the possibility that counterparties may default on their obligations. The maximum exposure to credit risk is represented by the carrying amount of each financial asset.

Non-derivative financial assets comprise mainly trade receivables and other receivables.

(3) Liquidity risk

Notes to the Financial Statements

Fo e ea e 31 ece be 2 2
(A o in B e o e ie a e)

13 H a di a i k (co in e)

(3) Liquidity risk (continued)

B k bo o in o e bo o in a e a e b ep a e e fo o :

	31 December 2020		31 ece be 2 1	
	Bank borrowings	Other borrowings	B k bo o in	e bo o in
i in 1 ea	315,500,000	–	0 000 000	17,40 000
1 2 ea	15,992,970	–	000 000	2,26 000
2 5 ea	64,000,000	–	17 000 000	
e 5 ea	31,000,000	–		
	426,492,970	–	30 000 000	,00 000

14 Fai a ee in a e

e e ee in ic fai a e ea e i ca e oi e i e e in e b e e e of efai a e ie a c of e o e e e ee in p a i in ifica o e e ie efai a e ea e :

Le e 1: o e ice (a j e) in ac i e in a e fo i e ica a e o iabiii e .

Le e 2: Yp o e a o e ice in c e i in Le e 1 a a e obe abe fo e a e o iabii , di e ec o in ec .

Le e 3: ob e abe in p fo e a e o iabii .

Notes to the Financial Statements

For the year ended 31 December 2020
(Amounts in Brackets are Expressed)

14 Fair value measurement (continued)

(1) Assets measured at fair value on a recurring basis

As at 31 December 2020 and 31 December 2019, the Group's financial assets measured at fair value are presented below:

	31 December 2020		
	Level 1	Level 2	Level 3
Financial assets -			
Equity-accounted investees	–	–	57,404,918
Non-financial assets			
Investment properties	–	–	107,804,936
Total	–	–	165,209,854

	31 December 2019		
	Level 1	Level 2	Level 3
Financial assets			
Financial assets at fair		9,000,000	
Equity-accounted investees			51,281,86
Non-financial assets			
Investment properties			10 ,856,00
Total		9,000,000	162,137, 6

For equity-accounted investees, the Group's investments are based on the net asset value reported by the investee companies' financial statements.

The Group's policy is to recognise transfers into and transfers out of fair value hierarchy levels as at the end of the reporting period. There were no transfers between Level 1 and Level 2 during the year. Refer to note 28(a)(iii) for details.

Financial instruments measured at fair value comprise investments in equity securities and financial liabilities. Equity securities are classified as investments in equity-accounted investees. Refer to note 9 for details. Investments in equity-accounted investees are measured at cost, which approximates fair value. Refer to note 28(a)(iii) for details.

Notes to the Financial Statements

Fo e ea e 31 ece be 2 2
(A o in B e o e ie e)

14 Fai a ee a e (co in e)

(2) Assets and liabilities not measured at fair value but disclosed

H d a e a iabiie ea e a oie co an c e ecei abe, pa abe, o -e pa abe, bo o in , ec.

e iffe ence be ee e ca in o of c d a e a iabiie di fai ei o ei a.

15 api a a e

e o p' capi a a e poide an o afe a e o p' abi i o co in ea a on co ce in o e op oi e e fo a e o e an be ef fo o e ae o e , an o an an op a capi a c e o e ce eco of capi a.

o e o an an o a j e capi a c e, e o p a j e on of i i en pai o a e o e , ef capi a o a e o e , i e e a e o e ce eb .

e o p' o a capi a i ca c a e a q e 'e i ' a o in eco oi e ba ce ee. e o pi o bjec oe e a an a o capi a e i en , an onio capi a on e ba i of ea in io.

A 31 ece be 2 2 an 31 ece be 2 1, e o p' ea in io a a fo o :

	31 December 2020	31 ece be 2 1
ea in io	41.55%	0 .42%

Notes to the Financial Statements

Fo e ea d e 31 ece be 0 0
(A o in B e o e ie a e)

16 o e o eco pa ' in a d a a e e

(1) Accounts receivable

	31 December 2020	31 ece be 0
Acco ecei ab e	89,073,254	0 ,378,543
e : o ii fo ba eb	(10,529,013)	(0 ,173,228)
	78,544,241	0 5,315

Acco o e o p' ce poic , a bi a e pa ab e po i e .

(a) e a d of acco ecei ab e ba e o e eco a ei a e a fo o :

	31 December 2020	31 ece be 0
i 1 ea	65,324,295	810 48 13
1 2 ea	15,285,769	23,50 0 87
2 3 ea	8,461,922	4,748,652
e 3 ea	1,268	0 ,8 1
	89,073,254	0 ,378,543

Notes to the Financial Statements

Fo e ea_ e ' 31 ece be 2 2
(A o in B e o e ie a_e)

16 oe o eco pa ' in adia_ a_e e (co in e)

(1) Accounts receivable (co in e)

(b) ! o iio fo ba eb

e o pe ea_ e e o a_o ce of acco ecei abe a_ o e a_ o eife ee pec e ce oe, ea_e of e e co a_ i ifica_ in adeq co po e .

A a_ 31 ece be 2 2 , ee e e o acco ecei abe fo ic e ea_e poiio fo ba eb a_ poi e o ei i a_ bai (31 ece be 2 1 : B1,88 ,254).

(i) Acco ecei abe fo ic e ea_e poiio fo ba eb a_ poi e o e o pa ba i a_e a_ e a_ fo o :

	31 December 2020			31 ece be 2 1		
	Book value	Provision for bad debts		Book a_e	! oiio fo ba eb	
		Lifetime			ifeie e	
	Amount	ECL rate	Amount	A o	E a_e	A o
oo e e i e	7,317,813	1%	73,178	, ,441 38	1%	, 4,41
e e i 3 o	38,694,940	4%	1,547,798	45,7 , 87	5%	2,286,14
i 1 ea_	19,311,542	4%	772,462	25,4 5,551	6%	1,5 ,733
1 2 ea_	15,285,769	20%	3,057,154	23, 6,463	11%	2,551,611
2 3 ea_	8,461,922	60%	5,077,153	3,622,35	5 %	1,811,18
e 3 ea_	1,268	100%	1,268	,8 1	00 %	,8 1
o a_	89,073,254		10,529,013	7,48 ,28		8,283, 74

(ii) e o of poiio fo ba eb i ec e ea_ a_ B7,312,656 i o poiio fo ba eb ecei e/ e e e.

(iii) e ba_ce of acco ecei abe a_ e e i e off ec e ea_ a_ B6, 56,871, a e poiio fo ba eb a_ B6, 56,871, a inc in e ef o paie i a_e of o e 3 ea_ .

i ea_, o acco ecei abe i o a_ ee i a_ i ifica_ e e i e off.

Notes to the Financial Statements

Fo e ea_ e e 31 ece be 2 2
(A o i B a e o e i e a_e)

16 o e o e co pa ' i a d a_ a_e e (co i e)

(2) Other receivables (co i e)

(b) ! o i i o fo o e a c a e i book a_ e (co i e)

(i) A a_ 31 ece be 2 2 , fo o e ecd abe a_ S a_e 1, e e a_e p o i i o fo ba eb a a a_ e be o :

	Book value	12-month ECL rate	Provision for bad debts
! o i e o e o ba i :			

Notes to the Financial Statements

For e ea e 31 ece be 20
(A o in B e o e ie e)

16 o e o eco pa ' in ad a ed (co in e)

(3) Long-term equity investment

	31 December 2020	31 ece be 1
S bi ia ie (a)	420,377,432	5,477,432
A od a e (b)	33,465,928	2,15 ,27
	453,843,360	337,636,65

ee a o i ifica e icio o a e of o -e e i in e e e b e o pa .

(a) S bi ia ie

	31 ece be 1	A i io a in e e fo e c e ea	31 December 2020	I o ii o fo i pai e	31 December 2020
in i a in (o ia	32,000,000		32,000,000		32,000,000
o ja a in (o ia	20,000,000		20,000,000		20,000,000
a a a in (o ia	27,45 000	,70 000	37,150,000		37,150,000
e in a in (o ia	1,000,000		1,000,000		1,000,000
id a Fo ic e	50 000		500,000		500,000
S e in e e	10,000,000		10,000,000		10,000,000
in i a in (o ia	1,60 000		1,600,000		1,600,000
a ra in	10,000,000	847,6 8	–	(10 ,847,6 8)	–
ei a (a fe o., L .	34,627,432		34,627,432		34,627,432
ei a a in	168,50 000	31,70 000	200,000,000		200,000,000
e o L c e in (o ia		30,000,000	30,000,000		30,000,000
e o in (o ia		53,50 000	53,500,000		53,500,000
	5,477,432	125,747,6 8	420,377,432	(10 ,847,6 8)	420,377,432

Notes to the Financial Statements

Fo e ea_ ë e 31 ece be 2 2
(A o in B e o e ie a_e)

16 o e o e co pa ' in a d a_ a_e ë (co in e)

(3) Long-term equity investment (co in e)

(b) A od a_e

	31 ece be 2 1	Mii_ in e	ec ea_e in e	S a_e of e p ofi /(o) e i e o	31 December 2020	! o iid fo pai d a_ e of e ea_
(o Abe fo id						
ec oo	5,368,2 6	0 000 000		(4,0 2,278)	10,965,928	
(o Abe d in	26,7 10 21		(23) 34,663)	(3,756,358)	–	
Lo a in (o ia_		22,500 000			22,500,000	
	32,15 ,227	32,500 000	(23) 34,663)	(8,158,636)	33,465,928	

(4) Fixed assets

	Buildings	Medical equipment	Motor vehicles	Electronic and other equipment	Total
o					
31 ece be 2 1	326,10 ,267	37,367,314	3,10 ,636	18,431,58	385) 5 ,746
! c a_e	17,0 6, 46	7,0 2,642	173, 42	1,30 ,311	26,4 3,841
i po a_ e ei ë		(588) 78)	(34 , 5)	(1, 3 ,861)	(2,868,8 8)
e (oe 4(0))	(1 ,8 ,787)				(1 ,8 ,787)
31 ece be 2 2	324,117,426	43,881,878	2,983,619	17,801,979	388,784,902
Acc a_e ep edi a_io					
31 ece be 2 1	37) 53,353	23,366,00	2,382,0 8	11, 6,727	74,7, ,488
! o iid	, ,114,133	5,0 5,432	1 80) 66	2,721,543	17,53 ,174
i po a_ e ei ë		(576,38)	(323, 11)	(1,844,854)	(2,745,154)
31 ece be 2 2	46,167,486	28,295,943	2,256,663	12,873,416	89,593,508
a in a o					
31 ece be 2 2	277,949,940	15,585,935	726,956	4,928,563	299,191,394
31 ece be 2 1	28 0 56, 14	14,000 ,414	768,128	6,434,0 2	30 ,26 ,258

Notes to the Financial Statements

For the year ended 31 December 2020
(Amounts in Brazilian Reais)

16 Other Company's financial assets (continued)

(4) Fixed assets (continued)

As at 31 December 2020, the carrying amount of fixed assets pledged as collateral for bank loans amounted to approximately RMB17,537,174 (2019: RMB17,115,400), including carrying amount of buildings, leasehold improvements, electronic equipment and motor vehicles pledged for bank loans of approximately RMB14,647,361, RMB301,052, RMB4,887 and RMB225,874, respectively (2019: RMB13,742,443, RMB3,370,264, RMB183 and RMB510).

As at 31 December 2020 and 31 December 2019, the Company had no fixed assets held for sale.

For the year ended 31 December 2020, the Company had no fixed assets transferred from investment properties (for the year ended 31 December 2019: Nil).

(5) Intangible assets

	Land use rights	Software	Contractual right to provide management service	Total
Cost				
At 31 December 2019	23,602,729	4,610,090		28,212,819
Additions		429,000	2,829,386	3,258,386
At 31 December 2020	23,602,729	5,039,090	2,829,386	31,471,205
Accumulated amortisation				
At 31 December 2019	4,752,438	3,213,647		7,966,085
Increase during the year	471,054	600,216	49,207	1,120,477
At 31 December 2020	5,224,492	3,813,863	49,207	9,087,562
Impairment				
At 31 December 2020	18,378,237	1,225,227	2,780,179	22,383,643
At 31 December 2019	18,850,291	1,396,443		20,246,734

For the year ended 31 December 2020, amortisation of intangible assets charged to profit or loss amounted to approximately RMB1,120,477 (2019: RMB2,677,185). For the year ended 31 December 2020, amortisation expenses capitalised as costs of inventories and development costs amounted to approximately RMB253,627 and RMB867,850 respectively (2019: RMB1,793,231 and RMB883,954 respectively).

As at 31 December 2020 and 31 December 2019, the Company had no intangible assets held for sale.

Notes to the Financial Statements

Fo e ea e e 31 ece be 2 2
(A o in B e o e ie a e)

16 o e o e co pa ' fi a d a a e e (co in e)

(6) Provision for asset impairment

	31 ece be 2 1	c ea e in e c ea	ec ea ei e ea i e-off	31 December 2020
o i i o fo ba eb of acco				
ece ab e	0 ,173,228	7,312,656	(6 56,871)	10,529,013
o i i o fo ba eb of o e				
ece ab e	0 0 44,48	1 f/2 17 170 8 8	of o ,6 80 630 6 85	0 13

Notes to the Financial Statements

For e ea e e 31 ece be
(A o in B e o e ie a e)

16 o e o e co pa ' in a d a a e (co in e)

(8) Retained earnings

e a e ea in a e be in of e ea	200,462,672	18 , 130, 3
A : e p o	34,039,077	3 , 8 ,866
Le : A p o ia io o a o p e e e	(3,403,908)	(3, 8,287)
in a a e i i e p a ab e	–	(11,3 ,000)
e a e ea in a e e of e ea	231,097,841	0 ,46 ,67

accompanying notes form an integral part of these financial statements.

Notes to the Financial Statements

Fo e ea e 31 ece be 2 2
(A o in B e o e ie a e)

16 o e o eco p ' in a d a e (co in e)

(9) Revenue and cost of sales (co in e)

(a) e e e co of a e fo a b ine e

	2020	
	Revenue	Cost
a ace ica a e	107,453,075	98,319,580
ea e a e ea ca e ice	295,840,028	171,088,768
	403,293,103	269,408,348

	2 1	
	e e	o
a ace ica a e	111,30 ,285	, 5,41 ,7
ea e a e ea ca e ice	25 ,71 ,4	1 ,752,475
	371 ,27	266,171,554

(i) e o p' e e fo p a ace ica a e a e a e ea ca e ice i eco ie a c1 in in e.

(b) e e e co of a e fo o e b ine e

	2020	
	Revenue	Cost
a e e ice	9,576,790	4,170,935
e e fo oe a e e i of p a ace ica a e ica ice	1,481,575	1,450,832
e a co e	160,190	–
e	2,651,529	–
	13,870,084	5,621,767

	2 1	
	e e	o
a e e ice	11 ,46 63	6,85 ,156
e a co e	2 ,171	
e	1,30 ,127	
	13,576,361	6,85 ,156

Notes to the Financial Statements

Fo e ea e 31 ece be 2 2
(A o i B e o e ie a e)

16 o e o eco pa ' i a d a e (co i e)

(10) Financial expenses – net

	2020	2 1
Bo o i ee e pe e	16,578,305	7,215,776
A o i a io of eco ie i a d a c a e	–	1,841,80
ee e pe e	16,578,305	,0 57 76
Le : ee i co e	(15,041,897)	(2,427,741)
E c a e o e	258,603	642,578
e	318,690	473,158
	2,113,701	7,745 71

(11) Expenses by nature

e co of a e, e i a i ib io e pe e, e e a a i i e pe e a ee a
e e o pe e pe e i e co e a e e a ei e a o b a e:

	2020	2 1
E p o ee be e i	135,462,152	126,773,342
a ace ica a o e a ei a co e	131,582,583	122,7 , 2 5
e pe ia io of i e a e	17,539,174	17,115,40
e pe ia io of i -of- e a e	1,346,017	42,156
A o i a io of i a ibe a e	1,121,477	2,677,18
A o i a io of o -e e p e pe i e pe e	7,448,865	7,61 ,178
(o i ea e a p ope a a e e e pe e	1,278,086	1,3 7,226
a ee e pe i e	13,522,767	13,641,8 4
i i i e	6,707,463	7 , 6,646
o d e pe e	2,491,617	2,60 ,386
e i fee	6,3.0 T8e .f5/T10 1 Tf10.002c43,488,578	

2,3 1,8 .75 5 1 Tf 0 5,284,35 ,115,490
Cirti0 T72 expenditure
a e pe e) j/ 1 1 (318,60) j/ 0 0 1 5,72 ,351

Notes to the Financial Statements

Fo e ea e 31 ece be 2 2
(A o in B e o e ie a e)

16 oe o e co pa ' in a d a e e (co in e)

(12) Investment losses/(income)

	2020	2 1
Lo e o -e e i in e e e ee i e o	8,158,636	632, 38
e e in co e o i po a o -e e i in e e	34,663	138), 5
ee o c e epoi	(96,371)	(2,132)
ii e o	–	(824,373)
	8,096,928	(755,472)

ee a oi ifica e icio o i ce o in e e in co e o e pa .

(13) Credit impairment losses

	2020	2 1
Lo e o ba eb o acco ec i be	7,312,656	6,623) 37
Lo e o ba eb o o e ec i be	180,454	7,0 8,8 1
o a	7,493,110	14,531, 28

(14) Income tax expenses

	2020	2 1
in co e a cac a e ba e o a e aio a		
ee e aio	8,472,297	11,1 ,248
e e in co e a	2,222,037	(4,424)
	10,694,334	,515,824

e eco ci aio o in co e a cac a e ba e o e ica be a a e o a p o e in e co oi a e in co e a e o ei co e a e e i i e beo :

	2020	2 1
o a p o	44,733,411	42,5 8,60
co e a e e cac a e a ica be a a e o 25%	11,183,353	,64 ,672
o , e e o e o e cibe o a p oe	865,025	4 ,1
A i a e cio o ea c o e o e e	(1,354,044)	(563)0 8)
co e a e e	10,694,334	,515,824

Definitions

A	e a e a ee of e for e e a o be co e e a e e 18, 21
A ice	e a ice of a od a io of e , a e e, o ife o e f o e o e
A i o ee	e a i co i ee of e Bo a
Bei i o i a	Bei i o i a o., . (北京怡寧醫院有限公司), a co e abi e i e! i ie ia bii o A 17, 15, o e of e ' i ec o- o o e bi ia ie

Definitions

ae ! acicabe ae	Ap i 21, 21, be e ae p acicabe a efo c io of ce fo ai i a epo pio oi p bicaio
i ai a (o pi a	i ai a (o pi a o., . (臨海康寧醫院有限公司), aco pa e abi e i e! i ie iabii o Feb a 2, 15, e of e pa ' o - o -o e bi ia ie
iao (o pi a	ai o iao (o pi a o., . (台州市路橋慈寧醫院有限公司, p eio o a ai o iao (o pi a o., . (台州市路橋怡寧醫院有限公司)), aco pa e abi e i e! i ie iabii o ece be 12, 16, e of e pa ' i ec o - o o e bi ia ie
aca	e aca Speda A i ai e ei of e!
o e o e	e o e o efo Sec iie a acio b iec o of i e e e o Appe i o e(o o i e
aji (o pi a	aji (o pi a o., . (南京怡寧醫院有限公司), aco pa e abi e

Definitions

in ia a in [opia	in ia a in [opia o., [*. (青田康寧醫院有限公司), a co* pa e abi e* in e! i ie* ia bii o Api 1, 2 11, o e of e o pa ' o o e* bi*ia ie
o in [opia	o in [opia o., [*. (衢州怡寧醫院有限公司), a co* pa e abi e* in e! i ie* ia bii o o be 2 , 2 15, o e of e o pa ' in*iec o - o o e* bi*ia ie
e epo in !eio* o epo in !eio*	e ea e* ece be 31, 2 2
e e ai o o i ee	e e ai o co* i ee of e Boa*
B	e a f c c of e!
SF	e Sec iie a* F e *a ce (a e 571 of e [a of [o o), a a e*, pp e e* o o e ie o*ie* f o e o e
S a e( )	S a e( ) e a e ca a of e o pa , i a o in a a e of B100 ea , in c *in e o e ic S a e( ) a* e [S a e( )
S a e o*e( )	o*e( ) of e S a e( )
S e e in [opia	S e e in [opia (深圳怡寧醫院, pei o *o a S e e in [opia o., [*. (深圳市怡寧醫院有限公司)), a co* pa e abi e* in e! i ie* ia bii o Sep be 22, 2 14, o e of e o pa ' in*iec o - o o e* bi*ia ie
S a e a* i a e e co* i ee of e Boa*
bi*ia o bi*ia ie	a e* ea in a cibe* e e o in e o pa ie *a ce (a e 622 of e a of [o o)
b a i a S a e o*e( )	a e* ea in a cibe* e e o in e [o o [i in e
S pe i o( )	e e be of e S pe i o o i ee
S pe i o o i ee	e o pa ' pe i o co* i ee e abi e* p a o e! o pa [a

Definitions

ai o [illegible] [illegible]	ai o [illegible] [illegible] o., [illegible]. (台州康寧醫院有限公司), a co[illegible] pa[illegible] e abi e[illegible] e! i [illegible]ie[illegible] iabii [illegible] [illegible]e[illegible], [illegible] 16, [illegible]e of e [illegible] pa[illegible] ' [illegible]i ec[illegible] [illegible]- o o[illegible]e[illegible] bi[illegible]a ie
[illegible] [illegible] [illegible]	[illegible] [illegible] ! ci a ic Spec a [illegible] o., [illegible]. (溫嶺南方精神疾病專科醫院有限公司), a co[illegible] pa[illegible] e abi e[illegible] e! i [illegible]ie[illegible] iabii [illegible] [illegible]e[illegible], [illegible] 18, [illegible]e of e [illegible] pa[illegible] ' [illegible]i ec[illegible] [illegible]- o o[illegible]e[illegible] bi[illegible]a ie
[illegible] o [illegible] [illegible]	[illegible] o [illegible] [illegible] o., [illegible]. (溫州慈寧醫院有限公司), a co[illegible] pa[illegible] e abi e[illegible] [illegible] e! i [illegible]ie[illegible] iabii [illegible] [illegible] a [illegible]25, [illegible]0 6, [illegible]e of e [illegible] pa[illegible] ' o - o[illegible]e[illegible] bi[illegible]a ie
[illegible] o o[illegible]a	[illegible] o o[illegible]a [illegible] e [illegible]e[illegible] o., [illegible]. (溫州國大投資有限公司), a co[illegible] pa[illegible] e abi e[illegible] [illegible] e! i [illegible]ie[illegible] iabii [illegible] Feb a [illegible], [illegible]0 [illegible], [illegible]e of e [illegible] pa[illegible] ' [illegible]i ec[illegible] [illegible]- o o[illegible]e[illegible] bi[illegible]a ie
[illegible]jiao F [illegible] [illegible]	[illegible]jiao F [illegible] [illegible] of a[illegible]i[illegible]a [illegible]ee[illegible][illegible] e [illegible] e[illegible]d[illegible]e (燕郊輔仁中西醫結合醫院) [illegible]e e [illegible] pa[illegible] ' ope a i[illegible] a[illegible][illegible] a[illegible] e[illegible] [illegible] [illegible]e[illegible] [illegible]a[illegible] e[illegible] a ee[illegible] [illegible]a[illegible] a c [illegible]6, [illegible] 15 [illegible] e e[illegible] o be ee[illegible] [illegible]a[illegible] S[illegible] e [illegible]jiao F [illegible] [illegible] a (廊坊三河燕郊輔仁醫院, [illegible] e i o [illegible] o[illegible] a [illegible]jiao F [illegible] [illegible] a of a[illegible]i[illegible]a [illegible]ee[illegible][illegible] e [illegible] e[illegible]d[illegible]e (燕郊輔仁中西醫結合醫院)) a[illegible] e [illegible] pa[illegible], e[illegible] a[illegible] e[illegible] a[illegible] co[illegible] a c b [illegible]e [illegible]e ic a bee[illegible] pe[illegible]e a of e[illegible] of e e[illegible]o [illegible] e i o
e[illegible]i [illegible] pa[illegible]	[illegible] a[illegible] o e[illegible]i[illegible]o[illegible] a i[illegible] ec[illegible]oo o., [illegible]e[illegible] (杭州耶利米信息科技有限公司), a co[illegible] pa[illegible] e abi e[illegible] e! i [illegible]ie[illegible] iabii [illegible] ece[illegible] be [illegible]7, [illegible] 18, [illegible]e of e [illegible] pa[illegible] ' [illegible]i ec o -o[illegible]e[illegible] bi[illegible]a ie
[illegible]i[illegible] ! c oo [illegible]e[illegible]e [illegible] [illegible]	[illegible]i[illegible] ! c oo [illegible]e[illegible]e [illegible] ([illegible] o) o., [illegible]. (怡寧心理互聯網醫院(溫州)有限公司), a co[illegible] pa[illegible] e abi e[illegible] e! i [illegible]ie[illegible] iabii [illegible] a c [illegible], [illegible] [illegible], [illegible]e of e [illegible] pa[illegible] ' [illegible]i ec o -o[illegible]e[illegible] bi[illegible]a ie
[illegible] ji a [illegible] [illegible]	[illegible] ji a [illegible] [illegible] o., [illegible]. (永嘉康寧醫院有限公司), a co[illegible] pa[illegible] e abi e[illegible] e! i [illegible]ie[illegible] iabii [illegible] ece[illegible] be [illegible]2, [illegible] [illegible]2, [illegible]e of e [illegible] pa[illegible] ' o o[illegible]e[illegible] bi[illegible]a ie
e[illegible] [illegible] [illegible]	e[illegible] [illegible] [illegible] o., [illegible]. (樂清康寧醫院有限公司), a co[illegible] pa[illegible] e abi e[illegible] e! i [illegible]ie[illegible] iabii [illegible] Sep[illegible] be 3, [illegible] 13, [illegible]e of e [illegible] pa[illegible] ' o o[illegible]e[illegible] bi[illegible]a ie
%	pe ce[illegible] a e a io

溫州康寧醫院股份有限公司

Wenzhou Kangning Hospital Co.,